



NSW
Therapeutic
Advisory
Group Inc.

Advancing
quality use
of medicines
in NSW

Fortnightly TAG Mail – resources list 10th October 2024

NSW TAG ACTIVITIES

2024 Meetings

NSW TAG General Meetings

- 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions- nil

Recently completed email discussions and surveys

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs
- Protocols for critical medicines in NSW public facilities
- Ongoing infliximab for immune therapy colitis
- Handling of medicines by perfusionists

Contact *Sasha Bennett* at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Evaluating the impact of an automated drug retrieval cabinet and robotic dispensing system in a large hospital central pharmacy - [link](#)

AJHP: Collaborative pharmacy research across integrated health systems- [link](#)

AIM: NIH COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned - [link](#)

BJCP: Evaluating the capability of ChatGPT in predicting drug–drug interactions- [link](#)

BMJ: Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug - [link](#)

BMJ: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline - [link](#)

BMJ: Regulator's list of 50 substandard drugs raises questions about oversight and manufacturing in India - [link](#)

BMJ: Switching from inhaled to intravenous general anaesthesia - [link](#)

CJEM: - Intranasal midazolam for procedural distress in children in the emergency department: a systematic review and meta-analysis - [link](#)

ContempNurs: Reduction in preventable time-critical dose omissions: impact of electronic medication management systems on in-patients - [link](#)

IMJ: Position Paper: Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals - [link](#)

IJCP: - Implementation and evaluation of specialist heart failure pharmacist prescribing clinics - [link](#)

IJCP: Association of polypharmacy with clinical outcomes and healthcare utilization in older adults with cardiometabolic diseases: a retrospective cohort study - [link](#)

JAGS: Association between potentially inappropriate medications prescription and health-related quality of life among US older adults - [link](#)

JAMA: N-of-1 Studies in an Era of Precision Medicine - [link](#)

JAMA: Making Pragmatic Clinical Trials More Pragmatic - [link](#)

JAMA Card: Estimated Long-Term Benefits of Finerenone in Heart Failure - [link](#)

JAMA Card: Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure - [link](#)

JAMA IntMed: Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial - [link](#)

JAMA NO: Semaglutide and Opioid Overdose Risk in Patients with Type 2 Diabetes and Opioid Use Disorder - [link](#)

JAMA Ped: Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis - [link](#)

JPS: Implementation and Evaluation of Clinical Decision Support for Apixaban Dosing in a Community Teaching Hospital - [link](#)

JPPR: Active Ingredient Prescribing in Australia: exploring pharmacists' experiences - [link](#)
Lancet HIV: - HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study - [link](#)
Lancet Onc: Rising costs of cancer medicines - [link](#) ; The tyranny of non-inferiority trials - [link](#)
MDPI: Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment- [link](#)
MJA: Adherence to clinical care standards and mortality after hip fracture surgery in New South Wales, 2015–2018- [link](#)
MJA: Aligning legislation with clinical practice: off-label prescribing under the microscope - [link](#)
Neurology: Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack - [link](#)
PedQualSaf: Reducing falls in hospitalized children and adolescents with cancer and blood disorders: a quality improvement journey - [link](#)
Prescribe Int: - Drugs to avoid in the name of better patient care - [2024 update](#)
Ped: - Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline - [link](#)
Thorax: - GLP-1 Ras may benefit cardiopulmonary outcomes in patients with COPD - [link](#)

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- First national COPD Clinical Care Standard – coming soon - [link](#)

NSW Health

- Vaccination the best protection against mpox [[3 October 2024](#)]
- Warning: High-dose MDMA tablets (ecstasy) circulating in NSW [[2 October 2024](#)]
- Serious scarcity medicine substitution; Approval for use of an Electronic National Residential Medication Chart (eNRMC) - [link](#)

TGA

- Updates to the Prescribing Medicines in Pregnancy database - September 2024 - [link](#)
- Enhanced product standards for therapeutic vapes in 2025 - [link](#)
- Therapeutic vapes available without a prescription following consultation with a pharmacist - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Living Evidence Collaboration (ALEC)

- Australian Pregnancy Care Guideline - includes updated and new recommendations for hypertension and pre-eclampsia - [link](#)
-- Strong recommendation: Use aspirin 150mg/day for those at high risk of developing preeclampsia, unless contraindicated, commencing before 16 weeks' gestation where possible
-- Conditional recommendation against: Do not universally recommend aspirin to those at low risk of preeclampsia; Do not routinely use low molecular weight heparin (LMWH) in addition to aspirin for prevention of preeclampsia
- Australian Postnatal Care Guideline - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Joint Statement: Working together to achieve sustainable high-quality health care in a changing climate - [link](#)
- Medication without harm – WHO Global Patient Safety Challenge: Australia's Response – [status report](#) – [priority action status summary](#)
- Real-Time Prescription Monitoring resources - [link](#)

Australian Government Department of Health

- New Aged Care Infection Prevention and Control Guide – [Video](#) - [Webinar](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists
ABN: 82 707 308 091

- Obesity epidemic in Australia – [Final report](#)
- Medication Management Review Programs [Dataset](#)

CATAG

- Consumer counselling tool: Understanding high-cost medicines in public hospitals - [link](#)

MIMS monthly updates

- New Products
 - Selpercatinib ([Retevmo](#)) - provisional approval for adults with locally advanced or metastatic RET fusion positive non-small cell lung cancer. 40 mg or 80 mg capsules
 - Zilucoplan (tetrasodium) ([Zilbrysg](#)) - add-on to standard therapy for generalised myasthenia gravis in adults, who are AChR antibody positive. Contraindicated in patients with unresolved Neisseria meningitidis infection and in patients who are not currently vaccinated against Neisseria meningitidis, unless they receive appropriate prophylactic antibiotic treatment until 2 weeks after the first vaccination dose. Various strengths in prefilled syringes.
- New Presentation
 - Tirzepatide ([Mounjaro](#)) - multidose prefilled pen 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg in 0.6 mL
- New Indication
 - Tirzepatide ([Mounjaro](#)) - adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes mellitus)

Safer Care Victoria

- Victorian Safety Culture Guide - [link](#)
- Morbidity and Mortality meetings – Framework and toolkit - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
 - [Nubega](#) has been approved to treat metastatic hormone-sensitive prostate cancer in combination with docetaxel
- Australian prescription medicine decision summaries:
 - Voranigo (vorasidenib) for Grade 2 astrocytoma or oligodendroglioma in adults and paediatric patients 12 years and older who are not in need of immediate chemotherapy or radiotherapy following surgical intervention

REPORTS AND PUBLICATIONS – INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA

- Zero Harm: Striving to Reduce Preventable Harms – Point, Counterpoint, and Areas of Agreement - [link](#)

British Generic Manufacturers Association

- Solutions to UK Medicines Shortages - [link](#)

Canadian Agency for Drugs and Technologies in Health

- Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant - [link](#)
- Switching Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis - [link](#)
- Association Between Opioid Use and the Development of Diverticulitis - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)
 - Iqirvo (elafibranor) tablets - for primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy unable to tolerate UDCA

-- Sogroya (somapacitan) in pre-filled pen - long-acting recombinant human growth hormone derivative licensed for replacement of endogenous growth hormone in children aged ≥3 years, and adolescents with growth failure due to growth hormone deficiency, and in adults with growth hormone deficiency

European Medicines Agency (EMA)

- EMA recommends suspension of sickle cell disease medicine Oxbryta - [link](#)

Food and Drug Administration (FDA) USA

- Alerts to patients and healthcare professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns - [link](#)
- New Drug approvals
-- neoadjuvant/adjuvant [nivolumab](#) for resectable non-small cell lung cancer
-- imaging drug for evaluation of myocardial ischemia and infarction - [Flycado](#) (flurpiridaz F 18)
-- [selpercatinib](#) for medullary thyroid cancer with a RET mutation
-- First Home Flu and COVID-19 Combination Test Outside of Emergency Use Authorities - [link](#)
-- [Dupilumab](#) as Add-On for COPD

Healthcare Quality Improvement Partnership, UK

- Cardiovascular Disease-Inequalities in cholesterol management by sex (CVDPrevent) - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- Elafibranor approved as first medicine to treat adults primary biliary cholangitis - [link](#)
- Approves first medicine for activated phosphoinositide 3-kinase delta syndrome (APDS) - [link](#)
- Report safety concerns with insulin pumps and continuous glucose monitoring equipment - [link](#)

NHS England

- Urgent and emergency mental health care for children and young people: national implementation guidance - [link](#)

NHS Scotland

- Accepted for use:
-- [Faricimab](#) (Vabysmo®) for visual impairment due to macular oedema secondary to retinal vein occlusion
-- [Pembrolizumab](#) (Keytruda®) for non-small cell lung cancer (NSCLC) at high risk of recurrence
-- [Relugolix](#) (Orgovyx®) for prostate cancer
-- [Selinexor](#) (Nexpovio®) for refractory multiple myeloma
- Accepted for restricted use:
-- [Rezafungin](#) acetate (Rezzayo®) for invasive candidiasis
-- [Selinexor](#) (Nexpovio®) for multiple myeloma in adults who have received at least one prior therapy

National Institute for Health and Care Excellence (NICE) UK

- Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension ([TA1009](#))

National Institute for Health and Care Research (NIHR)

- NIHR commentaries: How to make remote consultations safer - [link](#)
- Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews - [link](#)
- Antidepressants for pain management in adults with chronic pain: a network meta-analysis - [link](#)
- Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling - [link](#)
- Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT - [link](#)
- NIHR commentaries: Schoolchildren with asthma face different risks at different ages - [link](#)

Neonatal & Paediatric Pharmacists Group

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists
ABN: 82 707 308 091

- Safe Use of Transdermal Clonidine Patches in the Management of Childhood Motor and Movement Disorders - [link](#)

Office for Health Improvement and Disparities UK

- Deaths linked to potent synthetic opioids - [link](#)

Patient Safety Learning

- Electronic patient record systems: Putting patient safety at the heart of implementation - [link](#)

Royal Pharmaceutical Society

- ... responds to consultation on puberty blockers - [link](#)

- New RPS and RCGP Repeat Prescribing Toolkit aims to improve patient safety and efficiency - [link](#)

The King's Fund (UK)

- Tackling health inequalities: seven priorities for the NHS – [link](#)

- Public health and population health: leading together - [link](#)

UK Health Security Agency

- Tuberculosis (TB) notifications reported to enhanced TB surveillance systems: UK, 2000-2023 - [link](#)

- Rise in HIV diagnoses steepest among heterosexual men and women - [link](#)

- COVID-19 vaccination: information for healthcare practitioners - [link](#)

- Interventions to reduce harms for people who inject drugs in prisons - [link](#)

World Health Organisation (WHO)

- Accelerating digital health transformation - [link](#)

- WHO adds an HPV vaccine for single-dose use - [link](#)

- Statement of the WHO Global Advisory Committee on Vaccine Safety on the safety of the mpox vaccines for use in high-risk groups - [link](#)

- WHO approves first mpox diagnostic test for emergency use, boosting global access - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

-- Alkindi (hydrocortisone) - patients and/or caregivers advised to contact their healthcare provider if most of the granules in a dose are regurgitated, vomited or spat out, as a repeat dose may be required to avoid adrenal insufficiency

-- Aspaveli (pegcetacoplan) – urticaria added as an undesirable effect (frequency uncommon) based on postmarketing data

-- Benilexa (Levonorgestrel) One Handed IUD System effective for eight years for contraception and has demonstrated efficacy for three years for use in heavy menstrual bleeding. It should be removed or exchanged after 8 years of use, or earlier if heavy or bothersome menstrual bleeding returns

-- Boostrix-IPV (diphtheria, tetanus, pertussis-acellular and poliomyelitis, inactivated) - immunogenicity & safety data of dTpa vaccination in patients with obstructive airway disease added from descriptive meta-analysis (n=222 adults) showing immune responses consistent with responses obtained in general adult population, and with a similar safety profile

-- Brabio (glatiramer acetate) - data on pregnant women (300-1000 pregnancy outcomes) indicate no malformative or fetoneonatal toxicity, and thus Brabio may be considered during pregnancy if necessary. Additionally, SPC now notes Brabio can be used during breast-feeding

-- Depo-Medrone (methylprednisolone) with Lidocaine - no additional benefit derives from intramuscular administration of Depo-Medrone with Lidocaine; its administration this way is not recommended. Where parenteral corticosteroid therapy for sustained systemic effect is desired, plain Depo-Medrone should be used

-- Evrenzo (roxadustat) – cases of cerebrovascular accidents, including fatal cases of cerebral infarction, reported. An increase in blood copper added as an ADR of unknown frequency

-- Fencino (fentanyl) Transdermal Patch – dysphagia added as an uncommon potential ADR

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Imfinzi (durvalumab) - rhabdomyolysis in the list of immune-related ADRs observed in patients treated with durvalumab in combination with tremelimumab, including advice on when to withhold the dose and when it should be permanently discontinued
- Lamictal (lamotrigine) – erythema multiforme added as a rare potential ADR
- Movicol - shelf life of reconstituted solution changed from 24 hours to 6 hours
- Myfortic (mycophenolate sodium) - hypersensitivity reactions (including anaphylaxis) as an ADR reported during post-marketing experience
- Naprosyn (naproxen) Tablets- drug reaction with eosinophilia and systemic symptoms (DRESS) added as rare ADR associated with NSAID use, with highest risk early in the course of therapy. If patients develop DRESS, or any other serious skin reaction, naproxen must be permanently discontinued
- Novofem (estradiol hemihydrate, norethisterone acetate) - drug interaction between lamotrigine and HRT products. Hormone contraceptives containing oestrogens shown to significantly decrease plasma concentrations of lamotrigine, & it is expected that a similar interaction exists with HRT
- Oncaspar (pegaspargase) - hepatic veno-occlusive disease, including severe, life-threatening and potentially fatal cases observed in patients treated with in combination with standard chemotherapy, including during the induction phase of multiphase chemotherapy
- Ozempic, Rybelsus (semaglutide), Victoza (liraglutide), Xultophy (insulin degludec and liraglutide) - warning pulmonary aspiration reported in patients undergoing general anaesthesia (GA)/deep sedation (DS). Increased risk of residual gastric content due to delayed gastric emptying should thus be considered prior to performing procedures with GA/DS
- Rifinah (isoniazid) - alopecia added as an ADR of unknown frequency
- Siklos (hydroxycarbamide) - may interfere with certain continuous glucose monitoring sensors resulting in falsely high readings (compared to actual blood glucose readings)
- Skyrizi (risankizumab) - eczema added as a common potential ADR
- Sodiofolin (folinic acid) - removal of pregnancy as a contraindication for 5-FU treatment
- Suliqua (insulin glargine, lixisenatide) - dysgeusia (taste disorder) added as an ADR of uncommon frequency
- Risk minimisation materials
- Immedica: [pegzilarginase](#) (Loargys) - This guide informs patients/caregivers about the importance of proper handling, preparation & administration to reduce the risk of medication errors, & the risk of hypersensitivity reactions. It should supplement information from the treating doctor & patient information leaflet
- Santhera: [Agamree](#) (vamorolone) 40 mg/ml oral suspension – patient alert card - dissociative corticosteroid for chronic treatment of Duchenne Muscular dystrophy. The card notes it must be taken as prescribed, and that missed doses, illness or surgery can cause adrenal crisis, which requires urgent medical attention
- UCB Pharma: [zilucoplan](#) sodium (Zilbrysq) – HP guide describes potential increased risk of meningococcal infections & requirement for meningococcal vaccines (& prophylactic antibiotics if needed), important information before starting a patient on treatment, and counselling

EMA

- Review of medicines containing finasteride and dutasteride started - assesses data related to suicidal thoughts and behaviours; New safety information for healthcare professionals: risk of medication errors due to change of dosing syringe for Keppra and Levetiracetam UCB oral solution - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Drug Safety Update [September 2024](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Nitrous Oxide Advisory – [September 2024](#)
- Updates to the Guidelines on the Regulation of Therapeutic Products in New Zealand: Requirements for information for prescribers and consumers - [link](#)

MIMS monthly updates

- New Contraindications

- Dorzolamide (hydrochloride) and timolol (maleate) ([Cosopt](#)) is now contraindicated in patients with sick sinus syndrome, severe renal impairment (CrCl < 30 mL/min) and hyperchloraemic acidosis
- Gemcitabine (hydrochloride) ([DBL Gemcitabine Solution for Injection](#)) is now contraindicated in pregnancy and breastfeeding
- Glecaprevir and pibrentasvir ([Maviret](#)) is now contraindicated for concomitant use with products containing more than 20 mcg of ethinylestradiol
- Trandolapril ([Gopten](#)) is now contraindicated in liver cirrhosis with ascites

Specialist Pharmacy Services NHS UK

- Medication Safety Update [September 2024](#)
- Managing medicines for people with sulfonamide allergy - [link](#)
- Safe management of therapeutic drug monitoring - [link](#)
- Managing the risk of confusion between intravenous penicillin salts - [link](#)

TGA

- Substitution allowed to address shortage of Ryzodeg 70/30 FlexTouch insulin - [September 2024](#)
- Product Information safety updates - [September 2024](#)
- Counterfeit Ozempic pens detected and adverse event reported - [link](#)

PAPERS OF INTEREST

American Journal of Cardiology

- Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Left Ventricular Thrombus After Myocardial Infarction: A Meta-Analysis - [link](#)

American Journal of Clinical Nutrition

- Pregnancy vitamin D supplementation and offspring bone mineral density in childhood - Follow-up of a randomised controlled trial - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Evaluating the impact of an automated drug retrieval cabinet and robotic dispensing system in a large hospital central pharmacy - [link](#)
- Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative - [link](#)
- Insomnia in ambulatory care: A clinical review - [link](#)
- Management of obesity - [link](#)
- Collaborative pharmacy research across integrated health systems: A purpose and promise for opportunities to study the complete medication-use process - [link](#)
- The 12-digit National Drug Code – [link](#) ; The National Drug Code explained - [link](#)

Annals of Internal Medicine

- National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned - [link](#)
- The Misplaced Push to Restrict Access to Gabapentin - [link](#)
- Time-Restricted Eating in Adults with Metabolic Syndrome: A Randomized Controlled Trial - [link](#)
- Diabetes Risk Factors in People with HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention: A Randomized Trial - [link](#)
- HIV Reservoir Landscape in Breast Milk from Long-Term Virally Suppressed Individuals - [link](#)

British Journal of Clinical Pharmacology

- Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real-world evidence using hospitalized patient data - [link](#)
- Letter: Cyproheptadine is preferable to benzodiazepines in mild cases of serotonin syndrome (toxicity) - [link](#) - [response](#)
- A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy - [link](#)

- Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices - [link](#)

British Journal of General Practice

- Managing chronic cough in adults in primary care - [link](#)
- What's new in osteoporosis management? Leading the fight in primary care - [link](#)
- Healthcare avoidance during the early stages of the COVID-19 pandemic and all-cause mortality: a longitudinal community-based study - [link](#)

British Journal of Psychiatry

- Mortality associated with clozapine: what is the evidence? - [link](#)
- Clozapine monitoring requirements: is it time for an update? - [link](#)
- Maternal mental disorders and neonatal outcomes: Danish population-based cohort study - [link](#)

British Medical Journal (BMJ)

- Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug - [link](#)
- World leaders commit to reduce deaths from antimicrobial resistance (AMR) by 10% by 2030 - [link](#)
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline - [link](#)
- Regulator's list of 50 substandard drugs raises questions about oversight and manufacturing in India - [link](#)
- Switching from inhaled to intravenous general anaesthesia - [link](#)
- How covid, flu, and other seasonal vaccine programmes are changing - [link](#)
- Protecting healthcare and patient pathways from infection and antimicrobial resistance - [link](#)
- Research priorities for future shocks - [link](#)

BMJ Open

- Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data - [link](#)
- Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study - [link](#)

Canadian Journal of Emergency Medicine

- Intranasal midazolam for procedural distress in children in the emergency department: a systematic review and meta-analysis - [link](#)

Circulation

- Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial - [link](#)
- Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure - [link](#)
- Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial - [link](#)
- Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up - [link](#)

Cochrane

- Vitamin D for the management of chronic obstructive pulmonary disease - [link](#)

Contemp Nurse

- Reduction in preventable time-critical dose omissions: impact of electronic medication management systems on in-patients - [link](#)

CNS Drugs

- Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study - [link](#)

Diabetes Care

- Continuous Glucose Monitoring With Geriatric Principles in Older Adults With Type 1 Diabetes and Hypoglycemia: A Randomized Controlled Trial - [link](#)
- Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial - [link](#)
- Metformin Use and Risk of Delirium in Older Adults With Type 2 Diabetes - [link](#)

Diabetes, Obesity and Metabolism

- A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations - [link](#)

European Heart Journal

- Breast cancer and cardiovascular health - [link](#)
- Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study - [link](#)
- Non-vitamin K oral anticoagulants in valvular heart disease before surgery: a tale of bridging vs. no bridging - [link](#)

European Journal of Hospital Pharmacy

- Ceftriaxone-induced thrombocytopenia during tuberculosis treatment: a case report - [link](#)
- A single harmonised pharmacy process to improve clinical trial set-up times - [link](#)

Internal Medicine Journal

- Position Paper: Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals - [link](#)
- Letter: Managing cancer-related pain in the setting of proven IgE-mediated opioid anaphylaxis - [link](#)

International Journal of Clinical Pharmacy

- Implementation and evaluation of specialist heart failure pharmacist prescribing clinics - [link](#)
- Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study - [link](#)
- Association of polypharmacy with clinical outcomes and healthcare utilization in older adults with cardiometabolic diseases: a retrospective cohort study - [link](#)
- Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion–positive non-small cell lung cancer in the United States - [link](#)

JAMA

- N-of-1 Studies in an Era of Precision Medicine - [link](#)
- Making Pragmatic Clinical Trials More Pragmatic - [link](#)
- Chronic Spontaneous Urticaria: A Review - [link](#)
- Dialysis for Chronic Kidney Failure: A Review - [link](#)
- Decline of Mpox Antibody Responses After Modified Vaccinia Ankara–Bavarian Nordic Vaccination - [link](#)
- Patient Page: What Are Uterine Fibroids? - [link](#)
- COVID-19 Therapeutics for Nonhospitalized Older Adults - [link](#)

JAMA Cardiology

- Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial - [link](#)
- Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial - [link](#)

- Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure - [link](#)

JAMA Dermatology

- Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis - [link](#)
- Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial - [link](#)

JAMA Internal Medicine

- Clinician Specialty and HIV PrEP Prescription Reversals and Abandonments - [link](#)
- Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial - [link](#)

JAMA Network Open

- Semaglutide and Opioid Overdose Risk in Patients with Type 2 Diabetes and Opioid Use Disorder - [link](#)

JAMA Neurology

- Antiseizure Medications and Cardiovascular Events in Older People with Epilepsy - [link](#)
- Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS - [link](#)

JAMA Oncology

- Prevalence and Factors Associated with Prostate Cancer Among Transgender Women - [link](#)

JAMA Pediatrics

- Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis - [link](#)

Journal of Allergy and Clinical Immunology

- Effects of pregnancy and lactation prebiotics supplementation on infant allergic disease: A randomized controlled trial - [link](#)
- Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP - [link](#)

Journal of the American College of Cardiology

- The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial - [link](#)
- Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy - [link](#)
- Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial - [link](#)

Journal of the American Geriatrics Society

- Association between potentially inappropriate medications prescription and health-related quality of life among US older adults - [link](#)
- Cardiovascular health, measured using Life's Essential 8, is associated with reduced dementia risk among older men and women - [link](#)

Journal of Clinical Endocrinology and Metabolism

- Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity - [link](#)

Journal of Clinical Oncology

- Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study - [link](#)
- Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 - [link](#)

Journal of Patient Safety

- Implementation and Evaluation of Clinical Decision Support for Apixaban Dosing in a Community Teaching Hospital - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Active Ingredient Prescribing in Australia: exploring pharmacists' experiences - [link](#)
- A retrospective study of duloxetine for phantom limb pain post lower-limb amputation - [link](#)
- Impact of sacubitril/valsartan on atrial fibrillation burden in heart failure: a retrospective observational study - [link](#)

Lancet

- Endovascular management of acute stroke - [link](#)
- Hypothyroidism - [link](#)
- WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines - [link](#)

Lancet HIV

- HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study - [link](#)

Lancet Infectious Diseases

- Advancing the chemotherapy of tuberculous meningitis: a consensus view - [link](#)
- New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine - [link](#)

Lancet Oncology

- Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations - [link](#)
- Rising costs of cancer medicines - [link](#) ; The tyranny of non-inferiority trials - [link](#)

Lancet Public Health

- Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study - [link](#)

Lancet Respiratory Medicine

- Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial - [link](#)
- Respiratory Syncytial Virus 2024 - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Discrepancy between Subjective and Objective Measurements for the Evaluation of Medication Adherence—A Cross-Sectional Study in Patients with Cardiovascular Diseases - [link](#)
- Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment: A Systematic Review of the Evidence - [link](#)

Medical Journal of Australia

- Adherence to clinical care standards and mortality after hip fracture surgery in New South Wales, 2015–2018: a retrospective population-based study - [link](#)
- Aligning legislation with clinical practice: off-label prescribing under the microscope - [link](#)
- Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021: a retrospective cohort study - [link](#)

Neurology

- Anti-CD20 Therapies in Drug-Naive Patients with Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study - [link](#)

- Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack - [link](#)

New England Journal of Medicine

- Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B - [link](#)
- [link](#)
- Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection - [link](#)
- Neuroleptic Malignant Syndrome - [link](#)

Pediatr Qual Saf

- Reducing falls in hospitalized children and adolescents with cancer and blood disorders: a quality improvement journey - [link](#)

Pediatrics (American Academy of Pediatrics)

- Evidence for the Use of Opioid Medication for Pediatric Acute Pain in the Outpatient Setting: Technical Report - [link](#)
- Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline - [link](#)

Pharmacotherapy

- Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report - [link](#)
- Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis - [link](#)

Prescribe International - [October 2024](#) includes

- Finerenone (Kerendia[®]) in chronic kidney disease with albuminuria associated with type 2 diabetes
- Solifenacin + tamsulosin (Vecalmys[®]/Vesomni[®]) in benign prostatic hyperplasia: not acceptable
- Short-term interruption of treatment with a xaban or dabigatran: [treatment interruption](#), even for one day, was associated with a 2-fold increase in the risk of premature death and a 10-fold increase in the risk of stroke, transient ischaemic attack or systemic embolism.
- Drugs to avoid in the name of better patient care - [2024 update](#)

Thorax

- Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD - [link](#)

CONSULTATIONS (new additions in bold)

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Stroke Intravenous Thrombolysis - Closes 11 October 2024 - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Draft Medication Management at Transitions of Care Stewardship Framework - Closing 27 October 2024 - [link](#)

TGA

- Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS JUNE, 2024 - Closes on 18 October 2024 - [link](#)
- Consultation: Proposed amendments to the Poisons Standard – ACMS and Joint ACMS-ACCS meetings, November 2024 - Closes on 22 October 2024 – [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 173](#): Management of occupational exposure to blood and body fluids in primary care

FDA Division of Drug Information is presenting a [series](#) of CE webinars

- The Bad Ad Program - September 24, 2024 - [link](#)

MJA Podcasts

- [Episode 26](#): What have we learned about TAVI in low risk patients?
- [Episode 25](#): Gastric and oesophageal cancer - a community perspective

UPCOMING EVENTS

AHHA

- The John Deeble Lecture and Panel Discussion, Beyond boundaries: leadership for health - National Museum of Australia, Canberra, ACT - October 15, 2024 09:00-16:00 AEST – [register](#)
- Embedding patient-reported measures in practice – October 29, 2024, 12:30-13:00 AEDT - [register](#)

AHRQ

- Improving Hospital Handoffs Using AHRQ's Surveys on Patient Safety Culture® Hospital Survey – webinar - Oct. 30, 2024 13:00-14:00 ET - [register](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- First national Chronic Obstructive Pulmonary Disease Clinical Care Standard Launch, with expert panel discussion - Thursday 17 October 12:00–13:00 AEDT - [register](#)
- NMS 2024: Ageing well: safe medicines, better lives – Tuesday, 19 November 2024 10.00- 15.00 - [Register](#)

Canadian Pharmacists Association

- Practice Development: Tools pharmacists can use to help sow the seed of deprescribing – free webinar - Thursday, October 17 | 12:00-13:00 ET - [register](#)

Institute for Healthcare Improvement-BMJ Group

- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – [registration](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

Fortnightly TAG Mail – resources list 26th September 2024

NSW TAG ACTIVITIES

2024 Meetings

NSW TAG General Meetings

- 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions- nil

Recently completed email discussions and surveys

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs
- Protocols for critical medicines in NSW public facilities
- Ongoing infliximab for immune therapy colitis
- Handling of medicines by perfusionists

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

BJCP: Errors associated with co-names of medicines - [link](#)

BJCP: Efficacy and safety of antidepressants for pain in older adults- [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

BJCP: The effect of down-titration and discontinuation of heart failure pharmacotherapy in older people: A systematic review and meta-analysis - [link](#)
BMJ: Protecting early career physicians from commercial influence - [link](#)
BMJ Open: Cost comparison analysis of continuous versus intermittent antimicrobial therapy infusions in inpatient and outpatient care: real-world data from Finland - [link](#)
BMJ Quality & Safety: Editorial- Measuring gist-based perceptions of medication benefit-to-harm ratios - [link](#)
IJQHC: Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)
JAMA: JAMA Clinical Guidelines Synopsis: Evaluation of Suspected Antibiotic Allergies - [link](#)
JAMA IM: - Patient-Directed Education to Promote Deprescribing- [link](#)
JAMA Psychiatry: - Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial - [link](#)
MJA: Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective - [link](#)
MJA: Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood - [link](#)
Pediatrics: Special Requirements of Electronic Health Record Systems in Pediatrics- [link](#)
Pharmacotherapy: Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data - [link](#)

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- New milestones achieved in medication safety - [link](#)
- Have your say on the draft Medication Management at Transitions of Care Stewardship Framework - [link](#)
- Launch of Australia's first care standard for COPD - [link](#)

NSW Health

- Mental Health Outcomes and Assessment Tools (MHOAT) Collection and Reporting Requirements ([PD2024_031](#)) [24 September 2024]
- Responding to the health care needs of people with disability ([PD2024_030](#)) [19 September 2024]
- Finalists announced for the NSW Health Awards 2024 [[23 September 2024](#)]
- Public health warning: Heroin overdoses after using drugs thought to be cocaine [[13 September 2024](#)]
- Community urged to get vaccinated as whooping cough notifications continue to rise [[12 September 2024](#)]

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

- The latest weekly Evidence Digest can be found [here](#)
- Improving access to menopause care in NSW - [link](#)
 - Flexible diuretic action plan for heart failure - [link](#)

AHHA

- Australian Collaborative Commissioning program supporting frail and elderly recognised internationally - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Patient-Reported Outcome Measure Recommendations for Low Back Pain - [link](#)

AHPRA

- Meeting your professional obligations when using Artificial Intelligence in healthcare - [link](#)

Australian Government Department of Health

- Palliative care education and training for the aged care workforce – Communication [toolkit](#)

Australian Institute for Health and Welfare (AIHW)

- Suicide and self-harm monitoring: Suicide registers - [update](#) ; Dementia in Australia – [update](#)
- Pharmaceutical Benefits Scheme prescriptions - [over time](#) – [monthly data](#)

PBS

- PBS arrangements due to shortage of tenofovir with emtricitabine tablets - 23 September 2024 - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
 - [Amvuttra](#) (vutrisiran) for hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy
 - [COMIRNATY](#) Original/Omicron BA.4-5 Vaccine has been provisionally approved for immunisation against coronavirus disease 2019 (COVID-19) in individuals 6 months of age or older
 - [Lokelma](#) (sodium zirconium cyclosilicate hydrate) for hyperkalaemia in adult patients
 - [Kyprolis](#) (carfilzomib) approved to treat relapsed or refractory multiple myeloma
 - [Mounjaro](#) (tirzepatide) as an adjunct to a reduced-calorie diet and increased physical activity, for chronic weight management
 - [Opdivo](#) (nivolumab), in combination with platinum-doublet chemotherapy, for the neoadjuvant treatment of patients with resectable non-small cell lung cancer
 - [Velsipity](#) (Etrasimod) approved for adults with moderately to severely active ulcerative colitis who have not benefited from prior therapies
- Australian prescription medicine decision summaries:
 - [Zilbrysq](#) (zilucoplan) approved as an add-on to standard therapy for generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- Infliximab can be made available within NHS Wales for the treatment of immune checkpoint inhibitor (ICI)-induced enterocolitis – [link](#)
- Vedolizumab can be made available within NHS Wales for the treatment of immune checkpoint inhibitor (ICI)-induced enterocolitis - [link](#)

Agency for Healthcare Research and Quality (AHRQ) USA

- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain - [link](#)

British National Formulary

- BNF/BNFC newsletter: [September 2024](#) including:
 - Cabergoline: updated important safety information
 - Hyperkalaemia: updated guidance on management
 - Salbutamol: new indication and dose for moderate to severe hyperkalaemia.
 - Topiramate (Topamax®): introduction of new safety measures, including a Pregnancy Prevention Programme [MHRA/CHM advice]
 - Warfarin: be alert to the risk of drug interactions with tramadol [MHRA/CHM advice] (advice in warfarin sodium and acenocoumarol)

Canadian Agency for Drugs and Technologies in Health

- Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years - [link](#)
- Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update - [link](#)
- Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia - [link](#)
- Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Agamree (vamorolone) for Duchenne muscular dystrophy in patients aged 4 years and older
- Influenza vaccine Tetra MYL for prophylaxis of influenza in adults and children from 6 months of age, especially those who run an increased risk of associated complications. Its use should be based on official recommendations
- Obgemsa (Vibegron) 75 mg tablets for adult patients with overactive bladder syndrome
- Pedmarqsi (sodium thiosulfate) 80 mg/mL infusion - for prevention of ototoxicity induced by cisplatin in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours

- [Updated SPCs](#)

- Dupixent (dupilumab) 200 mg - pre-filled pen is for use in adult and paediatric patients aged 2 years and older, pre-filled syringe is for use in adult and paediatric patients aged 6 months and older. In children aged 6 months to ≤12 years, it should be given by a caregiver. All formulations now cover treatment of eosinophilic esophagitis and COPD
- Tagrisso (osimertinib) - for use in combination with pemetrexed and platinum based chemotherapy as 1st-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations, based on final results of FLAURA2 study

European Medicines Agency (EMA)

- European Medicines Agency recommends extending indication of Imvanex® mpox and smallpox vaccine to include adolescents - [link](#)
- European CHMP recommends the granting of marketing authorisations for:
 - aflibercept biosimilar ([Aflgir](#)) ([Opuviz](#)) for wet AMD, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema & visual impairment due to myopic choroidal neovascularisation
 - Elahere ([mirvetuximab soravtansine](#)) for adults with folate receptor-alpha (FR α) positive epithelial ovarian, fallopian tube and primary peritoneal cancer
 - Hetrionfly ([serplulimab](#)) in combination with carboplatin and etoposide for first-line treatment of adults with extensive-stage small cell lung cancer
 - Hympavzi ([marsracimab](#)) for prophylaxis of bleeding episodes in patients with severe haemophilia A or B ≥ 12 yrs, weighing ≥ 35 kg, with severe haemophilia A without factor VIII inhibitors or severe haemophilia B without factor IX inhibitors
 - [Penbray](#) (Meningococcal group A, B, C, W and Y vaccine) for active immunisation of individuals 10 years of age and older to prevent invasive disease caused by Neisseria meningitidis groups A, B, C, W, and Y. The use of this vaccine should be in accordance with official recommendations
 - generic pomalidomide ([Teva](#)) in combination with bortezomib and dexamethasone for multiple myeloma in adults who have received at least one prior treatment regimen including lenalidomide
 - [Theralugand](#) (lutetium [177Lu] chloride) for the radiolabelling of carrier molecules that have been specifically developed/authorised for radiolabelling with lutetium (177Lu) chloride. Not for direct use.
- European CHMP recommends a change to the marketing authorisation for:
 - [Aflunov](#) (zoonotic influenza vaccine [H5N1] (surface antigen, inactivated, adjuvanted) - to include vaccination of children from the age of 6 months for active immunisation against H5N1 subtype of Influenza A virus
 - benralizumab ([Fasenra](#)) to include use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis
 - [Buccolam](#) (midazolam) to include treatment of prolonged, acute, convulsive seizures in infants from 3 months to adults
 - dupilumab ([Dupixent](#)) to include treatment of eosinophilic esophagitis in adults and children aged ≥ 1 year, weighing ≥ 15 kg who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy
 - pembrolizumab ([Keytruda](#)) to include use in combination with chemoradiotherapy for treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer in adults, who haven't received prior definitive therapy
 - [Pravafenix](#) (fenofibrate/pravastatin) to include use for treatment of mixed hyperlipidaemia in adults at high CV risk when LDL-C levels are adequately controlled on treatment with moderate-intensity statin regimen

- [Synjardy](#) (empagliflozin/metformin) to include use in children aged 10 years and above for type 2 diabetes mellitus as an adjunct to diet and exercise
- turoctocog alfa pegol ([Esperoct](#)) for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), to include use in all age groups (currently limited to use in those aged 12 years and above)
- [Zaficefta](#) (ceftazidime/avibactam) to include treatment of infants from birth for complicated intra-abdominal infection, complicated urinary tract infection, including pyelonephritis & hospital-acquired pneumonia including ventilator associated pneumonia

- European CHMP recommends adoption of new indication for:

- apremilast ([Otezla](#)) for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years and weighing at least 20 kg who are candidates for systemic therapy
- daratumumab ([Darzalex](#)) in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
- pembrolizumab ([Keytruda](#)) in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy

- European CHMP recommends refusal of authorisation for pegcetacoplan ([Syfovre](#)) for the treatment of geographic atrophy caused by age-related macular degeneration (AMD)

- Companies withdraw applications for:

- marketing authorisation of bimatoprost ([Durysta](#)) for the reduction of intraocular pressure in adults with open angle glaucoma or ocular hypertension
- use of [Sialanar](#) (glycopyrronium bromide) in the treatment of severe drooling in children aged 2 to 3 years old
- extending use of atezolizumab (Tecentriq) to include treatment of adults with hepatocellular carcinoma whose cancer has been removed by surgery or other techniques and is at high risk of coming back

European Respiratory Society

- Results of ELVIS-Kids trial show hypertonic saline nasal drops can reduce the duration of the common cold in young children - [link](#)

Food and Drug Administration (FDA) USA

- New Drug approvals
- [Agneursa](#) (levacetylleucine) and [Miplyffa](#) (arimocloleamol) for Niemann-Pick Disease Type C
- [amivantamab-vmjw](#) with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
- atezolizumab and hyaluronidase-tqjs for subcutaneous injection - [link](#)
- [Benralizumab](#) for EGPA Vasculitis Indication
- [Bimekizumab](#) for Three Rheumatologic Conditions, the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases
- [Cobenfy](#) (xanomeline and trospium chloride) drug with new mechanism of action for schizophrenia
- [Ebglyss](#) (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis
- [FluMist](#) Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration
- [Isatuximab](#) First-Line for Transplant-Ineligible MM
- Subcutaneous [Ocrelizumab](#) for relapsing MS
- [osimertinib](#) for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
- [Kisqali](#) with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer
- [pembrolizumab](#) with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
- Adjuvant [Ribociclib](#) in Earlier Stage Breast Cancer

Medicines and Healthcare products Regulatory Agency (MHRA)

- Launches new strategy for improving safety communications on World Patient Safety Day: Improving information to patients and healthcare professionals - [link](#)
- Fruquintinib approved to treat adults with metastatic colorectal cancer - [link](#)
- Dupilumab approved for adults with uncontrolled COPD and raised eosinophils - [link](#)

Monthly Index of Medical Specialities (MIMS) UK

- Benilexa (levonorgestrel) IUD approved for longer contraceptive use - [link](#)
- MIMS summary: Trokide, a new tiotropium inhaler for patients with COPD - [link](#)
- Obesity treatments compared in new MIMS resource - [link](#)

NHS England

- Healthier You NHS Diabetes Prevention Programme Gestational Diabetes Mellitus (GDM) – [leaflet](#)
- Patient Group Direction (PGD) for the administration of COVID-19 vaccines to individuals aged 5 years and over - [link](#)
- Service specification: hepato-pancreatic biliary (HPB) – pancreatic and periampullary cancers - [link](#)
- Service specification: hepato-pancreatic biliary (HPB) – primary liver, secondary liver, perihilar biliary tract and gallbladder cancers - [link](#)
- Service specification: specialist gynaecological cancer - [link](#)
- ACT NOW Sickle Cell Acronym - [link](#)
- National Dose Banding Table – [Teclistamab 10mg/mL](#) - [Teclistamab 90mg/mL](#)
- National patient safety alert: Risk of oxytocin overdose during labour and childbirth - [link](#)

National Institute for Health and Care Excellence (NICE) UK

- Implementing an antimicrobial prescribing strategy for ear infection in children - [link](#)
- Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer ([TA1007](#))
- Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments ([TA1008](#))
- NICE-recommended digital therapies for depression and anxiety could free up thousands of NHS therapist hours - [link](#)
- Burosumab for treating X-linked hypophosphataemia in children and young people, updated ([HTS8](#))

National Institute for Health and Care Research (NIHR)

- NIHR Commentaries: How can we support the mental health of children with epilepsy? - [link](#)
- Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model - [link](#)
- Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT - [link](#)
- NIHR commentaries: Chronic migraine: which drugs are best? - [link](#)
- NIHR Commentaries: Dialysis for kidney failure: evidence to improve care - [link](#)
- NIHR Commentaries: Is long COVID linked with orthostatic intolerance? - [link](#)

Office of Health Economics, UK

- Report: The Cost of Drug Shortages - [link](#)

Reform, UK

- Prescription for Prevention: A new model of primary care - [link](#)

Royal Pharmaceutical Society

- Launches two new Advanced Pharmacist curricula, mental health and critical care - [link](#)

Specialist Pharmacy Services NHS UK

- Understanding the characteristics of Comirnaty 10 (JN.1) ready to use vaccine - [link](#)
- Understanding the characteristics of Comirnaty 3 (THREE) (JN.1) concentrate vaccine - [link](#)
- Understanding the characteristics of Comirnaty 30 (JN.1) vaccine - [link](#)
- Understanding the characteristics of Spikevax (JN.1) vaccine - [link](#)
- Using generic liposomal amphotericin B - [link](#)

UK Health Security Agency

- Green Book updated for [Covid-19](#), smallpox and [mpox](#)
- Antimicrobial resistance awareness: toolkit for healthcare providers - [link](#)
- Collection: Public health in prisons and secure settings - [link](#)

World Health Organisation (WHO)

- Guidance for best practices for clinical trials - [link](#)
- WHO recommendation on screening of pregnant women for intrapartum antibiotic prophylaxis for the prevention of early onset group B streptococcus disease in newborns - [link](#)
- World leaders commit to decisive action on antimicrobial resistance - [link](#)

MEDICATION SAFETY

Electronic Medicines Compendium (eMC)

- [Revised SPCs](#)

- Adcetris (brentuximab) - updates to the already approved Hodgkin lymphoma indication, to include patients with stage III disease
- Dexamethasone - hiccups added as potential ADR with frequency unknown
- Dostinex (cabergoline) Tablets should not be used in women with pregnancy-induced hypertension, for example, post-partum hypertension, unless the potential benefit is judged to outweigh the possible risk, except for toxemia of pregnancy
- Dynastat (parecoxib) – updated with European PRAC recommendation regarding the systemic use of NSAID-containing products during pregnancy
- Epilim (sodium valproate) products - potential increased risk of neurodevelopmental disorders in children born to men treated with valproate in the 3 months prior to conception. Male patients & their female partners should use effective contraception during and for ≥3 months after stopping treatment
- Equasym XL (methylphenidate hydrochloride) - 'logorrhoea' (incoherent talkativeness) as an ADR of unknown frequency.
- FEIBA (factor VIII inhibitor bypassing activity) - increases Fibrin D-dimer with unknown frequency
- Gardasil 9 (human papillomavirus 9-valent vaccine) - 'Injection site nodule' as a possible ADR
- Gaviscon Advance (sodium alginate, potassium bicarbonate) including Aniseed flavour Oral Suspension and Mint Chewable Tablets - diarrhoea, nausea, & vomiting added as uncommon ADRs
- Isovorin Solution (calcium levofolinate) - several changes including: information about interactions between levofolinic acid and chloramphenicol, and levofolinic acid and fluorouracil
- Leflunomide - may impair wound healing after surgery. Prescribers are advised to consider pausing treatment in the peri-surgical period based on an individual risk benefit assessment
- MenQuadfi (meningococcal Group A, C, W135 and Y conjugate vaccine) - anaphylaxis (very rare) and hypersensitivity (frequency unknown) added as potential ADRs
- Metoject PEN (methotrexate) – information on photosensitivity reactions & interaction with metamizole updated, following a European periodic safety update report single assessment
- Mounjaro (tirzepatide) KwikPen - dysgeusia (taste disorder) as an uncommon ADR
- Octagam 5% and Panzyga (human normal immunoglobulin) – now for use in measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (0-18 years) in whom active immunisation is contraindicated or not advised
- Retsevmo (selpercatinib) - epiphysiolysis of femoral head reported in ≤ 6.4% of paediatric patients
- Revestive (teduglutide) - use in children aged 4 months corrected gestational age and above
- Scopoderm (hyoscine) 1.5mg Patch - risk of anticholinergic side effects, including hyperthermia
- Tecentriq (atezolizumab) - IV formulation is not intended for SC administration and should be administered via IV infusion only (not IV push/bolus). It stresses importance of checking product labels to ensure correct formulation (IV or SC) is being administered to the patient, as prescribed
- Tioguanine, in combination with other immunosuppressive or chemotherapeutic agents, increases risk of severe or atypical viral, fungal or bacterial infections
- Tranexamic acid (Tillomed) – in cases of haematuria of renal origin, especially in haemophilia, there is a risk of urinary obstruction which if left untreated can lead to renal insufficiency, UTI, hydronephrosis and anuria

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Veklury (remdesivir) - pharmacodynamic properties changed due to availability of new preclinical data on the antiviral activity of remdesivir against the Omicron subvariants XBF, XBB.1.16, FL.22, XBB.2.3.2, EG.5.1, EG.1.2, BA.2.86 and XBB.1.9.2
- Yescarta (axicabtagene ciloleucel) - secondary malignancies (T-cell malignancies) following treatment of haematological malignancies with BCMA- or CD19-directed CART-cell therapy. In this event the company is to be contacted to obtain instructions on patient samples to collect for testing
- Risk minimisation materials
- Biogen - Healthcare Professional Guide to the risk of progressive multifocal leukoencephalopathy (PML) associated with Tysabri™ ([natalizumab](#)) and a related administration checklist for administering subcutaneous natalizumab outside a clinical setting. The guide discusses the risk factors for PML, its diagnosis, patient monitoring, and important considerations
- Novartis - Fabhalta ([iptacopan](#)) Vaccination Confirmation Form to verify that iptacopan can only be dispensed once Novartis receives written confirmation that each patient has received vaccination against N. meningitidis and S. pneumoniae infections &/or receipt of prophylactic antibiotic treatment

Food and Drug Administration (FDA) USA

- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flushes due to menopause - [link](#)
- Information about Nitrosamine Impurities in Medications - [link](#)
- FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns - [link](#)

Health Canada

- Health Product InfoWatch, [September 2024](#): Mounjaro PI updated with the risk of malnutrition

Specialist Pharmacy Services NHS UK

- Managing risks associated with oxytocin infusions during labour - [link](#)

TGA

- Substitution allowed to address shortage of Ryzodeg 70/30 FlexTouch insulin - [September 2024](#)
- Update on supply of Mounjaro (tirzepatide) injections - [link](#)
- Upcoming changes to supply of some insulin products - [link](#)

PAPERS OF INTEREST

American Journal of Psychiatry

- Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women with Schizophrenia or Schizoaffective Disorder - [link](#)

Annals of Internal Medicine

- Ethics and Academic Discourse, Scientific Integrity, Uncertainty, and Disinformation in Medicine: An American College of Physicians Position Paper - [link](#)
- Artificial Intelligence–Supported Development of Health Guideline Questions - [link](#)

Arthritis & Rheumatology

- Efficacy Versus Effectiveness: The HORIZON-Pivotal Fracture Trial and Its Emulation in Claims Data - [link](#)
- Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled Phase III INVIGORATE-2 Study - [link](#)
- Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study - [link](#)
- Weight loss after initiating anti-obesity medications and gout among overweight and obesity individuals: a population-based cohort study - [link](#)
- Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis - [link](#)

British Journal of Clinical Pharmacology

- Efficiency of computerized clinical decision support systems involving anticoagulants: A flashmob study in Dutch hospital pharmacies - [link](#)
- Flucloxacillin instantly decreases serum levels of valproic acid: A case report - [link](#)
- Errors associated with co-names of medicines: The nomenclature of combination medicinal products - [link](#)
- Efficacy and safety of antidepressants for pain in older adults: A systematic review and meta-analysis - [link](#)
- The effect of down-titration and discontinuation of heart failure pharmacotherapy in older people: A systematic review and meta-analysis - [link](#)
- Apixaban anti-Xa levels in clinical practice: A case report - [link](#)
- MCF classifier: Estimating, standardizing, and stratifying medicine carbon footprints, at scale - [link](#)
- Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis - [link](#)
- Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist - [link](#)
- Calcium channel blocker overdose: Not all the same toxicity - [link](#)
- Adoption of clinical pharmacist roles in primary care: Longitudinal evidence from English general practice - [link](#)
- Malaria in pregnancy: Modern approaches—Spotlight commentary - [link](#)

British Journal of Psychiatry

- Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada - [link](#)
- Electroconvulsive therapy response and remission in moderate to severe depressive illness: a decade of national Scottish data - [link](#)

British Medical Journal (BMJ)

- Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial - [link](#)
- Protecting early career physicians from commercial influence - [link](#)
- Measures of how well a vaccine works - [link](#)
- Stevens-Johnson syndrome/toxic epidermal necrolysis: initial assessment - [link](#)
- Management of atrial fibrillation in older adults - [link](#)
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis - [link](#)
- Optimising inhaled therapy for patients with asthma - [link](#)

BMJ Open

- Cost comparison analysis of continuous versus intermittent antimicrobial therapy infusions in inpatient and outpatient care: real-world data from Finland - [link](#)
- Prescription charge policy acceptance among UK adults with and without long-term health conditions: a mixed-method survey - [link](#)

BMJ Quality & Safety

- Editorial: Measuring gist-based perceptions of medication benefit-to-harm ratios - [link](#)

Circulation

- 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - [link](#)
- Kidney Disease as a Cardiovascular Disease Priority - [link](#)

Cochrane

- Erythropoiesis-stimulating agents for preventing acute kidney injury - [link](#)
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases - [link](#)

Diabetes Care

- The Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Antidiabetic Medication under Conditions of Clinical Uncertainty - [link](#)
- Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial - [link](#)
- Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program - [link](#)
- Initiation of Intermittently Scanned Continuous Glucose Monitoring Is Associated With Reduced Hospitalization for Acute Diabetes Events and Cardiovascular Complications in Adults With Type 1 Diabetes - [link](#)

Drug and Therapeutics Bulletin

- Editorial: (Un)common sense in oncology - [link](#)
- Recent updates from the BNF (BNF 88) - [link](#)
- DTB select: Intravenous vitamin C for COVID-19-no benefit - [link](#)
- Managing hypertension in older people: current concepts - [link](#)

European Heart Journal

- Clinical trials in-a-dish for cardiovascular medicine - [link](#)

European Journal of Hospital Pharmacy

- Pharmaco-economic and clinical impact of pharmaceutical service in the intensive care unit: a systematic review - [link](#)

Heart

- Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study - [link](#)
- Advancing the access to cardiovascular diagnosis and treatment among women with cardiovascular disease: a joint British Cardiovascular Societies' consensus document - [link](#)

Internal Medicine Journal

- Progesterone hypersensitivity: successful use of progesterone desensitisation and omalizumab to facilitate in vitro fertilisation - [link](#)

International Journal of Clinical Pharmacy

- A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation - [link](#)
- Assessing the cost-effectiveness of replacing antimetabolites with mTOR inhibitors in heart transplant immunosuppression in China: a network meta-analysis-based economic evaluation - [link](#)

International Journal for Quality in Health Care

- Optimizing Warfarin and Dual Oral Anticoagulation Practices in an Academic Clinic During a Merger Amid the COVID-19 Pandemic in a Marginalized Population - [link](#)
- Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)

JAMA

- JAMA Clinical Guidelines Synopsis: Evaluation of Suspected Antibiotic Allergies - [link](#)
- Tenecteplase vs Alteplase for Patients with Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial - [link](#)
- Why the Rise of This Drug-Resistant Fungus Is Raising International Concern - [link](#)
- Chemistry Matters—From a Putative Peptide to Effective Treatments for Diabetes and Obesity: 2024 Lasker-DeBaakey Clinical Medical Research Award - [link](#)
- The Science of Biosimilars—Updating Interchangeability - [link](#)
- RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older - [link](#)

JAMA Dermatology

- Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials - [link](#)

JAMA Internal Medicine

- Reaction Risk to Direct Penicillin Challenges. A Systematic Review and Meta-Analysis - [link](#)
- GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease - [link](#)
- Deprescribing of Antihypertensive Medications and Cognitive Function in Nursing Home Residents - [link](#)
- Direct-to-Consumer Educational Brochures to Promote Gabapentinoid Deprescribing in Older Adults - [link](#)
- Patient-Directed Education to Promote Deprescribing: A Nonrandomized Clinical Trial - [link](#)

JAMA Network Open

- Community-Acquired Pneumonia A Review - [link](#)

JAMA Neurology

- Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine. A Phase 4, Randomized, Placebo-Controlled Trial - [link](#)
- Comorbidity and Disease Activity in Multiple Sclerosis - [link](#)
- Antiepileptic Medication Use and Outcomes After Suspected or Confirmed Acute Symptomatic Seizures - [link](#)
- Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation - [link](#)

JAMA Psychiatry

- Clinical Outcomes of Continuation and Maintenance Electroconvulsive Therapy - [link](#)
- Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial - [link](#)

Journal of the American College of Cardiology

- Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison from AUGUSTUS - [link](#)
- Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared with Placebo for Initial Treatment of Hypertension - [link](#)

Journal of the American Medical Informatics Association

- Longitudinal study of the manifestations and mechanisms of technology-related prescribing errors in pediatrics - [link](#)

Journal of Clinical Oncology

- Naldemedine for Opioid-Induced Constipation in Patients with Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial - [link](#)
- Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis - [link](#)
- Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief with Cancer Risk - [link](#)

Lancet

- Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 - [link](#)
- Lipoprotein(a) and cardiovascular disease - [link](#)
- Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial - [link](#)

Lancet Diabetes & Endocrinology

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists
ABN: 82 707 308 091

- Osteopenia: a key target for fracture prevention - [link](#)

Lancet Gastroenterology and Hepatology

- Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis - [link](#)
- Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis - [link](#)
- Disorders of gastric motility - [link](#)

Lancet HIV

- Role of HIV self-testing in strengthening HIV prevention services - [link](#)

Lancet Infectious Diseases

- Optimising vaccine immunogenicity in ageing populations: key strategies - [link](#)
- The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access - [link](#)

Lancet Neurology

- Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 - [link](#)
- Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial - [link](#)
- Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial - [link](#)

Lancet Psychiatry

- Optimising psychiatric care through pain management - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacteriales - [link](#)
- Improving the Monitoring and Management of Clozapine-Induced Gastrointestinal Hypomotility (CIGH) in Community Mental Health Services: A Quality Improvement Approach - [link](#)

Medical Journal of Australia

- Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective - [link](#)
- Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood - [link](#)
- 6-Methylnicotine: a new nicotine alternative identified in e-cigarette liquids sold in Australia - [link](#)

New England Journal of Medicine

- Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment - [link](#)
- Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial - [link](#)
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer - [link](#)
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma - [link](#)
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer - [link](#)
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma - [link](#)
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer - [link](#)
- Pembrolizumab in HER2-Positive Gastric Cancer - [link](#)
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer - [link](#)
- Ponegromab for the Treatment of Cancer Cachexia - [link](#)
- Preoperative Chemoradiotherapy for Resectable Gastric Cancer - [link](#)
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer - [link](#)
- Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma - [link](#)
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors - [link](#)
- Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease - [link](#)

- Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia - [link](#)
- Primary Central Nervous System Vasculitis - [link](#)

Pediatrics

- Special Requirements of Electronic Health Record Systems in Pediatrics: Clinical Report - [link](#)
- Use of Antibiotics in Animal Agriculture: Implications for Pediatrics: Technical Report - [link](#)
- Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children - [link](#)
- Posterior Reversible Encephalopathy Syndrome Due to Vitamin D Toxicity - [link](#)

Pharmaceutical Journal

- Mpox: how is the UK preparing for the latest variant? - [link](#)

Pharmacotherapy

- Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data - [link](#)

Research in Social and Administrative Pharmacy

- Relationships between medications used in a mental health hospital and types of medication errors: A cross-sectional study over an 8-year period - [link](#)

Thorax

- Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis - [link](#)
- Intensive care unit interventions to promote sleep and circadian biology in reducing incident delirium: a scoping review - [link](#)

CONSULTATIONS

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Stroke Intravenous Thrombolysis – closes 4 October 2024 - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Draft Medication Management at Transitions of Care Stewardship Framework - Closing 27 October 2024 - [link](#)

TGA

- Consultation on temporary labelling exemptions for paracetamol - Closes 30 September 2024 - [link](#)
- Consultation: Draft Guidance - Regulatory changes for medical devices containing medicinal substances or materials of animal, microbial or recombinant origin - Closes on 9 October 2024 - [link](#)
- Consultation: Clarifying and strengthening the regulation of Artificial Intelligence (AI) - Closes on 13 October 2024 - [link](#)
- Consultation: Proposed amendments to the Poisons Standard – ACMS and Joint ACMS-ACCS meetings, November 2024 - Closes on 22 October 2024 – [link](#)
- Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS JUNE, 2024 - Closes on 18 October 2024 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 172](#): Utility of common investigations for suspected inflammatory arthritis in adults

MJA Podcasts

- [Episode 24](#): Interventional techniques in stroke treatment

Purple Pen Podcast

- [PPP 165](#): Fever with A/Prof Rebekah Moles
- [PPP 166](#): Special Episode World Pharmacist Day 2024 - Pharmacist Wellbeing with Dr Karlee Johnston

UPCOMING EVENTS

AHHA

- 'Cyber safety is patient safety': Lessons from the U.S. on securing the health system from cyber attacks - October 3, 2024 08:00-09:00 AEST – [link](#) - [register](#)
- The John Deeble Lecture and Panel Discussion, Beyond boundaries: leadership for health - National Museum of Australia, Canberra, ACT - October 15, 2024 09:00-16:00 AEST – [register](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- First national Chronic Obstructive Pulmonary Disease Clinical Care Standard Launch, with expert panel discussion - Thursday 17 October 12:00–13:00 AEDT - [register](#)
- NMS 2024: Ageing well: safe medicines, better lives – Tuesday, 19 November 2024 10.00- 15.00 - [Register](#)

Institute for Healthcare Improvement-BMJ Group

- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – [registration](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

TGA

- Product standards for therapeutic vaping goods webinar - an overview of changes to the product standards commencing early 2025 - Thursday 3 October 2024 12:00-13:00 AEST - [register](#)

Fortnightly TAG Mail – resources list 12th September 2024

NSW TAG ACTIVITIES

2024 Meetings

NSW TAG General Meetings

- 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs Closes September 14th 2024

Recently completed email discussions and surveys

- Protocols for critical medicines in NSW public facilities
- Ongoing infliximab for immune therapy colitis
- Handling of medicines by perfusionists

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

Age and Ageing: Evaluation of glucose-lowering medications in older people - [link](#)

AJHP: Human microbiome: Impact of newly approved treatments on C. difficile infection - [link](#)

BJCP: Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022 - [link](#)

BJCP: Developing a process to measure actual harm from medication errors in paediatric inpatients - [link](#)

BJGP: Primary prevention of cardiovascular disease in people living with HIV: a clinical update - [link](#)

BMJ Open: Enhancing the efficacy of healthcare information websites - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

BMJ QS: Editorial- the key to effectiveness of large-scale pharmacist-led medication reviews? - [link](#)
Cochrane: Immunomodulators and immunosuppressants for progressive multiple sclerosis- [link](#)
IMJ: The Australian Team Approach to Polypharmacy Evaluation and Reduction (AusTAPER) hospital study- [link](#)
IMJ: Active deprescribing attitudes and practices in a large regional tertiary health service - [link](#)
IJQHC: Identification of risk factors for adverse drug events in a general hospital - [link](#)
IJQHC: Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)
JAMA: Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery - [link](#)
JAMA: The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits - [link](#)
JAMA Dermatology: Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis- [link](#)
JAMA Oncology: Externally Controlled Studies Using Real-World Data in Patients with Hematological Cancers - [link](#)
JAMA Psychiatry: Adverse Events in Studies of Classic Psychedelics - [link](#)
JGIM: Vitamin D Supplementation and the Incidence of Fractures in the Elderly Healthy Population- [link](#)
JPPR: A surgical preadmission pharmacist service in a tertiary paediatric hospital: a pilot study - [link](#)
Lancet: Mineralocorticoid receptor antagonists in heart failure - [link](#)
Lancet GH: Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC) - [link](#)
Lancet RM: An international consensus on the use of asthma biologics in pregnancy - [link](#)
MDPI: Drug Shortage and Ethical Issues - [link](#)
MDPI: Evaluation of Anti-Xa Target Attainment with Prophylactic Enoxaparin Dosing Regimens for Venous Thromboembolism Prophylaxis in Morbidly Obese Patients - [link](#)
MJA: Pharmaceuticals in pregnancy: a multifaceted challenge in Australia - [link](#)
MJA: Calling time on the use of modified-release opioids for acute pain - [link](#)
NEJM: Inflammation, Cholesterol, Lipoprotein(a), and 30-Year CV Outcomes in Women - [link](#)
Paediatrics: Improving Timely Administration of Essential Outpatient Medications in a Pediatric ED - [link](#)
Pharmacotherapy: Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management - [link](#)

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Antimicrobial use in the community falls overall, but use in aged care on the rise - [link](#)

CATAG

- Launch of MAIA: Medicines and the kidney toolkit - [link](#)

NSW Health

- NSW Health Research Handbook - [link](#)

- NSW Health Services Functional Area Supporting Plan (NSW HEALTHPLAN) ([PD2024_029](#))

Advanced Pharmacy Australia

- previously Society of Hospital Pharmacists of Australia- [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Medicines Handbook

- renaming and restructure of the [anticancer drugs](#) and [immunomodulators](#) chapters, including revision of the [General principles: immunomodulators](#) section

- new drugs, eg [tirzepatide](#) for type 2 diabetes, and new drug classes, eg [sphingosine 1-phosphate receptor modulators](#) for MS

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- new indications, eg [melatonin](#) for jet lag, [empagliflozin](#) for chronic kidney disease
- new drug interactions, eg [ticagrelor + rosuvastatin](#)
- treatment of [hypertension in pregnancy](#) revised, in line with updated guidelines
- severe GI adverse effects and pre-surgery considerations added for [GLP-1 analogues](#)

Australian Institute for Health and Welfare (AIHW)

- GEN Aged Care data 2022-23 updates - [link](#)
- Essential Vaccines: performance report 2022–23 - [link](#)
- Medicare Benefits Scheme funded services: monthly data – [update](#)

MIMS monthly updates

- New Products
 - Bulevirtide (acetate) ([Hepcludex](#)) for chronic HDV infection in adults with compensated liver disease
 - Icosapent ethyl ([Vazkepa](#)) capsules containing icosapent ethyl 998 mg to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated TG (≥ 1.7 mmol/L) and either established cardiovascular disease; or diabetes and at least one other cardiovascular risk factor. Vazkepa is contraindicated in patients with hypersensitivity to soya
- New Presentation
 - Atezolizumab ([Tecentriq SC](#)) available as solution for SC injection containing 1875 mg/15 mL
- New indications
 - Ceftolozane (sulfate) and tazobactam (sodium) ([Zerbaxa](#)) for paediatric (birth to less than 18 years of age) patients with complicated intra-abdominal infections in combination with metronidazole; and, complicated urinary tract infections including pyelonephritis, caused by designated susceptible microorganisms
 - Pembrolizumab (rch) ([Keytruda](#)) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment for resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC; and, in combination with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract carcinoma

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
 - [Polivy](#) (Polatuzumab vedotin) for adults with previously untreated diffuse large B-cell lymphoma
 - [Enhertu](#) (trastuzumab deruxtecan) for adults with unresectable or metastatic HER2-low breast cancer
 - [Onakta](#) (tirbanibulin) for topical field treatment of actinic keratosis of the face or scalp in adults
 - [Wegovy](#) for weight management in obese adolescents ages 12 years and above (as an adjunct to a reduced-calorie diet and increased physical activity)
 - [Wegovy](#) (semaglutide) as adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults
 - [Xeljanz](#) (tofacitinib) for ankylosing spondylitis and active polyarticular course juvenile idiopathic arthritis

Victorian Institute of Forensic Medicine

- Residential Aged Care Communiqué Volume 19 Issue 3 [August 2024](#)

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- All Wales Medicines Strategy Group updates primary care antimicrobial guidelines - [link](#)
- National Prescribing Indicators in Wales 2022–2025 – August 2024 [update](#)

Agency for Healthcare Research and Quality (AHRQ) USA

- Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: 2024 Update of the Evidence Base for the PTSD Trials Standardized Data Repository - [link](#)

Canadian Agency for Drugs and Technologies in Health

- Drug Shortages and Patient Harms - [link](#)
- Safety of Ozempic for Type II Diabetes - [link](#)

Compassion in Dying UK

- Rethinking the UK's approach to dying: Lessons from an end-of-life helpline - [link](#)

Department of Health and Social Care

- Revised recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Agilus (dantrolene) 120 mg powder for solution for injection, in combination with adequate support measures, for malignant hyperthermia in adults and children
- Imraldi (adalimumab) 40 mg in 0.4mL prefilled pen/syringe, indications as for originator Humira
- Leqembi (lecanemab) for mild cognitive impairment and mild dementia due to Alzheimer's disease in adults that are ApoE ε 4 heterozygotes or non-carriers
- Skyrizi (risankizumab) 180 mg solution for injection in cartridge, new strength/presentation, for Crohn's disease and ulcerative colitis. (360mg cartridge, 600mg infusion also available)
- Steqeyma (ustekinumab) 45 mg pre-filled syringe for plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis and Crohn's disease. Unlike the originator product, Stelara, it is not licensed for UC

Food and Drug Administration (FDA) USA

- FDA grants emergency use authorisation for updated Novavax COVID-19 vaccine to target currently circulating variants - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- MHRA approves Spikevax JN.1 COVID-19 vaccines for adults and children from infancy - [link](#)

Monthly Index of Medical Specialities (MIMS) UK

- MIMS summary: Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg) for the symptomatic treatment of endometriosis - [link](#)

NHS England

- Decision support tool: making a decision about ... [glue ear if your child has hearing loss](#) - [stable angina](#) - [managing depression](#) - [to help you live well with chronic primary pain](#)

NHS Scotland - Scottish Medicines Consortium

- Accepted for use:
 - [Dabrafenib](#) (Finlee) in combination with trametinib (Spexotras) for paediatric patients 1 year +
 - [Elranatamab](#) (Elrexfio) on an interim basis subject to ongoing evaluation and future reassessment as monotherapy for relapsed & refractory multiple myeloma, who have received ≥3 prior therapies, including an immunomodulatory agent, proteasome inhibitor & an anti-CD38 antibody & demonstrated disease progression on the last therapy
 - [Ivosidenib](#) (Tibsovo) as monotherapy for adult locally advanced or metastatic cholangiocarcinoma
 - [Teclistamab](#) (Tecvayli) as monotherapy for adult relapsed and refractory multiple myeloma

National Institute for Health and Care Excellence (NICE) UK

- Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma ([TA997](#))
- Vibegron for treating symptoms of overactive bladder syndrome ([TA999](#))
- Iptacopan for treating paroxysmal nocturnal haemoglobinuria ([TA1000](#))
- Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment ([TA1001](#))
- Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over ([TA1002](#))
- Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over ([TA1003](#))

- Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion ([TA1004](#))
- Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement ([TA1005](#))

National Institute for Health and Care Research (NIHR)

- Community-based complex interventions to sustain independence in older people, stratified by frailty: a systematic review and network meta-analysis - [link](#)
- Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis - [link](#)
- The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation - [link](#)
- Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT - [link](#)
- NIHR commentaries: How to choose the right antidepressant or antipsychotic - [link](#)
- Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis - [link](#)
- Initial assessment and management of adults with suspected acute respiratory infection: a rapid evidence synthesis of reviews and cost-effectiveness studies - [link](#)
- Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT - [link](#)
- NIHR Collection: Can stratified care help primary care teams manage long-term conditions? - [link](#)

Neonatal & Paediatric Pharmacists Group UK

- The use of calcium and phosphate supplementation in neonates and children: updated position statement - [link](#)

The King's Fund

- 10 early actions the government can take to improve NHS working conditions - [link](#)

UK Health Security Agency

- Complete routine immunisation schedule – incl (RSV) for pregnant women and older adults - [link](#)
- Updated guidance - Gonorrhoea: guidance, data and analysis - [link](#)

World Health Organisation (WHO)

- Guidance on wastewater and solid waste management for manufacturing of antibiotics - [link](#)
- WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- ChloroPrep (chlorhexidine gluconate, isopropyl alcohol) - previous warning on eyes and mucous membranes updated in line with PRAC recommended wording, and details on eyes toxicity added
- Diclofenac 2.32% gel - additional information on why the medicine is contraindicated during the third trimester of pregnancy
- Dobutamine – asthmatic patients with hypersensitivity to sulfites and phaeochromocytoma added as contraindications. It is recommended that hypovolaemia is corrected before dobutamine is administered and it is noted that entacapone may potentiate the effects of dobutamine
- Evkeeza (evinacumab) for use 5 years and older (previously ≥ 12 years); additional ADR of fatigue noted in 15% of those aged ≥ 5 to 11 in a small study
- Fobumix Easyhaler 80/4.5 inhalation powder (budesonide, formoterol fumarate dihydrate) - use extended to children and adolescents
- Jaydess (levonorgestrel) - updated to increase awareness that use of excessive force during removal of the intrauterine device may cause breakage of the system. It is recommended that after removal, the system should be examined to ensure it is intact and has been completely removed

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Kymriah cells dispersion for infusion (tisagenlecleucel) updated to state that T-cell malignancies have been reported following treatment with CAR-T cell therapy. It is advised that patients should be monitored life-long for secondary malignancies following treatment
- Li-Liquid (lithium citrate) - information included about lithium-topiramate interaction
- Ninlaro (ixazomib) - pyrexia and arthralgia added as very common ADRs (all grades)
- Nutriflex - "due to the risk of developing a severe lactic acidosis and/or a Wernicke encephalopathy, a preexisting thiamin (Vitamin B1) deficiency must be corrected before infusion of glucose containing solutions."
- Palexia (tapentadol) SR - updated for use in children aged above 6 years and adolescents, for severe chronic pain, which can be adequately managed only with opioid analgesics
- Propofol - hepatomegaly added as a potential ADR of unknown frequency
- Relevtec (buprenorphine) patch – concomitant use with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death; advice on drug dependence included
- Remsima (infliximab) three IV induction doses for Crohn's disease (CD) and ulcerative colitis added, and the possibility for dose adjustment from 120mg to 240mg (subcutaneous) for patients with CD with loss of response
- Ryeqo 40mg/1mg/0.5mg (estradiol hemihydrate, norethisterone acetate, relugolix) for endometriosis in women with history of previous medical/surgical endometriosis treatment. Information about bone density monitoring with DXA scans, and updated ADR trial information added
- Saxenda (liraglutide) - intestinal obstruction added as an ADR of unknown frequency
- Signifor (pasireotide) - steatorrhoea and discoloured faeces added as ADRs of unknown frequency
- Velcade (bortezomib) - genotoxic potential, women of childbearing potential must use effective contraception & avoid pregnancy during & for 8 months after treatment. Male patients should use effective contraception & not father a child during & for 5 months after treatment
- Risk minimisation materials
- Fabhalta (iptacopan hydrochloride monohydrate) – HPs brochure aims to provide guidance and mitigate possible risk of infections during iptacopan treatment, and haemolysis after discontinuation. A patient and caregiver guide and patient safety card are also available

EMA

- Metamizole: measures to minimise the serious outcomes of known risk of agranulocytosis - [link](#) - [link](#)
- Medroxyprogesterone: increased risk of meningioma with high doses and after prolonged use - [link](#)
- Medicines for chemotherapy containing 5-fluorouracil: in patients with moderate or severe renal impairment, phenotyping for dihydropyrimidine dehydrogenase (DPD) deficiency by measuring blood uracil levels should be interpreted with caution - [link](#)

Health Canada – MedEffect Notice

- Health Product InfoWatch: [August 2024](#)

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Pharmacovigilance following agreement of the Windsor Framework - [link](#)
- Valproate use in men: as a precaution, men and their partners should use effective contraception - [link](#) ; Valproate safety measures - [updated](#)
- Finds evidence does not support a link between Glucagon-Like Peptide-1 (GLP-1) receptor agonists and suicidal and self-injurious thoughts and actions - [link](#)
- Early Access to Medicines Scheme: Overview - [link](#)

MIMS monthly updates

- New Contraindications
- Atazanavir ([Reyataz](#)) with irinotecan and drugs that are strong inducers of CYP3A4
- Colistin (as colistimethate sodium) ([Colistin Link](#)) in patients with myasthenia gravis
- Dorzolamide (hydrochloride) ([Trusopt](#)) in patients with severe renal impairment (CrCl < 30 mL/min) or with hyperchloremic acidosis
- Safety Related Changes
- Influenza virus (inactivated, surface Ag) quadrivalent vaccine ([Influvac Tetra](#)) is no longer contraindicated in patients with hypersensitivity to egg protein

-- Ritonavir ([Norvir](#)) is no longer contraindicated for concomitant use with piroxicam

Specialist Pharmacy Services NHS UK

- Medication Safety Update: [August 2024](#)

TGA

- Orencia (abatacept) subcutaneous medicines shortages have resolved - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Cooling the flames: Navigating menopausal vasomotor symptoms with nonhormone medications - [link](#)

- Exploring combination treatment options for persistent methicillin-susceptible *Staphylococcus aureus* bacteremia - [link](#)

- Human microbiome: Impact of newly approved treatments on *C. difficile* infection - [link](#)

- The evolution of evidence-based medicine - [link](#)

Annals of Internal Medicine

- Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention - [link](#)

- Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022) - [link](#)

- Long-Term Effects of Individualized Acupuncture for Chronic Neck Pain: A Randomized Controlled Trial - [link](#)

- Complementary and Alternative Therapies for Genitourinary Syndrome of Menopause: An Evidence Map - [link](#)

- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review - [link](#)

Arthritis & Rheumatology

- Emapalumab Use in Patients with Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis in the United States: the REAL-HLH Study - [link](#)

British Journal of Clinical Pharmacology

- Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database - [link](#)

- Safe and supportive prescribing in transgender and non-binary patients with cancer - [link](#)

- Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022 - [link](#)

- Antidotes for poisoning by alcohols that form toxic metabolites - [link](#)

- Clinical characteristics and risk factors for antituberculosis drug-induced hypersensitivity - [link](#)

- Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: A retrospective cohort study - [link](#)

- Medication adherence for people with acquired communication disorders: A systematic review - [link](#)

- Developing a process to measure actual harm from medication errors in paediatric inpatients: from design to implementation - [link](#)

British Journal of General Practice

- Primary prevention of cardiovascular disease in people living with HIV: a clinical update - [link](#)

British Medical Journal (BMJ)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study - [link](#)
- Covid inquiry: the flaws that led to system failure - [link](#)
- Whooping cough: Why have vaccination rates plummeted in pregnant women? - [link](#)
- Practical Prescribing: Direct oral anticoagulants - [link](#)
- Practice 10-Minute Consultation: Chronic cough in preschool aged children - [link](#)
- Cholera: Data show marked increase in cases and deaths globally - [link](#)

BMJ Open

- Enhancing the efficacy of healthcare information websites: a case for the development of a best practice framework - [link](#)

BMJ Quality and Safety

- Editorial: Integration and connection: the key to effectiveness of large-scale pharmacist-led medication reviews? - [link](#)

Circulation

- Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis - [link](#)
- Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults with Treated Type 2 Diabetes: A Target Trial Emulation - [link](#)
- Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials - [link](#)
- Flecainide to Prevent Atrial Arrhythmia after Patent Foramen Ovale Closure, the AFLOAT Study: A Randomized Clinical Trial - [link](#)
- Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial – [link](#)
- Comparison of American and European Guideline Recommendations for Diagnostic Workup and Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack - [link](#)
- Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial - [link](#)

Cochrane

- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis - [link](#)
- Donor human milk for preventing necrotising enterocolitis in very preterm or very low-birthweight infants - [link](#)
- Stem cell treatment for acute myocardial infarction – [link](#)
- Transitional discharge interventions for people with schizophrenia - [link](#)
- Local corticosteroid injection versus surgery for carpal tunnel syndrome - [link](#)

Diabetes Care

- Diabetes, Prediabetes, and Brain Aging: The Role of Healthy Lifestyle - [link](#)

Drug and Therapeutics Bulletin

- Icosapent ethyl for CV risk reduction - [link](#)
- Supporting the treatment of obesity - [link](#)

EClinicalMedicine

- Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: [2024 update](#)

European Heart Journal

- Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial - [link](#)
- 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the

management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO) - [link](#)

- 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) - [link](#)
- 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO) - [link](#)
- 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM) - [link](#)
- Obesity and cardiovascular disease: an ESC clinical consensus statement - [link](#)
- Aspirin versus Clopidogrel Monotherapy After Percutaneous Coronary Intervention: 1-Year Follow-up of the STOPDAPT-3 Trial - [link](#)
- Gender and contemporary risk of adverse events in atrial fibrillation - [link](#)
- Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry - [link](#)
- Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy - [link](#)
- Semaglutide and blood pressure: an individual patient data meta-analysis - [link](#)
- Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry - [link](#)
- Management of aortic disease in children with FBN1-related Marfan syndrome: A joint statement from the paediatric subgroup of the European Reference Network of Vascular Diseases (VASCERN, Heritable Thoracic Aortic Disease working group) and the Association for European Paediatric and Congenital Cardiology (AEPC) - [link](#)

European Journal of Hospital Pharmacy

- Reimagining the ADR Alert Card: a novel approach to recurrence prevention in low-cost settings for adverse drug reactions - [link](#)
- Letter: Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights - [link](#)
- Development of hospital clinical pharmacy services in Denmark from 2008 to 2023 - [link](#)
- Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts' interviews - [link](#)
- Case report: Therapeutic drug monitoring of inhaled tobramycin in a patient with chronic kidney disease - [link](#)

Heart

- Percutaneous coronary intervention plus medical therapy versus medical therapy alone in chronic coronary syndrome: a propensity score-matched analysis from the Swedish Coronary Angiography and Angioplasty Registry - [link](#)

Internal Medicine Journal

- 6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy - [link](#)
- The Australian Team Approach to Polypharmacy Evaluation and Reduction (AusTAPER) hospital study: effect of a collaborative medication review on the number of current regular medicines for older hospital inpatients - [link](#)
- Letter: Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib - [link](#)
- Letter: Insulin amyloidosis: an under-recognised entity - [link](#)
- Active deprescribing attitudes and practices in a large regional tertiary health service: a mixed methods study - [link](#)

International Journal of Clinical Pharmacy

- Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database - [link](#)
- Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence - [link](#)

International Journal for Quality in Health Care

- Identification of risk factors for adverse drug events in a general hospital - [link](#)
- Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)
-

JAMA

- Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial - [link](#)
- Patient Page: What Are Canker Sores? - [link](#) ; What Is Pertussis? - [link](#) ; What Is Plantar Fasciitis? - [link](#)
- Renal Cell Carcinoma: A [Review](#) ; Scabies, Bedbug, and Body Lice Infestations: A [Review](#)
- Greenhouse Gas Emissions and Costs of Inhaler Devices in the US - [link](#)
- Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial - [link](#)
- The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease - [link](#)
- Diagnosis, Risk Stratification, and Treatment of Pericarditis - [link](#)
- The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits - [link](#)

JAMA Cardiology

- Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials - [link](#)
- Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial - [link](#)
- Echoes of Concern—AI and Moral Agency in Medicine - [link](#)
- Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial - [link](#)

JAMA Dermatology

- Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial - [link](#)

JAMA Internal Medicine

- GLP-1 Receptor Agonist Use and Risk of Suicide Death - [link](#)
- Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology. Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials - [link](#)
- Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes - [link](#)

JAMA Neurology

- A Unique Case of Opioid-Induced Myoclonus - [link](#)

JAMA Oncology

- Externally Controlled Studies Using Real-World Data in Patients with Hematological Cancers: A Systematic Review - [link](#)
- Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis - [link](#)
- Identification of Immune Checkpoint Inhibitor-Induced Diabetes - [link](#)
- Patient Page: Caring for Your Heart During Cancer Treatment - [link](#)

JAMA Psychiatry

- Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis - [link](#)

Journal of the American College of Cardiology

- Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization - [link](#)

Journal of Clinical Oncology

- Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records - [link](#)

Journal of General Internal Medicine

- Vitamin D Supplementation and the Incidence of Fractures in the Elderly Healthy Population: A Meta-analysis of Randomized Controlled Trials - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- A surgical preadmission pharmacist service in a tertiary paediatric hospital: a pilot study - [link](#)
- The pharmacologic management of status epilepticus in pregnant patients: a scoping review - [link](#)
- Pharmacotherapy profile for mothers with schizophrenia and bipolar affective disorder in a psychiatric mother–baby unit - [link](#)

Lancet

- First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial - [link](#)
- Primary biliary cholangitis - [link](#) ; Respiratory Syncytial Virus - [link](#)
- De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials - [link](#)
- Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis - [link](#)
- Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children - [link](#)

Lancet Diabetes & Endocrinology

- Transitioning to stage 3 type 1 diabetes: when to start insulin - [link](#)
- Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials - [link](#)
- Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial - [link](#)

Lancet Gastroenterology and Hepatology

- Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial - [link](#)
- Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium - [link](#)
- Natural history and progression of metabolic dysfunction-associated steatotic liver disease - [link](#)

Lancet Infectious Diseases

- The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review - [link](#)
- Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 - [link](#)
- Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial - [link](#)

Lancet Oncology

- Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE - [link](#)

Lancet Psychiatry

- Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study - [link](#)
- Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study - [link](#)

Lancet Public Health

- Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis - [link](#)
- A public health approach to suicide prevention - [link](#)

Lancet Respiratory Medicine

- An international consensus on the use of asthma biologics in pregnancy - [link](#)
- Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients - [link](#)
- Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- An Internationally Derived Process of Healthcare Professionals' Proactive Deprescribing Steps and Constituent Activities - [link](#)
- Drug Shortage and Ethical Issues: Integrating Multidisciplinary Perspectives with a Shared Ethical Framework - [link](#)
- The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study - [link](#)
- Evaluation of Anti-Xa Target Attainment with Prophylactic Enoxaparin Dosing Regimens for Venous Thromboembolism Prophylaxis in Morbidly Obese Patients - [link](#)
- Effective Supply Chain Strategies in Addressing Demand and Supply Uncertainty: A Case Study of Ethiopian Pharmaceutical Supply Services - [link](#)

Medical Journal of Australia

- Pharmaceuticals in pregnancy: a multifaceted challenge in Australia - [link](#)
- Calling time on the use of modified-release opioids for acute pain - [link](#)
- Hidden danger: maize starch excipient allergy – [link](#) - [letter](#)

Neurology

- Effect of Ubrogapant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results from the Randomized PRODROME Trial - [link](#)

New England Journal of Medicine

- Mpox in Pregnancy — Risks, Vertical Transmission, Prevention, and Treatment - [link](#)
- The Mpox Global Health Emergency — A Time for Solidarity and Equity - [link](#)
- Beta-Blocker Interruption or Continuation after Myocardial Infarction - [link](#)
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy - [link](#)
- Asundexian versus Apixaban in Patients with Atrial Fibrillation - [link](#)
- Continuation versus Interruption of Oral Anticoagulation during TAVI - [link](#)
- Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease - [link](#)
- Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction - [link](#)
- Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women - [link](#)
- Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk - [link](#)
- Invasive Treatment Strategy for Older Patients with Myocardial Infarction - [link](#)
- A Monoclonal Antibody to PACAP for Migraine Prevention - [link](#)
- Adjunctive Intravenous Argatroban or Eptifibatid for Ischemic Stroke - [link](#)
- Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma - [link](#)
- Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype - [link](#)

Pediatrics

- Improving Timely Administration of Essential Outpatient Medications in a Pediatric ED - [link](#)

Pharmacotherapy

- Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018 - [link](#)
- Influence of intravenous iron on bacterial infection risk immediately following kidney transplantation - [link](#)
- Real-world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study - [link](#)
- Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management - [link](#)
- Physiologically based pharmacokinetic models for predicting lamotrigine exposure and dose optimization in pediatric patients receiving combination therapy with carbamazepine or valproic acid - [link](#)

Prescribe International – September 2024 including:

- Editorial: Phasing out patient leaflets in paper form: eco-responsible or irresponsible? - [link](#)
- Selinexor (Nexpovio) in relapsed or refractory multiple myeloma: not acceptable
- Bupropion + naltrexone (Mysimba) for weight loss: set to be withdrawn from the market in the European Union?
- In-utero exposure to corticosteroids: increased risk of serious infections during the first year of life

Prescriber UK

- The management of chronic hepatitis B - [link](#) ; Current treatments in schizophrenia - [link](#)

CONSULTATIONS

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Stroke Intravenous Thrombolysis – closes 4 October 2024 - [link](#)
- Consultation - Organisational Models of Care and Clinical Priorities Brief for Older People Living with Frailty – closes 27 September 2024 – [link](#)

TGA

- Consultation: 2024-2025 Proposed changes to the Permissible Ingredients Determination – Low-negligible risk - closes on 13 September 2024 - [link](#)
- Consultation: Draft Guidance - Regulatory changes for medical devices containing medicinal substances or materials of animal, microbial or recombinant origin - closes on 9 October 2024 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 171](#) – Controversies in the management of community-acquired pneumonia in adults

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- NMS 2024: Ageing well: safe medicines, better lives – Tuesday, 19 November 2024 10.00- 15.00 - [Register](#)

Australian Healthcare and Hospitals Association (AHHA)

- National Rural Health Conference, Perth Convention & Exhibition Centre - September 16-18, 2024 – [register](#)
- AHHA Member Roundtable: Meet the Chief Health Economist – online - September 24, 2024 12:00-13:30 AEST – [register](#)

Deeble Institute-AHHA

- The John Deeble Lecture and Panel Discussion, Beyond boundaries: leadership for health - National Museum of Australia, Canberra, ACT - October 15, 2024 09:00-16:00 AEST – [register](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Safer Care Victoria

- For World Sepsis Day on Friday 13 September
- Understanding Sepsis: Awareness, Prevention, and Action Across All Ages, online clinical conversation - Thursday 19 September at 2pm (AEST) – [register](#)
- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – [registration](#)

Society of Hospital Pharmacists (SHPA) now called AdPha

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

Fortnightly TAG Mail – resources list 29th August 2024

NSW TAG ACTIVITIES

2024 Meetings

NSW TAG General Meetings

- 6th September 10-11.30am
- 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs Closes September 14th 2024

Recently completed email discussions and surveys

- Protocols for critical medicines in NSW public facilities
- Ongoing infliximab for immune therapy colitis
- Handling of medicines by perfusionists

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Clinical review of substitutions or alternatives for critical chemotherapy drug shortages in hematologic malignancies - [link](#)

AJHP: An international, multicenter post hoc analysis comparing in-person and virtual medication management strategies in post-ICU recovery clinics - [link](#)

AJM: Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - [link](#)

AIM: How Would You Treat This Inpatient with Type 2 Diabetes Mellitus? Grand Rounds Discussion from Beth Israel Deaconess Medical Center - [link](#)

AIM: Kratom: An Emerging Issue for Research and Physician Education - [link](#)

AP: Editorial: Achieving safe medication management during transitions of care from hospital: time for a stewardship approach - [link](#)

BJCP: - Promoting medication safety for older adults upon hospital discharge: Guiding principles for a medication discharge plan - [link](#)

BJCP: The effect of deprescribing interventions on mortality and health outcomes in older people: An updated systematic review and meta-analysis - [link](#)

BMJ: Opinion: Does the METHOD study show that ZOE works? - [link](#)

BMJ: Reducing drug waste in hospitals - [link](#)

BMJ QS: Assessing patient work system factors for medication management during transition of care among older adults: an observational study - [link](#)

CPJ: - Harmonizing leadership: Blending transactional and transformational styles in pharmacy practice - [link](#)

DTB: Medicines optimisation opportunities: driving change? - [link](#)

EHJ: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Heart: Treating iron deficiency in patients with heart failure: what, why, when, how, where and who - [link](#)
IJCP: Medication errors in emergency departments: a systematic review and meta-analysis of prevalence and severity - [link](#)
IMJ: - Initiating or switching to insulin degludec/insulin aspart in a real-world population of adults with type 2 diabetes in Australia: results from a prospective, non-interventional study - [link](#)
JAGS: - Discontinuation versus continuation of statins: A systematic review - [link](#)
JAMA: - Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions - [link](#)
MJA: - Outcomes for people admitted to Australian and New Zealand intensive care units with primary, exacerbating, or incidental SARS-CoV-2 infections, 2022–23 - [link](#)
PJ: Weekly medicines data to be collected from hospital electronic prescribing systems - [link](#)
PJ: More than 2000 patients tested in UK's first routine genotyping project for clopidogrel prescribing - [link](#)
NICE: Alzheimer's treatment, lecanemab, benefits too small to justify the cost to the NHS - [link](#)

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Join the conversation on medicines in an ageing population - [link](#)
- New Framework driving healthcare improvements - [link](#)
- Update on the Framework for Clinical Quality Registries - [link](#)

NSW Health

- Warning: High-dose MDMA tablets (ecstasy) circulating in NSW - [link](#)
- Be aware of mpox symptoms as number of cases rise - [link](#); Everything you need to know about Mpox - [link](#)
- NSW Health Accessible Communications ([PD2024_028](#))

Pharmacy Board of Australia

- Applying your code of conduct to evolving technologies - AI in healthcare - [link](#)

TGA

- New quality standards for MDMA and psilocybine - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

- Flexible diuretic regimen: [Clinical practice guide](#) ; [Evidence check](#)
- Evidence brief: Menopause model of [care](#); Managing bone [health](#) ; ... and more

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Osteoarthritis of the Knee Clinical Care [Standard](#) – [infographic](#) – [media release](#)
- National Safety and Quality Primary and Community Healthcare Standards Guide for healthcare services - [link](#)
- The Aged Care Infection Prevention and Control Guide - [link](#)
- Antimicrobial use in the community: [2023](#)
- AI Implementation in Hospitals: Legislation, Policy, Guidelines and Principles, and Evidence about Quality and Safety. Literature Review and Environmental Scan Report - [link](#)

Australian Government Department of Health

- Eighth Community Pharmacy Agreement fact sheets - [link](#)
- New payments under the Eighth Community Pharmacy Agreement - [link](#)
- Webinars 1 and 2: Aged Care Reforms – Impacts on the Multi-Purpose Service (MPS) program and providers - [link](#) and [link](#)
- COVID-19 outbreaks in Australian residential aged care facilities - [link](#)
- Shield yourself from shingles – Resources collection - [link](#)
- COVID-19 vaccines in Australia – A3 poster - [link](#)
- National Roadmap to Improve the Health and Mental Health of Autistic People – Information webinar - [link](#)
- ATAGI statement on the transition from quadrivalent to trivalent seasonal influenza vaccines in Australia - [link](#)
- Avian influenza in humans – CDNA National Guidelines for Public Health Units - [link](#)
- Department of Health and Aged Care organisational chart - [link](#)

Australian Institute for Health and Welfare (AIHW)

- Cancer data in Australia – [update](#) ; COVID-19 Register: linkage results – [update](#) ; Mesothelioma in Australia [2023](#) ; GEN: Aged care data [2023](#) ; Potentially preventable hospitalisations in Australia by small geographic areas, [2020–21 to 2021–22](#)

PBS

- Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – July 2024 - [23 August 2024](#) ; PBAC Update August 2024 - [19 August 2024](#)
- New PBS listing for migalastat (Galafold) for Fabry disease - [19 August 2024](#)
- Publication of 12-month review of Minimum Stockholding Requirements and Excel breach notification form - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
 - [Spy Agent Green](#) - imaging agent for the fluorescence imaging of vessels, blood flow, tissue perfusion, extrahepatic biliary ducts, lymph nodes and lymphatic vessels
 - Tevimbra ([tislelizumab](#)) for oesophageal squamous cell carcinoma and non-small cell lung cancer
 - [Radicava](#) for amyotrophic lateral sclerosis patients who are independent in activities of daily living with normal respiratory function and where treatment is initiated within two years of disease onset
 - [Sidapvia](#) (dapagliflozin+sitagliptin) for type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycaemic control
 - Sohonos ([palovarotene](#)) for heterotopic ossification in individuals with fibrodysplasia ossificans progressiva
 - Winlevi ([clascoterone](#)) cream for acne vulgaris in patients 12 years of age or older
 - [Xenpozyme](#) - enzyme replacement therapy for the treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency in paediatric and adult patients with Niemann-Pick disease (types A/B or B)
 - [Nelarabine-Reach](#) for relapsing /refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
 - [Rinvog](#) for adults with active non-radiographic axial spondyloarthritis
- Australian prescription medicine decision summaries:
 - Fabhalta ([iptacopan](#)) for adult patients with paroxysmal nocturnal haemoglobinuria
 - Hepcludex ([bulevirtide acetate](#)) for chronic hepatitis delta virus infection in adults with compensated liver disease

REPORTS AND PUBLICATIONS – INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA

- Treatment of Stage I-III Squamous Cell Anal Cancer - [link](#)
- Diagnosis and Management of Adult Attention Deficit Hyperactivity Disorder - [overview](#)

British Menopause Society

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
 An initiative of NSW clinical pharmacologists & pharmacists
 ABN: 82 707 308 091

- Testosterone warning from British Menopause Society - [link](#)

British National Formulary

- BNF/BNFC newsletter: [August 2024](#)

Canadian Agency for Drugs and Technologies in Health

- Review of Guidelines on Clonidine for Various Indications - [link](#)
- Efficacy and Safety of Treatment Options for Uncomplicated Gonococcal Infections - [link](#)
- Evidence Review of Treatment Options for Uncomplicated Gonococcal Infections - [link](#)
- Re-treatment with Immune Checkpoint Inhibitors - [link](#)

Department of Health and Social Care UK

- Temporary ban on prescription and supply of puberty blockers extended - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated) for prophylaxis of influenza in the elderly (65 years of age and older). It complies with the WHO recommendations (Northern Hemisphere) and EU recommendation for the 2024/2025 season
- Amgevita HCF (adalimumab) biosimilar licensed for rheumatoid arthritis, juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, psoriasis, Crohn's disease, ulcerative colitis, and uveitis
- Cell-based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus for prophylaxis of influenza in adults and children from 6 months of age. It should be used in accordance with official recommendations
- Emblaveo (aztreonam/avibactam) for adults with complicated intra-abdominal infection, hospital-acquired pneumonia, including ventilator-associated pneumonia, complicated UTI including pyelonephritis, and infections due to aerobic Gram-negative organisms when treatment options are limited
- Fabhalta (iptacopan hydrochloride monohydrate) - monotherapy for adults with paroxysmal nocturnal haemoglobinuria who have haemolytic anaemia
- Metalyse (tenecteplase) 5000 units (25mg) injection for use in adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from time last known well and after exclusion of intracranial haemorrhage
- Piasky (crovalimab) 340mg injection/infusion - IgG1-based monoclonal antibody for patients (≥12 years, ≥40kg) with paroxysmal nocturnal haemoglobinuria, who have haemolysis & symptoms indicative of high disease activity, or are clinically stable after use of complement component 5 inhibitor for ≥ 6 months
- Pyzchiva (ustekinumab) - biosimilar - not yet approved for use in ulcerative colitis like reference
- Xolair (omalizumab) - new pen presentation (already available pre-filled syringes) for adults, adolescents and children (≥6 years) with allergic asthma, adults with chronic rhinosinusitis with nasal polyps and adults and adolescents with chronic spontaneous urticaria
- Yselty (linzagolix) 200mg tablet - selective, non-peptide gonadotropin-releasing hormone receptor antagonist for moderate to severe symptoms of uterine fibroids in adult women of reproductive age

Food and Drug Administration (FDA) USA

- New Drug approvals
- lazertinib ([Lazcluze](#)) with amivantamab-vmjw ([Rybrevant](#)) for non-small cell lung cancer
- also authorises updated [mRNA COVID-19 vaccines](#) to better protect against currently circulating variants
- neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer - [link](#)
- axatilimab-csfr ([Niktimvo](#)) for chronic graft-versus-host disease - [link](#)
- vorasidenib ([Voraniqo](#)) for Grade 2 astrocytoma or oligodendroglioma - [link](#)
- seladelpar ([Livdelzi](#)) for primary biliary cholangitis (PBC)
- nemolizumab-ilotto ([Nemluvio](#)) for prurigo nodularis
- first nasal spray for treatment of anaphylaxis - [neffy](#) (epinephrine nasal spray)
- first nalmeferene hydrochloride auto-Injector to reverse opioid overdose – [Zurnai](#) - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

-- denileukin diftiox-cxdl ([Lymphir](#)) for R/R Cutaneous T-Cell Lymphoma

Health Quality & Safety Commission New Zealand

- New guides to manage stress urinary incontinence - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- Approves zolbetuximab to treat adults with stomach or gastro-oesophageal junction (GEJ) cancer - [link](#)

- Lecanemab (Leqembi) licensed in UK for patients in the early stages of Alzheimer's disease - [link](#)

Monthly Index of Medical Specialities (MIMS) UK

- MIMS summary: Launch in UK of osteoporosis treatment [abaloparatide](#) (Eladynos)

NHS England

- NHS England published position on access to medicines procurement and supply chain (formerly known as Commercial Medicines Unit) frameworks - [link](#)

- Clinical commissioning statement: plerixafor use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above) - [link](#)

- RightCare dementia scenario - [link](#) ; RightCare cystic fibrosis toolkit - [link](#)

NHS Scotland - Scottish Medicines Consortium

- Accepted for use:

-- [Etranacogene dezaparvovec](#) (Hemgenix®) - on an interim basis for severe and moderately severe haemophilia B (congenital factor IX deficiency) in adults without a history of factor IX inhibitors

-- [Trifluridine/tipiracil](#) (Lonsurf®) - in combination with bevacizumab for adults with metastatic colorectal cancer (CRC)

National Institute for Health and Care Excellence (NICE) UK

- Abaloparatide for treating osteoporosis after menopause ([TA991](#))

- Burosumab for treating X-linked hypophosphataemia in adults ([TA993](#))

- Diabetic retinopathy: management and monitoring ([NG242](#))

- Linzagolix for treating moderate to severe symptoms of uterine fibroids ([TA996](#))

- Relugolix for treating hormone-sensitive prostate cancer ([TA995](#))

- Risankizumab for treating moderately to severely active ulcerative colitis ([TA998](#))

- Adrenal insufficiency: identification and management [[NG243](#)]

- Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS - [link](#)

National Institute for Health and Care Research (NIHR)

- NIHR commentaries:

-- Gastrointestinal symptoms may be a sign of early ovarian cancer in postmenopausal women - [link](#)

-- How much does long COVID cost individuals, informal carers, and society? - [link](#)

- NIHR alert: Hot weather increases the risk of acute kidney injury - [link](#)

Safer Care Victoria

- Victorian Clinical Governance Framework - [link](#)

Specialist Pharmacy Services NHS UK

- Assessing injectables for enteral administration - [link](#)

- Assessing suitability of medicines in a ketogenic diet - [link](#)

- Treating acute hypokalaemia in adults - [link](#)

- Updated PGD templates for contrast agents: addition of previous 'drug reaction with eosinophilia and systemic symptoms' (DRESS) to exclusion criteria and DRESS as rare adverse reaction:

[lodixanol](#) (e.g. Visipaque®); [lomeprol](#) (e.g. Iomeron®); [lopamidol](#) (e.g. Niopam®); [loversol](#) (e.g. Optiray®) with transient changes in respiratory rate & respiratory distress also added as ADRs for [lohexol](#) (e.g. Omnipaque®)

- New product evaluations - [July 2024 update](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Pharmacy Institutional Readiness for Exagamglogene Autotemcel (Casgevy®) - [link](#)

Transformation Partners in Health and Care UK

- #AskAboutAsthma 2024 Campaign toolkit - [link](#)

UK Health Security Agency

- Antibiotic resistant gonorrhoea cases on the rise in England - [link](#)

- Guidance: Clade I mpox virus infection - [link](#)

- Tuberculosis (TB): diagnosis, screening, management and data – [Updated Guidance](#)

- PGD templates: Notice of extension of the [validity](#) of Smallpox vaccine ; BCG Vaccine AJV - [update](#)

World Health Organisation (WHO)

- Smallpox and mpox (orthopoxviruses): WHO position paper, August 2024 - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

-- Aubagio (teriflunomide) - Herpes virus infections including oral herpes and herpes zoster added as possible “common” ADR with some of them being serious. They may occur at any time during treatment.

-- Esbriet (pirfenidone) - ‘drug reaction with eosinophilia and systemic symptoms’ (DRESS), which can be life-threatening or fatal, reported post-marketing

-- Estradot (estradiol) transdermal - potential drug interactions listed including the potential for ritonavir and nelfinavir to act as enzyme inducers (although generally known as strong enzyme inhibitors) when used with steroid hormones

-- Fareston (toremifene citrate) - ‘hypertriglyceridemia’ added as ADR of unknown frequency

-- Gadovist (gadobutrol) "... must not be used intrathecally. Serious, life-threatening and fatal cases, primarily with neurological reactions (e.g. coma, encephalopathy, seizures), have been reported with intrathecal use"

-- Imfinzi (durvalumab) - coeliac disease and pancreatitis added as potential ADRs when used either as a monotherapy or in combination with other medicines

-- Imuran (azathioprine) - information about cholestasis in pregnancy with azathioprine included, advising that if it occurs, a case by case assessment is necessary on its risk-benefit profile to determine if potential withdrawal or dose reduction, is required

-- Jemperli (dostarlimab) - cases of coeliac disease and pancreatic exocrine insufficiency reported during treatment with other immune checkpoint inhibitors which might also occur with dostarlima

-- Lemsip Max (paracetamol, phenylephrine) products - Diabetes mellitus and closed-angle glaucoma added as contraindications (due to presence of phenylephrine), warning added about increased risk of high anion gap metabolic acidosis with concomitant use of flucloxacillin & paracetamol, and use with caution in patients with porphyria

-- Lovima (desogestrel) - lamotrigine interaction deleted

-- Mavenclad (cladribine) - serious, severe, and opportunistic infections (some fatalities) observed

-- Mayzent (siponimod fumaric acid) - additional information on the risk of bradyarrhythmia with this treatment and to include PML as a rare adverse event

-- Mirena (levonorgestrel) - information updated to make healthcare professionals aware that the use of excessive force during removal of intrauterine delivery system might lead to device breakage, and with detailed information on the onset of contraceptive efficacy

-- Onpattro (patisiran sodium) - additional advice on treatment initiation and continuation, infusion-related reactions and new clinical data from an open-label extension study; recommendation of ‘ranitidine 50mg’ as intravenous H2 blocker for use as premedication replaced with ‘famotidine 20mg’

-- Opdivo (nivolumab) - pancreatic exocrine insufficiency and coeliac disease added as ADRs (rare)

-- Orladeyo (berotralstat (BS)) - QT prolongation may be observed with higher concentrations & interaction data on use with cyclosporine (P-gp & BCRP inhibitor) showed decrease in Cmax of single 150mg dose of BS by 7% & increase in AUC by 27%, but no dose change of BS needed. Nausea also added as ADR, following reports during post marketing surveillance

-- Palexia (tapentadol) - extension for use in children aged over 2 years with a body weight over 16kg

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- QVAR (beclometasone dipropionate) - Cushing's syndrome & Cushingoid features added (very rare ADR)
- Rocephin (ceftriaxone) - hypersensitivity reactions that can also progress to Kounis syndrome a serious allergic reaction that can result in myocardial infarction. Unknown frequency.
- Rystiggo (rozanolixizumab) –information from cases of drug induced aseptic meningitis from spontaneous post-marketing reporting in generalised myasthenia gravis added
- Skyrizi (risankizumab) - moderate to severely active ulcerative colitis as new therapeutic indication
- Spinraza (nusinersen) - arachnoiditis (inflammation of arachnoid- one of membranes that surround & protect nerves of spinal cord) added as ADR (unknown frequency), and actions to take if suspected before injection, including carrying out MRI, & precluding use till local inflammation ruled out
- Tecentriq (atezolizumab) - hypophysitis (acute/chronic inflammation pituitary gland) now classified as an uncommon ADR (previously rare) with monotherapy and in combination therapy; reports of hypopituitarism & secondary adrenocortical insufficiency noted
- Teriflunomide - warning regarding use in patients that develop herpes infections and advice that if the patient develops any serious infection consider suspending treatment with teriflunomide
- Xenpozyme (olipudase alfa) - reports of overdose in paediatric patients during dose escalation. Some experienced serious adverse reactions within 24hrs of treatment initiation, including death. Main clinical findings included respiratory failure, hypotension, elevations in LFTs & GI bleeding
- Zydol (tramadol) - warnings reinforced on the risk of drug dependency/drug abuse through addition of negative consequences of opioid use disorder and risk factors identified in accordance with wordings already implemented for other opioids
- Zyvox (linezolid) – rare ADR of rhabdomyolysis with advice to use with caution in patients with pre-disposing factors for rhabdomyolysis; discontinue linezolid and initiate appropriate therapy
- Risk minimisation materials
- Amgen Amgevita HCF (adalimumab) Patient Reminder Card – important safety information for adults and paediatrics. Patients should show it to all of their healthcare providers to let them know they are on this treatment. In notes section on back of card, they should write down information about any tuberculosis tests or treatment received
- Roche Guide to Vabysmo® ([faricimab](#)) for macular oedema secondary to Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO) - provides important safety information for patients and on reporting side effects, as well as explaining what RVO is, how faricimab works, preparing for treatment visit, and what happens during and after treatment visit

European Medicines Agency (EMA)

- PRAC conclude that hydroxycarbamide can cause falsely high CGM sensor readings - [link](#)

Food and Drug Administration (FDA) USA

- Infants at risk for aluminum toxicity with unapproved potassium phosphates drug product - [link](#)
- Warns consumers to not purchase or use unapproved inhalant products marketed for alertness and energy boosting - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Drug Safety Update [August 2024](#)
- Yellow Card Biobank: call to contribute to study of genetic links to side effects - [link](#)
- Abecma®▼ (idecabtagene vicleucel), Breyanzi®▼ (lisocabtagene maraleucel), Carvykti®▼ (ciltacabtagene autoleucel), Kymriah®▼ (tisagenlecleucel), Tecartus®▼ (brexucabtagene autoleucel) and Yescarta®▼ (axicabtagene ciloleucel) (CD19- or BCMA-directed CAR T-cell therapies): risk of secondary malignancy of T-cell origin - [link](#)

MIMS, UK

- MIMS comparison table of ADHD treatments now includes information on release profiles of methylphenidate preparations - [link](#)

Neonatal & Paediatric Pharmacists Group UK

- NPPG Position statement: Shortage of Pancreatic Enzyme Replacement Therapy ([PERT](#))

Specialist Pharmacy Services NHS UK

- SPS Medication Safety Update July 2024 - [link](#)

TGA

- Product Information safety updates - [August 2024](#)
- Medicines containing Garcinia gummi-gutta (Garcinia cambogia) or hydroxycitric acid (HCA) - [link](#)

WHO

- Medical Product Alert N°3/2024: Falsified (contaminated) Oxycodone Hydrochloride 40mg - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Risk of age-related macular degeneration in men receiving 5 α -reductase inhibitors: a population-based cohort study - [link](#)

American Journal of Cardiology

- Comparison of Drug Therapy Efficacy in Patients with Hypertrophic Cardiomyopathy: A Network Meta-Analysis - [link](#)
- One-Month Dual Antiplatelet Therapy Reduces Major Bleeding Compared With Longer-Term Treatment Without Excess Stent Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Resources and strategies for learning infectious diseases pharmacotherapy during advanced pharmacy practice experiences and pharmacy residency - [link](#)
- Impact of a pharmacist-led collaborative approach to care for treatment of COVID-19 in the outpatient setting - [link](#)
- A case report of elevated bromide levels from pyridostigmine bromide for treatment of myasthenia gravis - [link](#)
- Use of dual intraventricular vasodilators for refractory cerebral vasospasm in a pediatric patient with traumatic subarachnoid hemorrhage: A case report - [link](#)
- Clinical review of substitutions or alternatives for critical chemotherapy drug shortages in hematologic malignancies - [link](#)
- An international, multicenter post hoc analysis comparing in-person and virtual medication management strategies in post-ICU recovery clinics - [link](#)
- Obesity management in the pediatric patient - [link](#)

American Journal of Medicine

- Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - [link](#)
- Kidney and Cardiovascular Protection Using Dietary Acid Reduction in Primary Hypertension: A Five-Year, Interventional, Randomized, Control Trial - [link](#)

Annals of Internal Medicine

- Gastroesophageal Reflux Disease - [link](#)
- How Would You Treat This Inpatient with Type 2 Diabetes Mellitus? Grand Rounds Discussion from Beth Israel Deaconess Medical Center - [link](#)
- Kratom: An Emerging Issue for Research and Physician Education - [link](#)
- Effect of Starting Dialysis Versus Continuing Medical Management on Survival and Home Time in Older Adults with Kidney Failure: A Target Trial Emulation Study - [link](#)
- Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia: A Population-Based Cohort Study - [link](#)

Australian Prescriber

- Pharmacological management of polycystic ovary syndrome - [link](#)
- Management of occupational exposure to blood and body fluids in primary care - [link](#)
- Utility of common investigations for suspected inflammatory arthritis in adults - [link](#)

- Editorial: Achieving safe medication management during transitions of care from hospital: time for a stewardship approach - [link](#)
- Medicinal mishap: Sum of the parts: a cascade of adverse effects - [link](#)
- Letters: Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea - [link](#) ; QUM revisited - [link](#)
- New drugs: [Difelikefalin](#) for pruritus associated with chronic kidney disease ; [Rimegepant](#) for migraine
- TGA Medicines Safety Update summary: Azithromycin and rare risk of cardiovascular death - [link](#)

British Journal of Clinical Pharmacology

- Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer - [link](#)
- Effectiveness of safety netting approaches for acutely ill children: a network meta-analysis - [link](#)
- The effects of diuretic deprescribing in adult patients: A systematic review to inform an evidence-based diuretic deprescribing guideline - [link](#)
- Evaluating the evidence for genotype-informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review - [link](#)
- Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation - [link](#)
- Factors affecting peripheral neuropathy induced by nanoparticle albumin-bound paclitaxel in patients with pancreatic cancer - [link](#)
- Promoting medication safety for older adults upon hospital discharge: Guiding principles for a medication discharge plan - [link](#)
- Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users - [link](#)
- The effect of deprescribing interventions on mortality and health outcomes in older people: An updated systematic review and meta-analysis - [link](#)
- Clinical pharmacology in adolescent transgender medicine - [link](#)
- Analysis of longitudinal patterns and predictors of medicine use in residential aged care using group-based trajectory modelling: The MEDTRAC-Polypharmacy longitudinal cohort study - [link](#)
- Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment - [link](#)

British Journal of General Practice

- Group-delivered interventions for lowering blood pressure in hypertension: systematic review and meta-analysis - [link](#)
- Incidence, antimicrobial prescribing practice and associated healthcare costs of paediatric otorrhoea in primary care in the UK: A longitudinal population study - [link](#)
- Low-dose amitriptyline for irritable bowel syndrome (IBS): a qualitative study of patients' and GPs' views and experiences - [link](#)

British Journal of Psychiatry

- Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals - [link](#)
- Association between a selective 5-HT₄ receptor agonist and incidence of major depressive disorder: emulated target trial - [link](#)
- Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study - [link](#)

BMC Geriatrics

- Exploring the impact of pharmacist-supported medication reviews in dementia care: experiences of general practitioners and nurses - [link](#)

British Medical Journal (BMJ)

- BMJ Opinion: Does the METHOD study show that ZOE works? - [link](#)
- Practice Pointer: Assessment and management of self-harm and suicide risk in young people - [link](#)
- Practice Pointer: Caring for dying patients in the community - [link](#)

- Device associated complications in the intensive care unit - [link](#)
- MDMA assisted therapy: Three papers are retracted as FDA rejects PTSD application - [link](#)
- Whooping cough: Health officials urge pregnant women to get vaccinated - [link](#)
- How do GLP-1 drugs work for weight loss . . . and everything else? - [link](#)
- US CDC warn over-the-counter painkillers may not be sufficient when fitting IUDs - [link](#)
- Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study - [link](#)
- Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis - [link](#)
- Practical prescribing: Bisphosphonates - [link](#)
- Reducing drug waste in hospitals - [link](#)

BMJ Open

- Pharmacist-led primary care interventions to promote medicines optimisation and reduce overprescribing: a systematic review of UK studies and initiatives - [link](#)
- Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial - [link](#)
- Quantitative analysis of nortriptyline's analgesic properties: a comparative systematic review and meta-analysis - [link](#)
- What do patients with heart failure disclose about medication adherence at home to their hospital and primary care doctors? Exploratory interaction-based observational cohort study - [link](#)
- Women's health in focus: Real-world data on valproate prescriptions during pregnancy – a cohort study in Catalonia (Spain) - [link](#)
- Effectiveness of silver and iodine dressings on wound healing: a systematic review and meta-analysis - [link](#)

BMJ Quality and Safety

- Optimising antibacterial utilisation in Argentine intensive care units: a quality improvement collaborative - [link](#)
- Assessing patient work system factors for medication management during transition of care among older adults: an observational study - [link](#)

Canadian Pharmacy Journal

- Harmonizing leadership: Blending transactional and transformational styles in pharmacy practice - [link](#)

Circulation

- Cardiovascular Management of Aortopathy in Children: A Scientific Statement from the American Heart Association - [link](#)
- Diagnosis of Brugada Syndrome with a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not? - [link](#)
- Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial - [link](#)

Cochrane

- Corticosteroid therapy for nephrotic syndrome in children - [link](#)
- Pharmacological interventions for pruritus in adult palliative care patients - [link](#)
- Daily oral iron supplementation during pregnancy - [link](#)
- Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder - [link](#)
- Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer – [link](#)
- Tamoxifen for adults with hepatocellular carcinoma - [link](#)
- Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases - [link](#)

- Stem cell treatment for acute myocardial infarction - [link](#)

Diabetes Care

- Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study - [link](#)
- Comprehensive Multiple Risk Factor Control in Type 2 Diabetes to Mitigate Heart Failure Risk: Insights From a Prospective Cohort Study - [link](#)
- Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study - [link](#)

Drug and Therapeutics Bulletin

- DTB select: Direct oral anticoagulants for stroke prevention in device-detected AF - [link](#)
- Medicines optimisation opportunities: driving change? - [link](#)

European Heart Journal

- Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score - [link](#)
- Triglycerides: the past, the present, and the future - [link](#)
- European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics - [link](#)

European Journal of Hospital Pharmacy

- Impact of the use of a drug–drug interaction checker on pharmacist interventions involving well-known strong interactors - [link](#)
- Pharmaceutical care in the screening process of phase I oncohaematological clinical trials - [link](#)
- Recommended doses of endovenous vancomycin are insufficient to achieve therapeutic concentrations in paediatric patients - [link](#)
- Stability of intravenous medicines – evidence of maximum temperature reached in both summer and winter within soft shell elastomeric pump - [link](#)
- Case report: Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die - [link](#)

Heart

- Emerging role of incretin-based therapy as first-line antihypertensives in obesity - [link](#)
- Treating iron deficiency in patients with heart failure: what, why, when, how, where and who - [link](#)

International Journal of Clinical Pharmacy

- Medication errors in emergency departments: a systematic review and meta-analysis of prevalence and severity - [link](#)

Internal Medicine Journal

- Initiating or switching to insulin degludec/insulin aspart in a real-world population of adults with type 2 diabetes in Australia: results from a prospective, non-interventional study - [link](#)
- Letter: Acute haemostasis with bevacizumab for upper gastrointestinal bleeding secondary to lymphoma - [link](#)
- Letter: Crohn stricture resolution following treatment with high-dose ustekinumab - [link](#)

JAMA

- E-Cigarette Use in Adolescents and Adults—A JAMA Collection - [link](#)
- Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions - [link](#)
- Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone - [link](#)
- Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review - [link](#)
- Edetate Disodium–Based Chelation for Patients with a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial - [link](#)
- Genital Herpes - [link](#)
- Medical Practice and the Climate Crisis - [link](#)
- Summary of WHO warning about counterfeit Ozempic (semaglutide) in the global supply chain - [link](#)

- Patient Page: What Is Dengue? - [link](#) ; Screening for Iron Deficiency and Iron Deficiency Anemia During Pregnancy - [link](#)
- Localized Nicardipine Release Implants for Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage - A Randomized Clinical Trial - [link](#)
- Tranexamic Acid in Patients Undergoing Liver Resection. The HeLiX Randomized Clinical Trial - [link](#)
- Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force - [link](#)
- Characterizing Long COVID in Children and Adolescents - [link](#)
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial - [link](#)
- Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial - [link](#)
- Long-Term Prognosis of Patients with Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies - [link](#)

JAMA Cardiology

- Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial - [link](#)
- Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation: The ACE-PROTAVI Randomized Clinical Trial - [link](#)
- Verinurad Plus Allopurinol for Heart Failure with Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial - [link](#)

JAMA Dermatology

- Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients with Atopic Dermatitis - [link](#)
- Baricitinib Withdrawal and Retreatment in Patients with Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial - [link](#)
- Smoking Cessation and Risk of Hidradenitis Suppurativa Development - [link](#)
- Tyrosine Kinase 2 Inhibition with Zascitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial - [link](#)

JAMA Internal Medicine

- Antiplatelet and Anticoagulant Use in Nursing Home Residents with Atrial Fibrillation - [link](#)
- Commentary: Deprescribing Equity—A Research Framework for Older Adults - [link](#)
- GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes - [link](#)
- Plant and Animal Fat Intake and Overall and Cardiovascular Disease Mortality - [link](#)
- Telehealth Mindfulness-Based Interventions for Chronic Pain: The LAMP Randomized Clinical Trial - [link](#)
- Buprenorphine for Opioid Use Disorder—An Essential Medical Treatment - [link](#)

JAMA Network Open

- Reducing Central Nervous System–Active Medications to Prevent Falls and Injuries Among Older Adults: A Cluster Randomized Clinical Trial - [link](#)
- Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality - [link](#)

JAMA Neurology

- Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial - [link](#)

JAMA Oncology

- Contemporary Management of Acute Myeloid Leukemia: A Review - [link](#)
- Immune Checkpoint Inhibitor–Induced Cardiotoxicity: A Systematic Review and Meta-Analysis - [link](#)

JAMA Psychiatry

- Hyperalgesia in Patients with a History of Opioid Use Disorder: A Systematic Review and Meta-Analysis - [link](#)
- COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People - [link](#)
- Semaglutide in Psychiatry—Opportunities and Challenges - [link](#)

Journal of the American Geriatrics Society

- Discontinuation versus continuation of statins: A systematic review - [link](#)

Journal of Clinical Oncology

- Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials - [link](#)
- Management of Locally Advanced Rectal Cancer: ASCO Guideline - [link](#)
- Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial - [link](#)
- Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study - [link](#)
- Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Editorial: Person- and carer-centred palliative care: consensus for the pharmacy profession - [link](#)

Lancet

- New promises and challenges in the treatment of advanced non-small-cell lung cancer - [link](#)
- International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches - [link](#)
- Obesity in adults - [link](#)
- X-linked hypophosphataemia - [link](#)
- Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis - [link](#)
- Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials - [link](#)

Lancet Diabetes & Endocrinology

- Diabetes-related complications: a toll too high - [link](#)
- Male hypogonadism: pathogenesis, diagnosis, and management - [link](#)

Lancet HIV

- Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study - [link](#)

Lancet Oncology

- Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis - [link](#)

Lancet Respiratory Medicine

- Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study - [link](#)
- The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Evaluating the Risk–Benefit Profile of Corticosteroid Therapy for COVID-19 Patients: A Scoping Review - [link](#)

- Development and Evaluation of Interprofessional High-Fidelity Simulation Course on Medication Therapy Consultation for German Pharmacy and Medical Students—A Randomized Controlled Study - [link](#)
- Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings - [link](#)
- Administration of Levetiracetam via Subcutaneous Infusion for Seizure Control in the Palliative Care Setting: A Narrative Review - [link](#)
- Examining Delineated Competencies within Blended Hospital/Health System Pharmacy and General Medicine Advanced Pharmacy Practice Experiences - [link](#)

Medical Journal of Australia

- Treatment-resistant tinea caused by *Trichophyton indotineae* in Australia - [link](#)
- Outcomes for people admitted to Australian and New Zealand intensive care units with primary, exacerbating, or incidental SARS-CoV-2 infections, 2022–23: a retrospective analysis of ANZICS data - [link](#)
- National pharmacovigilance of seasonal influenza vaccines in Australia - [link](#)

Nature Communications

- Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England - [link](#)

New England Journal of Medicine

- Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn - [link](#)
- Frailty in Older Adults - [link](#)
- Preventing and Controlling Global Antimicrobial Resistance — Implementing a Whole-System Approach - [link](#)
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma - [link](#)

Pediatrics

- Recommendations for Prevention and Control of Influenza in Children, 2024–2025: [Policy Statement](#), [Technical Report](#)
- Pediatric and Adolescent Hypertension: A Multidisciplinary Call to Action - [link](#)
- Disparities in Guideline Adherence for Febrile Infants in a National Quality Improvement Project - [link](#)

Pharmaceutical Journal

- Weekly medicines data to be collected from hospital electronic prescribing systems - [link](#)
- General Pharmaceutical Council (GPhC) to add net zero targets into its pharmacy regulatory processes - [link](#)
- Expanded 'subscription model' for companies to provide new antibiotics to be funded with £100m per year for contracts awarded during 2024/2025 procurement process - [link](#)
- Largest ever trial of ketamine to treat alcohol abuse launched across eight NHS sites - [link](#)
- More than 2000 patients tested in UK's first routine genotyping project for clopidogrel prescribing - [link](#)
- The unregulated semaglutide prescribing circus - [link](#)

Pharmacotherapy

- Lactated Ringer's versus normal saline in the management of acute diabetic ketoacidosis (RINSE-DKA) - [link](#)

PLOS ONE

- Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study - [link](#)

PROSPERO - International prospective register of systematic reviews

- New Onset Inflammatory Bowel Disease Risk Following Bariatric Surgery: A Systematic Review and Meta-Analysis of Observational Studies - [link](#)

Thrombosis Research

- Anticoagulants for the treatment of isolated lower limb superficial vein thrombosis a Bayesian network meta-analysis of randomized controlled trials - [link](#)

CONSULTATIONS

Agency for Clinical Innovation, NSW (ACI)

- Consultation - Organisational Models of Care and Clinical Priorities Brief for Older People Living with Frailty – closes 27 September 2024 - [link](#)

TGA

- Consultation: 2024-2025 Proposed changes to the Permissible Ingredients Determination – Low-negligible risk – closes 13 September 2024 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 170](#) – Quality use of medicines: who owns it now?

Purple Pen Podcast

- [PPP 164](#) Gout

UPCOMING EVENTS

Australian Healthcare and Hospitals Association (AHHA)

- National Rural Health Conference, Perth Convention & Exhibition Centre - September 16-18, 2024 – [register](#)

- AHHA Member Roundtable: Meet the Chief Health Economist – online - September 24, 2024 12:00-13:30 AEST - [register](#)

Deeble Institute-AHHA

- The John Deeble Lecture and Panel Discussion, Beyond boundaries: leadership for health - National Museum of Australia, Canberra, ACT - October 15, 2024 09:00-16:00 AEST - [register](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- NMS 2024: Ageing well: safe medicines, better lives – Tuesday, 19 November 2024 10.00- 15.00 - [register](#)

Safer Care Victoria

- For World Sepsis Day on Friday 13 September

-- Could It Be Sepsis? Comparative Insights from Three States on Early Detection and Management, online clinical conversation - Thursday 5 September at 2pm (AEST) – [register](#)

-- Understanding Sepsis: Awareness, Prevention, and Action Across All Ages, online clinical conversation - Thursday 19 September at 2pm (AEST) - [register](#)

- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – early bird [registration](#) closes 4 September 2024

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

Fortnightly TAG Mail – resources list

8th August 2024

NSW TAG ACTIVITIES

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Invitation to participate in survey: Protocols for critical medicines in NSW public facilities

To be completed by the healthcare professionals familiar with a hospital's/district's/service's protocols for critical care medicine (who may wish to answer as a group of healthcare professionals). It should take no more than 10-15 minutes. Survey closes **24th August 2024**.

Survey Link: <https://www.surveymonkey.com/r/PJZ3989>

New open email discussions

-Ongoing infliximab for immune therapy colitis Closes August 9th 2024

Contact *Sasha Bennett* at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AHR: The current state of sustainable healthcare in Australia - [link](#)

AJHP: Impact of connected dispensing technology with advanced analytics in a multicenter health system - [link](#)

BJCP: Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study - [link](#)

BJCP: Appropriateness of ChatGPT as a resource for medication-related questions - [link](#)

BJCP: Mobile applications on app stores for deprescribing: A scoping review - [link](#)

BJGP: Asthma: effect of excess short-acting β 2-agonist (SABA) inhaler prescriptions on healthcare resource utilisation - [link](#)

BMC Geri: A quantitative study on the impact of a community falls pharmacist role on medicines optimisation in older people at risk of falls - [link](#)

BMJ QS: Decoding behaviour change techniques in opioid deprescribing strategies following major surgery: a systematic review of interventions to reduce postoperative opioid use - [link](#)

CADTH: Drug Shortages in Canada - [link](#)

CADTH: Opioid Analgesics to Treat CNCP among Patients Prescribed Opioid Agonist Therapy or With OUD - [link](#)

Circulation: Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome - [link](#)

Circulation CVQO: Past, Present, and Future of Shared Decision-Making - [link](#)

Circulation CVQO: Recurring and Emerging Ethical Issues in Pragmatic Clinical Trials - [link](#)

EJHP: Patient reported medication-related problems, adherence and waste of oral anticancer medication -over time - [link](#)

Health Foundation UK: Health at the heart of government - [link](#)

IMJ: Position Paper: Diagnosis, management and follow-up of follicular lymphoma - [link](#)

IMJ: Omalizumab for management of hypersensitivity reactions to anticancer drugs - [link](#)

JACC: Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF - [link](#)

JAMA IM: Management of Elevated Blood Pressure in the Hospital-Rethinking Current Practice [link](#)

JAMDA: Top 10 Signs and Symptoms of Psychotropic Adverse Drug Events to Monitor in Residents of Long-Term Care Facilities - [link](#)

JPPR: Standard of practice in women's and newborn health for pharmacy services - [link](#)

JPPR: Prospective identification of medication harm in geriatric inpatients using a modified trigger tool - [link](#)

Lancet Inc: Dose selection of novel anticancer drugs: exposing the gap between selected and required doses - [link](#)

MDPI: Pharmacist-Led Deprescribing of Opioids and Benzodiazepines in Older Adults - [link](#)

MJA: Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)

MJA: National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030 - [link](#)

OTHER NEWS

NSW Health

- NSW Health Procurement (Goods and Services) ([PD2024 027](#))

Pharmacy Board of Australia

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Release of revised Pharmacy Board of Australia Guidelines on compounding of medicines - [link](#)
- Good virtual care practices - [link](#)

TGA

- Nitrosamine impurities acceptable intakes update - [link](#)
- TGA warns advertising prescription-only weight-loss medicine is prohibited - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Australian Passive AMR Surveillance: An update of resistance trends in multidrug-resistant organisms – 2006 to 2023 - [link](#)

Australian Institute for Health and Welfare (AIHW)

- Child protection Australia 2022-23 - [link](#) - Mental health online – Subsite [update](#)
- Admitted patient care 2022-23: Australian hospital statistics data cubes update: Principal diagnosis – [link](#) ; Australian refined diagnosis-related groups (AR-DRG) – [link](#) ; Procedures - [link](#)
- MyHospitals - Hospitals resources 2022–23 - [link](#) ; MyHospitals: Hospitals at a glance – [update](#)
- Australia's mothers and babies: Stillbirths and neonatal deaths - [update](#)
- Aboriginal and Torres Strait Islander Health Performance Framework website - [update](#)

CATAG

- MAIA Preventing progression to persistent pain toolkit: practice and teaching tools - [link](#)
- Collaborating with consumers: Understanding off-label medicines consumer counselling tool- [link](#)

Deeble Institute for Health Policy Research

- Issues Brief No.57: Reinforcing the Role of Eye Care Practitioners in Falls Prevention Among Older Adults - [link](#)

MIMS monthly updates

- New Products
 - Patisiran ([Onpattro](#)) for hereditary TTR-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy
 - PrabotulinumtoxinA ([Nuceiva](#)) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients
 - Selumetinib (as sulfate) ([Koselugo](#)) for paediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas
- New Presentations
 - Elexacaftor + tezacaftor + ivacaftor and ivacaftor ([Trikafta](#)) is now available as granules sachets
- New Indications
 - Azelastine and fluticasone propionate ([Dymista](#) 125/50) for symptomatic treatment of moderate to severe allergic rhinitis and rhinoconjunctivitis in children 6 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate
 - Respiratory syncytial virus pre-fusion F protein vaccine, recombinant ([Abrysvo](#)) for active immunisation of pregnant women between 24-36 weeks of gestation for prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age
 - Elexacaftor + tezacaftor + ivacaftor and ivacaftor ([Trikafta](#)) for cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CF transmembrane conductance regulator gene
 - Pembrolizumab (rch) ([Keytruda](#)) for combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GOJ) adenocarcinoma that is not HER2-positive; and in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

GOJ adenocarcinoma, whose tumours express PD-L1 [Combined Positive Score \geq 1] as determined by a validated test

NHMRC Impact Case Studies

- Improving stroke outcomes – [link](#) ; New treatments for leukaemia - [link](#)

PBS

- Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - [link](#)

TGA

- New semaglutide product becomes available - [link](#)
- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
 - Koselugo ([selumetinib sulfate](#)) for treatment of paediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas
 - Cibinqo ([Abrocitinib](#)) for moderate-to-severe atopic dermatitis in adults
 - Tukysa ([tucatinib](#)) in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2 positive unresectable or metastatic colorectal cancer
 - Lynparza ([olaparib](#)) for BRCA-mutated HER2-negative high risk early breast cancer and metastatic castration-resistant prostate cancer
- Australian prescription medicine decision summaries:
 - [Pluvicto](#) (Lutetium (177Lu) vipivotide tetraxetan) for adult patients with prostate cancer who have received prior treatments
 - Litfulo ([ritlecitinib](#)) for severe alopecia areata in adults and adolescents 12 years of age and older
 - [Relfydess](#) (relabotulinumtoxinA, purified Botulinum toxin type A) for temporary improvement in the appearance of glabellar lines ("frown lines") and lateral canthal lines ("crows feet")
 - Awiqli ([insulin icodec](#)) approved for the treatment of type 1 and type 2 diabetes in adults
 - [Elrexfio](#) (elranatamab) provisionally approved for the treatment of adult patients with relapsed or refractory multiple myeloma and who have not benefited from 3 prior therapies

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- All Wales guidance for penicillin allergy de-labelling in adults in secondary care - [link](#)

Canadian Agency for Drugs and Technologies in Health

- Evidence Review of Treatment Options for Uncomplicated Gonococcal Infections - [link](#)
- Drug Shortages in Canada - [link](#)
- Opioid Analgesics to Treat Chronic Noncancer Pain among Patients Prescribed Opioid Agonist Therapy or With Opioid Use Disorder - [link](#)

Department of Health and Social Care

- Joint Committee on Vaccination and Immunisation (JCVI) statement on influenza vaccines for 2025 to 2026 - [link](#)
- Patient Safety Commissioner annual report 2023 to 2024 - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)
- Truqap (capivasertib) - selective inhibitor of AKT1, AKT2 & AKT3 in combination with fulvestrant in adults with HR positive, HER2 negative locally advanced or metastatic breast cancer with \geq 1 PIK3CA/AKT1/PTEN-alterations after recurrence/progression on / after an endocrine based regimen
- [Changes to indications](#)
- Jardiance (empagliflozin) - for type 2 diabetes mellitus in children aged 10 years and above
- Omeprazole - treatment of Zollinger Ellison syndrome removed from the therapeutic indications
- Revestive (teduglutide) - indication extended to cover from 4 months gestational age

- Rybrevant (amivantamab) - new indication of use in combination with carboplatin and pemetrexed for first-line treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations
- Vabysmo (faricimab) – license extension covering treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. Three or more consecutive monthly injections might be needed. Thereafter, treatment may be individualised using a treat-and-extend approach
- Wegovy (semaglutide) – weight management indication extended to include reduction of major adverse cardiovascular events in adults with established cardiovascular disease and BMI ≥ 27 kg/m², based on new data from SELECT post-approval study

European Medicines Agency (EMA)

- European CHMP adopts/recommends:
- indication extension for [Arexvy](#) respiratory syncytial virus (RSV) vaccine
- marketing authorisation change for [amivantamab](#)
- marketing authorisation change for melatonin ([Slenyto](#))
- new indication for [spesolimab](#) and use in adolescents from 12 years of age
- approval of [atezolizumab](#) for the treatment of advanced non-small cell lung cancer
- approval of [encorafenib](#) for the treatment of non-small cell lung cancer
- approval of [rilpivirine](#) for HIV-1 in paediatric patients from 2 years of age
- approval of [binimetinib](#) for the treatment of non-small cell lung cancer
- approval of [macitentan](#) pulmonary hypertension (PAH) in paediatric patients
- approval of [pembrolizumab](#) in combination with enfortumab vedotin for urothelial carcinoma
- marketing authorisation for ciclosporin eye drops ([Vevizye](#)) for dry eye disease
- marketing authorisation for [delgocitinib](#) cream for chronic hand eczema
- marketing authorisation for [elafibranor](#) for the treatment of primary biliary cholangitis
- marketing authorisation for generic [axitinib](#) (Accord) for renal cell carcinoma
- marketing authorisation for [macitentan/tadalafil](#) (Yuvanci) for pulmonary arterial hypertension
- marketing authorisation for [odevixibat](#) for cholestatic pruritus in patients with Alagille Syndrome (ALGS) in patients aged ≥ 6 months
- marketing authorisation for three ustekinumab biosimilars ([Eksunbi](#), [Fymskina](#), [Otulfi](#))
- marketing authorisation for [toripalimab](#) for nasopharyngeal carcinoma and oesophageal squamous cell carcinoma (SCC)
- marketing authorisation for [zolbetuximab](#) for gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
- refusal of a marketing authorisation for [lecanemab](#) for the treatment of Alzheimer's disease

Food and Drug Administration (FDA) USA

- Should You Put Sunscreen on Infants? Not Usually - [link](#)
- New Drug approvals
- accelerated approval to [afamitresgene autoleucel](#) for unresectable or metastatic synovial sarcoma
- expands endometrial cancer indication for [dostarlimab-qxly](#) with chemotherapy
- [daratumumab](#) and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma
- First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma, [Tecelra](#) (afamitresgene autoleucel)
- Leqselvi ([deuruxolitinib](#)) to treat severe alopecia areata – [label/PI](#)
- [Voguezna](#) for Heartburn Relief in Nonerosive GERD

Health Foundation, UK

- Health at the heart of government - [link](#)

Lyme Disease UK

- Lyme disease - resources for pharmacy teams - [link](#)

Martindale Pharma

- Prenoxad® (naloxone) Injection Training Manual - Prenoxad® can be administered by anyone present at the scene of an overdose. This manual offers guidance on how to train a client &/or their

representative on its use, so they gain the knowledge and skills to administer it and provide appropriate aftercare

Medicines and Healthcare products Regulatory Agency (MHRA)

- MHRA approves capivasertib to treat patients with advanced breast cancer - [link](#)
- MHRA approves vibegron to treat adult patients with overactive bladder syndrome (OAB) - [link](#)
- MHRA approves the first generic raltegravir medicines to treat adult and paediatric patients infected by HIV - [link](#)
- MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults - [link](#)
- MHRA approves Comirnaty JN.1 COVID-19 vaccine for adults and children from infancy - [link](#)
- Medicines and medical devices: Five top tips for summer - [link](#)

Monthly Index of Medical Specialities (MIMS) UK

- Managing unscheduled bleeding on HRT: guidance summary published - [link](#)
- MIMS summary: Levosert IUD licensed for 8-year contraceptive use - [link](#)

Movember, UK

- The Real Face of Men's Health - [link](#)

NHS Business Services Authority

- NHSBSA publishes February to April 2024 clinical pathways data for NHS Pharmacy First Service - [link](#)

NHS England

- National dose banding table – [loncastuximab tesirine](#) - [siltuximab](#)

NHS Scotland

- Accepted for use:
 - Ivacaftor-tezacaftor-elexacaftor (Kaftrio®) in combination regimen with ivacaftor for treatment of cystic fibrosis in patients aged 2 years to less than 6 years (granules in sachet) and 6 years and older (film-coated tablets) who have at least one F508del mutation in the CFTR gene
 - Lumacaftor-ivacaftor (Orkambi®) for cystic fibrosis in patients aged 1 year and older (granules in sachet) or 6 years and older (film-coated tablets) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
 - Tezacaftor-ivacaftor (Symkevi®) with ivacaftor tablets for patients aged ≥6 years who are homozygous or heterozygous for F508del mutation & have 1 of following mutations in CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T

National Institute for Health and Care Excellence (NICE) UK

- Etranacogene dezaparovec for treating moderately severe or severe haemophilia B ([TA989](#))
- Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis ([TA988](#))
- Tenecteplase for treating acute ischaemic stroke ([TA990](#))
- Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy ([TA992](#))
- CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack ([DG59](#))
- Anaphylaxis: Quality standard update ([QS119](#))
- Forward view - our priority topics - [link](#)

National Institute for Health and Care Research (NIHR) Commentaries

- Vaccines reduce the risk of long COVID - [link](#)
- How to implement toothbrushing programmes to tackle tooth decay in children - [link](#)
- Children with anxiety problems - online therapy led by parents, supported by therapists, was effective - [link](#)

Neonatal & Paediatric Pharmacists Group

- The use of Calcium, Phosphate and Potassium supplementation in neonates and children ([updated](#))
- Standardising intravenous infusion concentrations in children in the UK - [link](#)

Nuffield Trust

- Productivity in the NHS: what's getting in the way? - [link](#)

Royal College of Physicians

- Royal College of Physicians publishes green physician toolkit - [link](#)

Royal Pharmaceutical Society

- RPS endorses call for improved women's reproductive health - [link](#)
- RPS warns pharmacists must not be criminalised over puberty blocking hormones - [link](#)
- RPS launches biggest ever Medicines, Ethics and Practice (MEP) - [link](#)

Specialist Pharmacy Services NHS UK

- Prescribing and ordering available pancreatic enzyme replacement therapies - [link](#) - [update](#)
- Using NSAIDs in asthma - [link](#)
- Medroxyprogesterone acetate (DMPA) IM injection for contraception: [updated](#) PGD template
- Medroxyprogesterone acetate (SC-DMPA) injection for contraception: [updated](#) PGD template
- Podophyllotoxin (topical) for external anogenital warts: [updated](#) PGD template
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception: [updated](#) PGD template
- Authorising and preparing to use a PGD - [link](#) ; Monitoring and reviewing a PGD in practice – [link](#) ; Planning for a PGD – [link](#) ; Writing a PGD - [link](#)
- SPS Spotlight Monthly Digest [July 2024](#)
- Good governance when implementing ustekinumab biosimilar - [link](#)
- The licence and supporting evidence for ustekinumab biosimilars - [link](#)

The King's Fund (UK)

- The reality of, and potential for, digitally enabled care in the community - [link](#)

UK Health Security Agency

- Respiratory syncytial virus (RSV) programme: information for healthcare professionals - [link](#)
- National measles guidelines - [updated July 2024](#)
- Guidance on the investigation, diagnosis and management of viral illness (plus syphilis), or exposure to viral rash illness, in pregnancy - [link](#)
- Hepatitis B in England 2024 – [link](#) - Hepatitis C in London: 2022 data - [link](#)

World Health Organisation (WHO)

- WHO clinical treatment guideline for tobacco cessation in adults - [link](#)

MEDICATION SAFETY

Australian and New Zealand College of Anaesthetists (ANZCA) & Faculty of Pain Medicine

- Australian impact of regional and global shortage of intravenous solutions - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Alecensa (alectinib) - in the adjuvant setting for Stage IB (tumours ≥ 4 cm) to IIIA ALK+ NSCLC. Treatment should continue until disease recurrence, unacceptable toxicity or for 2 years. Hyperuricaemia & haemolytic anaemia added as ADRs
- APO-go (apomorphine) - concomitant use with ondansetron may lead to severe hypotension and loss of consciousness, therefore contraindicated. Might also occur with other 5-HT₃ antagonists.
- Augmentin (co-amoxiclav) - Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE) added as a potential ADR of unknown frequency

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Betnovate (betamethasone valerate) – in topical steroid withdrawal syndrome section the ‘continuous or inappropriate’ statement has been removed. Also updated to state betamethasone valerate is a strong steroid
- Cefotaxime - eosinophilia and systemic symptoms (DRESS) added as an ADR; information on severe skin reactions included with advice to withdraw immediately if signs & symptoms appear
- Decapeptyl SR (triptorelin acetate) - convulsions reported with GnRH analogues, including triptorelin, particularly in women. Some of these patients had risk factors for seizures (e.g. history of epilepsy, intracranial tumours, co- medication with drugs known to present seizure risk)
- Eczmol 1% w/w Cream / Cetraben Protect Antimicrobial 1% (chlorhexidine) Cream - updated to warn it must not come into contact with eye as serious cases of persistent corneal injury, potentially requiring corneal transplant, have been reported following accidental ocular exposure to chlorhexidine-containing medicinal products, despite eye protective measures
- Ethambutol - drug reaction with eosinophilia and systemic symptoms (DRESS) added as an ADR; frequency unknown.
- Giapreza (angiotensin II) - concurrent venous thromboembolism prophylaxis to be used unless contraindicated during treatment with Giapreza
- Imjudo (tremelimumab) - updated to include more information on the use of corticosteroids in the treatment of immune-related ADRs
- Lagevrio (molnupiravir) - hypersensitivity, angioedema, erythema & pruritus included as uncommon ADRs; promptly discontinue if any signs/symptoms of a clinically significant hypersensitivity reaction
- Levosert (levonorgestrel) - duration of use for contraception updated from 6 to 8 years. The initial release of levonorgestrel is approximately 20 micrograms per day and declines progressively by about 70% after 8 years. The cumulative pearl index information updated
- Lonquex (lipegfilgrastim) - excursion period out of the refrigerator extended from 3 days to 7 days for pre-filled syringe
- Lunsumio mosunetuzumab - haemophagocytic lymphohistiocytosis including fatal cases reported. This life-threatening syndrome characterised by fever, hepatomegaly and cytopenias should be considered when presentation of cytokine release syndrome is atypical/prolonged
- Mintreleq (quetiapine) - subsection relating to serotonin syndrome added warning that concomitant administration with other serotonergic agents such as MAO inhibitors, SSRIs, SNRIs or tricyclic antidepressants may result in this potentially life-threatening condition, so caution to be exercised
- Mirapexin (pramipexole) - spontaneous penile erection added as a rare ADR
- Nexplanon (etonogestrel) idiopathic intracranial hypertension reported following post-marketing surveillance
- Olumiant (baricitinib) – reports of hypoglycaemia occurring in patients with diabetes when JAK inhibitor treatment (including baricitinib) is started. It is noted that dose adjustment of anti-diabetic medicines may be necessary should this occur
- Padcev (enfortumab vedotin) - serious infections such as sepsis as a commonly encountered ADR and diabetic ketoacidosis as ADR of unknown incidence. It is advised that patients should be carefully monitored for emergence of possible serious infections
- PecFent (fentanyl) - drug tolerance added as an ADR of unknown frequency, warning that toxic leukoencephalopathy also observed with fentanyl overdose, and a section on agreeing treatment strategy including duration & goals, and a plan for end of treatment
- Rezurock (belumosudil) - safety and efficacy in severe (Child-Pugh C) hepatic impairment has not been evaluated. For patients with pre-existing severe hepatic impairment (Child-Pugh C), the risks and potential benefits should be considered before initiating treatment
- Tavneos (avacopan) - drug induced liver injury and vanishing bile duct syndrome added as ADR of unknown frequency. Additional warnings/precaution information regarding hepatotoxicity also added
- Ultomiris (ravulizumab) - abdominal pain, nausea, nasopharyngitis, and headache added as the most common ADRs reported in three (23.1%) paediatric PNH patients in study ALXN1210-PNH-304. SPC also now notes that chronic IVIg treatment may decrease serum ravulizumab concentrations
- Xaluprine (mercaptopurine) - PRAC considers a causal relationship between mercaptopurine and stomatitis, cheilitis, mucosal inflammation, pellagra, cholestasis of pregnancy and decreased coagulation factors is at least a reasonable possibility. Product information amended accordingly
- Zeposia (ozanimod) can generally be started immediately after discontinuation of interferon or glatiramer. Addition of information related to a long-term extension study is also included
- Zyban (bupropion) – alopecia added as a very rare undesirable effect

- Risk minimisation materials
- [Nexviadyme](#) (avalglucosidase alfa) 100 mg powder for concentrate for solution for infusion - Materials comprise safety information for health care professionals on immunology testing services related to Nexviadyme and administering the infusion in the home setting
- Rimmyrah (ranibuzumab) - Booklets for patients treated with this medicine are available for each of the four separate indications. They cover how treatment is given, what will happen at the appointment and afterwards, and symptoms for which they should contact their doctor

EMA

- recommends strengthening advice to minimise risks from interactions between Mysimba (naltrexone/bupropion) and opioids - [link](#)

Food and Drug Administration (FDA) USA

- warns against purchasing or using chemical peel skin products without professional supervision - [link](#)
- alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products - [link](#)

Health Canada – MedEffect Notice

- Health Product InfoWatch, July 2024

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- National Patient Safety Alert: Shortage of Human Albumin 4.5% and 5% dose vials - [link](#)
- Drug Safety Update [July 2024](#)
- Epimax Ointment and Epimax Paraffin-Free Ointment: reports of ocular surface toxicity and ocular chemical injury - [link](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Outcome of Clozapine Survey/Consultation 2023 - [link](#)

MIMS monthly updates

- New Contraindications
- Bee (*Apis mellifera*), Yellow Jacket (*Vespula* spp.) and Paper Wasp (*Polistes* spp.) venom ([Albey Venom](#)) is now contraindicated in patients with unusual reactions (renal, muscular, articular, cutaneous, neurological, or haematological) after a sting; in active or poorly controlled autoimmune disorder; in severe or uncontrolled asthma (FEV1 < 70% of predicted value); and in children under the age of 2 years. The initiation of venom immunotherapy is contraindicated during pregnancy

Pharma – MSD

- [Patient Letter](#) for Lagevrio (molnupiravir) – Extended Use Beyond Labelled Expiry Date - Letter advising of extension to shelf life of specific batches and providing reassurance to patients that despite the packet appearing to be past expiration date, the medicine within the pack is still effective and appropriate for use, as agreed with MHRA

Specialist Pharmacy Services NHS UK

- Managing reactions to dental local anaesthetic injections – [link](#)

TGA

- Medicines Safety Update: Azithromycin and rare risk of cardiovascular death - [link](#)
- Shortage of intravenous (IV) fluids - [link](#)
- Robust Extreme capsules - [link](#)

PAPERS OF INTEREST

Age and Ageing

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists
ABN: 82 707 308 091

- Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial - [link](#)

Academic Emergency Medicine

- Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Risk evaluation and mitigation strategy compliance for pulmonary hypertension medications after policy implementation with computerized provider order entry support - [link](#)
- Preparing for drug diversion software: Enhancing technologies and diversion prevention program growth - [link](#)
- Evaluation of parenteral diluent contamination by caprolactam - [link](#)
- Modeling package size-conscious automated dispensing cabinet replenishment to improve efficiency - [link](#)
- Postintubation hypotension following rapid sequence intubation with full- vs reduced-dose induction agent - [link](#)
- Stability of extemporaneously prepared hydroxyurea solutions - [link](#)
- Strategic use of salvage long-acting antiretrovirals in the setting of resistance - [link](#)
- Development and assessment of an abbreviated medication regimen complexity index (the A-MRCI) - [link](#)
- Impact of connected dispensing technology with advanced analytics in a multicenter health system - [link](#)
- Central lines, aseptic batching services, and infection rates: A pharmacy-led initiative of intravenous tube priming within a NICU - [link](#)

Annals of Internal Medicine

- Clinical and Adverse Outcomes Associated with Concomitant Use of CYP2D6-Metabolized Opioids With Antidepressants in Older Nursing Home Residents: A Target Trial Emulation Study - [link](#)
- Regulatory Framework for Cannabis: A Position Paper from the American College of Physicians - [link](#)
- Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis - [link](#)
- Association of Semaglutide with Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data - [link](#)
- Pain Reduction with Oral Methotrexate in Knee Osteoarthritis: A Randomized, Placebo-Controlled Clinical Trial - [link](#)

Australian Health Review

- The current state of sustainable healthcare in Australia - [link](#)
- What is the impact of successive COVID-19 lockdowns on population mental health? Findings from an Australian natural experiment using health service data - [link](#)
- Clinical care ratios for allied health practitioners: an update and implications for workforce planning - [link](#)
- Are we missing opportunities to detect acute rheumatic fever and rheumatic heart disease in hospital care? A multijurisdictional cohort study - [link](#)

BMC Geriatrics

- A quantitative study on the impact of a community falls pharmacist role on medicines optimisation in older people at risk of falls - [link](#)

British Journal of Clinical Pharmacology

- A population pharmacokinetic model for sertraline in women during the perinatal period—A contribution from the ConcePTION project - [link](#)

- Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study - [link](#)
- Incidence, clinical classification and risk factors of cyclosporin A-induced liver injury in allogeneic haematopoietic stem cell transplant recipients - [link](#)
- Pan-European survey on medication adherence management by healthcare professionals - [link](#)
- Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database - [link](#)
- Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy – [link](#)
- Nurses' responses to patients' medication self-management problems in hospital and the use of recommendations - [link](#)
- Appropriateness of ChatGPT as a resource for medication-related questions - [link](#)
- Mobile applications on app stores for deprescribing: A scoping review - [link](#)

British Journal of General Practice

- Prescribing benzodiazepines in young adults with anxiety: A qualitative study of GP perspectives - [link](#)
- Asthma: effect of excess short-acting β 2-agonist (SABA) inhaler prescriptions on healthcare resource utilisation - [link](#)
- Cancer care reviews (CCR): a guide for primary care - [link](#)

British Journal of Cancer

- DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review - [link](#)

British Medical Journal (BMJ)

- Covid-19 infection and vaccination during first trimester and risk of congenital anomalies: Nordic registry based study - [link](#)
- Trends in long term vaping among adults in England, 2013-23: population based study - [link](#)
- Practical Prescribing: Insulin for people with type 2 diabetes mellitus - [link](#)
- Creon: Shortages of pancreatic enzyme replacement therapy are causing “worry and stress” - [link](#)
- Rivaroxaban: Lancet is under pressure to retract “unreliable” paper as investigation drags on – [link](#)
- Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling study - [link](#)
- Evaluation and management of hypertensive emergency - [link](#)
- Ban on puberty blockers is lawful, rules High Court judge - [link](#)

BMJ Open

- Schizophrenia, antipsychotic treatment adherence and driver responsibility for motor vehicle crash: a population-based retrospective study in British Columbia, Canada - [link](#)

BMJ Quality and Safety

- Decoding behaviour change techniques in opioid deprescribing strategies following major surgery: a systematic review of interventions to reduce postoperative opioid use - [link](#)
- Longitudinal cohort study of discrepancies between prescribed and administered polypharmacy rates: implications for National Aged Care Quality Indicator Programs - [link](#)

Cancer

- Use of cholesterol-lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink - [link](#)

Chest

- Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial - [link](#)

Circulation

- Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome - [link](#)

- Past, Present, and Future of Shared Decision-Making - [link](#)
- Recurring and Emerging Ethical Issues in Pragmatic Clinical Trials - [link](#)
- Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial - [link](#)
- Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid (RESPECT-EPA) - [link](#)
- Omega-3 Fatty Acids and Arrhythmias – [link](#)

Cochrane

- Topical anti-inflammatory treatments for eczema: network meta-analysis - [link](#)
- Interventions for tobacco use cessation in people living with HIV - [link](#)
- Cenobamate add-on therapy for drug-resistant focal epilepsy - [link](#)
- Antihypertensive treatment for kidney transplant recipients - [link](#)
- Vitamin D supplementation for women during pregnancy - [link](#)
- Clinical service organisation for adults with atrial fibrillation - [link](#)
- Strategies for cessation of caffeine administration in preterm infants - [link](#)
- Preoperative statin therapy for adults undergoing cardiac surgery - [link](#)

Diabetes Care

- Association of Insulin Resistance With Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: Systematic Review and Meta-analysis - [link](#)
- Association Between Accelerometer-Measured Irregular Sleep Duration and Type 2 Diabetes Risk: A Prospective Cohort Study in the UK Biobank - [link](#)
- Sitting Time and Its Interaction With Physical Activity in Relation to All-Cause and Heart Disease Mortality in U.S. Adults With Diabetes - [link](#)
- History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes - [link](#)
- Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus - [link](#)

Diabetes & Metabolic Syndrome: Clinical Research & Reviews

- The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis - [link](#)

Drug and Therapeutics Bulletin

- VTE risk with concomitant use of hormonal contraception and NSAID - [link](#)
- GI adverse effects associated with GLP-1 agonists for weight loss - [link](#)
- Safety update: tramadol-warfarin interaction - [link](#)
- Fezolinetant for menopausal vasomotor symptoms - [link](#)
- Editorial: Challenging use of psychotropic medication in young people - [link](#)
- Comparative efficacy of acne treatments - [link](#)

European Heart Journal

- Beyond the classic major cardiovascular event outcome for cardiovascular trials - [link](#)

European Journal of Hospital Pharmacy

- Pharmacotherapy of carbamazepine-treated patient after bariatric surgery: a complex interplay between altered absorption and drug–drug interactions - [link](#)
- Patient reported medication-related problems, adherence and waste of oral anticancer medication - over time - [link](#)
- Long-term stability of esketamine in polypropylene syringes at 5 ± 3°C - [link](#)

Heart

- Aspirin: latest evidence and developments - [link](#)

- Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial - [link](#)
- Blood pressure management in type 2 diabetes: a review of recent evidence - [link](#)

Internal Medicine Journal

- Position Paper: Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance - [link](#)
- Position paper: ANZTCT practice statement: sinusoidal obstruction syndrome/veno-occlusive disease diagnosis and management - [link](#)
- Omalizumab for management of hypersensitivity reactions to anticancer drugs - [link](#)

International Journal of Clinical Pharmacy

- Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials - [link](#)
- Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis - [link](#)
- Effectiveness and safety of remimazolam tosylate versus propofol for sedation in patients undergoing gastrointestinal endoscopy: a randomized controlled trial - [link](#)
- Development and validation of a national clinical pharmacy competency framework for hospital pharmacists in Austria: a multi-method study - [link](#)
- Occurrence of respiratory and urinary tract infections in patients treated with docetaxel compared with afatinib based on a health insurance claims database in Japan - [link](#)

JAMA

- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update - [link](#)
- Obesity in Adolescents: A review - [link](#)
- Patient page: What Is Polymyalgia Rheumatica? - [link](#); Obesity in Adults - [link](#)

JAMA Dermatology

- Multinational Drug Survival Study of Omalizumab in Patients with Chronic Urticaria and Potential Predictors for Discontinuation - [link](#)
- Cendakimab in Patients with Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial - [link](#)
- Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial - [link](#)

JAMA Internal Medicine

- Prenatal Cannabis Use and Maternal Pregnancy Outcomes - [link](#)
- Management of Elevated Blood Pressure in the Hospital—Rethinking Current Practice - [link](#)
- Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and Engagement: A Randomized Clinical Trial - [link](#)
- The CREATE TRUST Communication Framework for Patient Messaging Services - [link](#)
- Tirzepatide-Induced Rapid Weight Loss—Related Thyrotoxicosis - [link](#)

JAMA Network Open

- Multivitamin Use and Mortality Risk in 3 Prospective US Cohorts - [link](#)
- Risankizumab for Ulcerative Colitis, Two Randomized Clinical Trials - [link](#)
- Medications for Obesity: [a review](#)
- Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes - [link](#)

JAMA Oncology

- Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction - [link](#)
- BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients - [link](#)
- Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk - [link](#)

The Joint Commission Journal on Quality and Patient Safety

- Standardizing the Dosage and Timing of Dexamethasone for Postoperative Nausea and Vomiting Prophylaxis at a Safety-Net Hospital System - [link](#)

Journal of the American College of Cardiology

- Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF - [link](#)

Journal of the American Medical Directors Association

- Top 10 Signs and Symptoms of Psychotropic Adverse Drug Events to Monitor in Residents of Long-Term Care Facilities - [link](#)

J Am Med Inform Assoc

- Effect of digital tools to promote hospital quality and safety on adverse events after discharge - [link](#)

Journal of Clinical Oncology

- Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings from the Women's Health Initiative Randomized Clinical Trial - [link](#)

Journal of General Internal Medicine

- Vitamin D Supplementation and the Incidence of Fractures in the Elderly Healthy Population: A Meta-analysis of Randomized Controlled Trials - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Stability of flucytosine 100 mg/mL suspension as an alternative to intravenous administration - [link](#)

- Standard of practice in women's and newborn health for pharmacy services - [link](#)

- Prospective identification of medication harm in geriatric inpatients using a modified trigger tool - [link](#)

Lancet

- Renal cell carcinoma - [link](#) - Chronic lymphocytic leukaemia - [link](#) - Infective endocarditis - [link](#)

- Acute liver failure - [link](#)

- Lancet Commission: Dementia prevention, intervention, and care 2024 - [link](#)

- Long COVID: a clinical update - [link](#)

Lancet Diabetes & Endocrinology

- Understanding the cause of type 2 diabetes - [link](#)

- Bone health in adults with obesity before and after interventions to promote weight loss - [link](#)

- Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people - [link](#)

- Artificial intelligence for diabetes care: current and future prospects - [link](#)

- Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes - [link](#)

- Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation - [link](#)

Lancet Gastroenterology and Hepatology

- Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions - [link](#)

Lancet Infectious Diseases

- The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China - [link](#)

- Zoonotic infections by avian influenza virus: changing global epidemiology, investigation, and control - [link](#)

Lancet Neurology

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial - [link](#)

Lancet Oncology

- Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial - [link](#)
- Dose selection of novel anticancer drugs: exposing the gap between selected and required doses - [link](#)

Lancet Psychiatry

- Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK - [link](#)

Lancet Public Health

- Assessing the extent and determinants of socioeconomic inequalities in epilepsy in the UK: a systematic review and meta-analysis of evidence - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Medication Reconciliation as Part of Admission Management—A Survey to Improve Drug Therapy Safety in a Urology Department - [link](#)
- Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service - [link](#)
- Pharmacist-Led Deprescribing of Opioids and Benzodiazepines in Older Adults: Examining Implementation and Perceptions - [link](#)
- Development and Validation of a Tool to Explore Attitudes Towards medication adherence Using a Novel Self-Reported Questionnaire (ADHERE-7) - [link](#)

Medical Journal of Australia

- Preventing falls and fall-related injuries in older people - [link](#)
- Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)
- National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030 - [link](#)

Nature Medicine

- The recombinant shingles vaccine is associated with lower risk of dementia - [link](#)

New England Journal of Medicine

- Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A - [link](#)
- Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 - [link](#)
- Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras - [link](#)
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease - [link](#)
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults - [link](#)
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women - [link](#)
- HIV-Associated Tuberculosis - [link](#) - Parkinson's Disease - [link](#) - Management of Insomnia - [link](#)
- Preparing for the Next Pandemic — Expanding and Coordinating Global Regulatory Capacity - [link](#)

Pharmacotherapy

- Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections - [link](#)
- Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study - [link](#)

Shock

- Angiotensin II in the treatment of distributive shock: a systematic-review and meta-analysis - [link](#)

CONSULTATIONS

TGA

- Reforming Australia's Therapeutic Goods Testing Regulations, Closes 18 August 2024 - [link](#)
- Interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS MARCH, 2024, Closes 23 August 2024 - [link](#)
- Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2024-25, Closes 13 September 2024 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 169](#): Deprescribing antihypertensives in frail older adults
- [Episode 168](#): New and emerging drug therapies for Alzheimer disease

MJA Podcasts

- [Episode 23](#): Lung cancer screening to save lives
- [Episode 22](#): Lung cancer screening

Specialist Pharmacy Service

- Pharmacy technician coffee break conversation podcasts; A series of short podcast discussions with pharmacy technicians about their roles and the different ways they provide patient care - [25 July 2024](#)

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC) - NMS 2024 – save the date, 19 November 2024 - [link](#)

Australian Healthcare and Hospitals Association (AHHA)

- Enabling hospitals and healthcare leaders to advance their sustainability journey, FREE WEBINAR, Thursday 25 July 16:00-17:00 AEST – [register](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

Fortnightly TAG Mail – resources list

18th July 2024

NSW TAG ACTIVITIES

Invitation to participate in survey: Protocols for critical medicines in NSW public facilities

To be completed by the healthcare professionals familiar with a hospital's/district's/service's protocols for critical care medicine (who may wish to answer as a group of healthcare professionals). It should take no more than 10-15 minutes. Survey closes 24th August 2024.

Survey Link: <https://www.surveymonkey.com/r/PJZ3989>

New open email discussions

- Ongoing infliximab for immune therapy colitis Closes 26th July 2024

Recently completed email discussions

- Feedback for TGA Proposed Updates to Medicine Labelling Rules.
- Implementation of the Guiding Principles for Transition of Young People on Complex and/or Costly Medicines from Paediatric to Adult Care.

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHSP: Mapping the next steps for critical care pharmacists - [link](#)

BJCP: Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

BJCP: Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings- [link](#)

BMJ: New and emerging treatments for major depressive disorder - [link](#)

BMJ QS: -Frequency and preventability of adverse drug events in the outpatient setting - [link](#)

BMJ QS: Components of pharmacist-led medication reviews and their relationship to outcomes- [link](#)

EJHP: Safety of treating acute pulmonary embolism at home- [link](#)

EJHP: Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis - [link](#)

EJHP: Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management - [link](#)

IJCP: Impact of medicine shortages on hospital practice: role of a multidisciplinary medicine shortages team - [link](#)

IJCP: The impact of codeine rescheduling on non-opioid analgesic use by people who regularly use codeine: a prospective cohort study - [link](#)

IJCP: Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes - [link](#)

JAMA IM: Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity - [link](#)

JACCP: Impact of pharmacist-led discharge medication reconciliation on error and patient harm prevention at a large academic medical center - [link](#)

JPPR: Implementation of hospital electronic medical record Patient Friendly Medication Lists and Interim Medication Administration Charts - [link](#)

JPPR: Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals - [link](#)

Lancet ID: Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - [link](#)

MDPI: Factors Determining Quality of Drug Information by Hospital Pharmacies—Results from Five-Year Annual Quality Assessment - [link](#)

MJA: Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)

MJA: Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study – [link](#) - [editorial](#)

NEJM: Anticipating the Next Pandemic - [link](#)

Pharmacotherapy: Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1- [executive summary](#) - [link](#)

Pharmacotherapy: Update on the clinical applications of SGLTis- [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation (ACI), NSW

The latest weekly Evidence Digest can be found [here](#)

AHHA

- Updated Position Statement: Equality for LGBTIQ+ people in health - [link](#)
- Update on Modernising My Health Record Review – [summary report](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Australian Passive AMR Surveillance: Trends in macrolide resistance in Streptococcus agalactiae and Streptococcus pyogenes – 2006 to 2023 - [link](#)

Australian Institute for Health and Welfare (AIHW)

- Australia's health 2024 – [link](#) – [brief summary](#); Alcohol, tobacco & other drugs in Australia – [update](#)
- Health checks and follow-ups for Aboriginal and Torres Strait Islander people - [link](#)

PBS

- PBAC Public Summary Documents – March 2024 meeting - [5 July 2024](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Australian prescription medicine decision summaries:
- [Mirena](#) (levonorgestrel) intrauterine device - long-acting reversible contraceptive. The duration for use as a contraceptive has been extended from 5 years to 8 years
- [Oxlumo](#) (lumasiran) for primary hyperoxaluria type 1 (PH1) in all age groups
- [Amvuttra](#) (vutrisiran) for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
- [Cibinqo](#) (abrocitinib) for moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. Cibinqo can be used with/ without medicated topical therapies for atopic dermatitis

Victorian Institute of Forensic Medicine

- Clinical Communiqué Volume 11 Issue 2 [June 2024](#)

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- Cytisine recommended for use within NHS Wales for smoking cessation - [link](#)
- [Nivolumab](#) not recommended for use within NHS Wales for first-line treatment of deficient mismatch repair / high microsatellite instability oesophageal and gastric cancer

Canadian Agency for Drugs and Technologies in Health

- Somatropin - [link](#)
- Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy - [link](#)

Care Quality Commission (UK)

- The safer management of controlled drugs: Annual update 2023 - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)
- Lyfnua (gefapixant citrate) - selective antagonist of the P2X3 receptor for refractory or unexplained chronic cough in adults
- Ocrevus (ocrelizumab) - new subcutaneous formulation for adults with relapsing forms of multiple sclerosis or early primary progressive multiple sclerosis. Patients currently receiving intravenous ocrelizumab may transition to this formulation
- Tolak (fluorouracil) - topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade I and II) of the face, ears, and/or scalp in adults
- Uzpruvo (ustekinumab) - pre-filled syringe of biosimilar highly similar to Stelara for moderate to severe plaque psoriasis in adults and children aged ≥6 years, psoriatic arthritis (adults) and moderate to severely active Crohn's disease (adults)
- Yorvipath (palopecteriparatide) pre filled pen - prodrug of parathyroid hormone given once daily by subcutaneous injection, is licensed for the treatment of adults with chronic hypoparathyroidism
- Yuflyma (adalimumab) – 20mg prefill biosimilar for same indications as the originator Humira

Future Health

- Building new health system action to reduce obesity: Audit findings of Integrated Care Board Forward Plans - [link](#)

Health Foundation, UK

- What builds good health? - [link](#)

Homecare Association, UK

- Expecting the Unexpected: Homecare providers' views of hospital discharge - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- MHRA approves vibegron to treat adult patients with Overactive Bladder Syndrome (OAB) - [link](#)
- Capivasertib approved to treat patients with advanced breast cancer - [link](#)
- Ocrelizumab approved as an injection to treat multiple sclerosis in adults - [link](#)

MIMS, UK

- MIMS summary: New once-daily fluorouracil cream launched for actinic keratosis - [link](#)

NHS England

- Children and young people diabetes toolkit - [link](#)
- Framework for managing the response to pandemic diseases - [link](#)

NHS Providers

- Making sense of health inequalities - [link](#)

NHS Scotland

- SMC completes initial assessment of the evidence for birch bark extract gel (Filsuvez®) for treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients ≥6 months - [link](#)
- Accepted for use:
 - [Nivolumab with relatlimab](#) (Opdualag®) for first-line advanced melanoma in those aged ≥12 years
 - [Pembrolizumab](#) (Keytruda®) in combination with chemotherapy, for first-line HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1
 - [Voretigene neparvovec](#) (Luxturna®) for vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations
- Accepted for restricted use:
 - [Empagliflozin](#) (Jardiance®) for chronic kidney disease in adults
 - [Follitropin delta](#) (Rekovele®) for controlled ovarian stimulation in women undergoing assisted reproductive technologies
 - [Pegunigalsidase alfa](#) (Elfabrio®) for long-term enzyme replacement therapy in adults with a confirmed diagnosis of Fabry disease
- Not recommended:
 - [Pembrolizumab](#) (Keytruda®) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1

National Institute for Health and Care Excellence (NICE) UK

- Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over ([TA986](#))
- NICE recommends Hemgenix for severe haemophilia B - [link](#)
- Need for treatment pauses challenged by migraine prevention data - [link](#)
- Improving mood reduces inflammation in inflammatory bowel disease - [link](#)

National Institute for Health and Care Research (NIHR)

- Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT - [link](#)
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis - [link](#)

Specialist Pharmacy Services NHS UK

- New product evaluations – [June 2024 update](#)

The King's Fund (UK)

- Realising the potential of integrated care systems - [link](#)

UK Health Security Agency

- Your guide to the RSV vaccine for older adults - [link](#)
- A guide to Respiratory syncytial virus (RSV) vaccination for pregnant women - [link](#)
- Respiratory syncytial virus (RSV) programme: information for healthcare professionals - [link](#)
- UKHSA encourages timely vaccination as whooping cough cases rise - [link](#)
- Immunisations for teenagers and young people - [link](#)

World Health Organisation (WHO)

- Establishing quality specifications for medicines, vaccines and in vitro diagnostics - [link](#)
- Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts) - [link](#)
- WHO global action plan on promoting the health of refugees and migrants, 2019–2030 - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Bavencio (avelumab): information included on ADRs reported during treatment with other immune checkpoint inhibitors, which might also occur during treatment with avelumab
- Buvidal (buprenorphine): opioids can cause sleep-related breathing disorders, and dose reduction can be considered should this occur. Also, presence of traces of natural rubber & latex in product cannot be excluded, and there is a potential risk of allergic reaction in latex sensitive patients
- Camzyos (mavacamten): updated to remove the statement that bioequivalence between strengths has not been confirmed. The prohibition on the use of multiple capsules to achieve a prescribed dose has also been deleted
- Ceftriaxone: hypersensitivity reactions reported with all beta-lactam antibiotics; can also progress to Kounis syndrome (frequency unknown), a serious allergic reaction that can result in myocardial infarction
- Comirnaty (tozinameran) 12+ years, Omicron XBB.1.5 (raxtozinameran), Original/Omicron BA.1 (riltozinameran, tozinameran), Original/Omicron BA.4-5 (tozinameran, famtozinameran) mRNA vaccines updated to include information about, and safety data for, co-administration with Flu vaccine
- Dupixent (dupilumab) pre-filled pen for use in adult & paediatric patients (APPs) aged ≥2 years & pre-filled syringe in APPs aged ≥6 months. In children ≥12 years, dupilumab should be administered by/under supervision of adult & in children age 6 months to <12 years, by a caregiver
- Eviplera (emtricitabine, rilpivirine & tenofovir disoproxil) updated with warning/precaution on bone effects, and reduced bone mineral density has been added as a common potential ADR
- Glycopyrronium bromide: pregnancy & breastfeeding contraindication removed. Can cause thickening of secretions, which may increase risk of respiratory infection & pneumonia so it should be discontinued if pneumonia is present
- Hydrea (hydroxycarbamide): may falsely elevate sensor glucose results from certain continuous glucose monitoring systems, which may lead to missed hypoglycaemic episodes and can also cause hypoglycaemia if sensor glucose results are relied upon to dose insulin
- Keytruda (pembrolizumab): pancreatic exocrine insufficiency and coeliac disease added as rare potential ADRs
- Luforbec (beclometasone dipropionate & formoterol fumarate): pharyngeal erythema (uncommon), increased blood pressure (uncommon), and decreased blood pressure (rare) added as ADRs
- Mekinist: atrioventricular block (including complete block) added as an ADR with frequency “not known” for mono therapy and “uncommon” for combination therapy with dabrafenib
- Non-Drowsy Sinutab (paracetamol, pseudoephedrine) updated to warn of risk of abuse; increased doses may ultimately produce toxicity, and continuous use can lead to tolerance resulting in an increased risk of overdosing. Recommended maximum dose and treatment duration should not be exceeded
- Ovex (mebendazole) Suspension: following oral administration, less than 10% of the dose reaches the systemic circulation (previously stated ~ 20%)
- OxyContin (oxycodone): may cause dysfunction & spasm of the Sphincter of Oddi, raising intrabiliary pressure & increasing risk of biliary tract symptoms & pancreatitis. Therefore, it must be administered with caution in patients with pancreatitis & biliary tract diseases
- Peyona (caffeine citrate): noting it is a clear, colourless, aqueous solution with a pH of 4.7 and an osmolality of 144 to 166 mOsm/kg
- Phenergan (promethazine) must not be used in children <6 years of age due to potential for fatal respiratory depression, psychiatric & central nervous system events. Also highlights that phenothiazines may potentiate the action of other depressants (e.g. opiates, alcohol)
- Phenoxymethylpenicillin Sugar Free should ideally be given half an hour before (or at least three [previously 2] hours after) a meal, and to note excretion of metabolites in human milk presents a risk of candidiasis and also of CNS toxicity due to prematurity of the blood brain barrier

- Prostag (leuprorelin): severe cutaneous adverse reactions reported including Stevens-Johnson syndrome and toxic epidermal necrolysis (unknown frequency), which can be life-threatening or fatal, & metabolic changes linked to GnRH agonist may also include fatty liver disease
- Revestive (teduglutide) for short bowel syndrome in those aged 4 months corrected gestational age and above (previously from 1 year and above): dosing and clinical trial information added
- Rifampicin products (Rifadin; Rifanah): caspofungin included as an interacting medicine; note that after two weeks of repeated administration of rifampicin, trough levels of caspofungin were 30% lower than in adult subjects who received caspofungin alone
- Rinvoq (upadacitinib hemihydrate): updated with long term safety and efficacy data up to week 104 from SELECT-AXIS 2 study for patients with non-radiographic axial spondyloarthritis
- Seroquel (quetiapine): serotonin syndrome added as an ADR. If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases
- Sunitinib: hyperammonaemic encephalopathy added as a potential ADR of unknown frequency. Clinicians are advised to check ammonia levels in patients that develop unexplained lethargy or changes in mental status and treat as clinically appropriate
- Tafinlar (dabrafenib): peripheral neuropathy (including sensory and motor neuropathy) added as a common ADR
- Tecentriq (atezolizumab) injection: coeliac disease added as a rarely occurring ADR
- Tegretol (carbamazepine): maximum daily dose limited to 1200 mg per day for Tegretol Liquid
- Topamax (topiramate) new MHRA safety measures added, including a Pregnancy Prevention Programme, which must be fulfilled in women of childbearing potential, otherwise use would be contraindicated in this patient group
- Yentreve and Cymbalta (duloxetine) hard gastro-resistant capsules: neuroleptic malignant syndrome (NMS) may occur with duloxetine treatment, and that in its most severe form, serotonin syndrome can resemble NMS. Stress cardiomyopathy (Takotsubo cardiomyopathy) added as ADR

EMA

- Glatiramer acetate: anaphylactic reactions may occur months up to years after treatment initiation - [link](#)
- New EU recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation - [link](#)

MIMS, UK

- New MIMS resource summarises pancreatin options amid supply shortages - [link](#)

Specialist Pharmacy Services NHS UK

- Clinical considerations for patients prescribed clozapine - [link](#)
- Managing the risks associated with patients prescribed clozapine - [link](#)
- Administration of contrast agents under a PGD by multiple HCPs - [link](#)
- Legal mechanisms and contrast agents - [link](#)
- Occupational health services explainer videos - [link](#)
- Preparing to use ustekinumab biosimilar - [link](#)

TGA

- Zactin Tabs (fluoxetine 20 mg dispersible tablets) shortage resolved - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Inappropriate prescribing in older people: not only a patient safety issue but an avoidable source of environmental harm - [link](#)

American Journal of Emergency Medicine

- Efficacy of second-line anticonvulsant agents with adult status epilepticus: A systematic review and network meta-analysis - [link](#)

American Journal of Health-System Pharmacy (AJHSP)

- Impact of connected dispensing technology with advanced analytics in a multicenter health system - [link](#)
- Risk factors for treatment of asymptomatic bacteriuria in a rural health system - [link](#)
- Pharmacotherapy considerations for pediatric acute agitation management in the emergency department - [link](#)
- Central lines, aseptic batching services, and infection rates: A pharmacy-led initiative of intravenous tube priming within a NICU - [link](#)
- A call to action: Studying the shortened duration of ceftriaxone for inpatient management of acute uncomplicated cystitis - [link](#)
- Using quality improvement frameworks to develop, implement, and evaluate a novel ambulatory oncology pharmacy practice model: A descriptive example - [link](#)
- Exploring the therapeutic utility of the factor XIa inhibitor asundexian - [link](#)
- Mapping the next steps for critical care pharmacists - [link](#)
- A national survey of medication utilization for cardiac resuscitation in the emergency department: A survey of emergency medicine pharmacists - [link](#)
- From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics - [link](#)

Annals of Internal Medicine

- Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients with Cirrhosis and Atrial Fibrillation: A Nationwide Cohort Study - [link](#)
- Effect of Acupuncture for Methadone Reduction: A Randomized Clinical Trial - [link](#)
- Best Practices in Caring for Seriously Ill Patients - [link](#)
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults with Type 2 Diabetes: A Target Trial Emulation Study - [link](#)

Arthritis & Rheumatology

- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases - [link](#)

Australian Health Review

- Leveraging existing data to improve antimicrobial resistance-related mortality estimates for Australia - [link](#)

British Journal of Clinical Pharmacology

- Initiation of lipid-lowering therapy as primary prevention of cardiovascular disease in the elderly - [link](#)
- Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants: a single-centre modified Delphi study - [link](#)
- Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time-trend analysis from 2004 to 2021 - [link](#)
- Infringement of clinical pharmacist's authority - [link](#)
- Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review - [link](#)
- Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta-analysis - [link](#)
- Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes - [link](#)

British Journal of General Practice

- Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling study - [link](#)
- Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial - [link](#)
- Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention - [link](#)

British Medical Journal (BMJ)

- State of the Art Review: New and emerging treatments for major depressive disorder - [link](#)
- Novo Nordisk failed to disclose £7.8m in payments to doctors and others over three years - [link](#)
- Does frailty need a new name? - [link](#)
- Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration - [link](#)

BMJ Open

- Are adverse events higher among patients with acute optic neuritis prescribed glucocorticoids? A retrospective, longitudinal cohort study - [link](#)

BMJ Quality and Safety

- Frequency and preventability of adverse drug events in the outpatient setting - [link](#)
- Components of pharmacist-led medication reviews and their relationship to outcomes: a systematic review and narrative synthesis - [link](#)
- Longitudinal cohort study of discrepancies between prescribed and administered polypharmacy rates: implications for National Aged Care Quality Indicator Programs - [link](#)

Circulation

- Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice - [link](#)
- Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial - [link](#)
- Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial - [link](#)

Cochrane

- Adjunctive antimicrobial photodynamic therapy for treating periodontal and peri-implant diseases - [link](#)
- Treatment of uncomplicated hepatic cystic echinococcosis (hydatid disease) - [link](#)
- Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis - [link](#)
- Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders - [link](#)

Diabetes Care

- Sustained 3-Year Improvement of Glucose Control With Hybrid Closed Loop in Children With Type 1 Diabetes While Going Through Puberty - [link](#)
- Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses - [link](#)

Drug and Therapeutics Bulletin

- Safety update: more on topical steroid severe adverse effects - [link](#)

EClinical Medicine

- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study - [link](#)

European Heart Journal

- Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists - [link](#)
- Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis - [link](#)
- Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study - [link](#)

European Journal of Hospital Pharmacy

- Taking care of caregivers: enhancing proper medication management for palliative care children with polypharmacy - [link](#)
- Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis - [link](#)
- Clopidogrel-induced thrombotic microangiopathy: a case report - [link](#)
- Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management - [link](#)

Internal Medicine Journal

- Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder - [link](#)
- Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia - [link](#)

International Journal of Clinical Pharmacy

- Impact of medicine shortages on hospital practice: role of a multidisciplinary medicine shortages team - [link](#)
- The impact of codeine rescheduling on non-opioid analgesic use by people who regularly use codeine: a prospective cohort study - [link](#)
- The evolving role of pharmacists in depression care: a scoping review - [link](#)
- Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study - [link](#)
- Anti-CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years - [link](#)
- Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States - [link](#)
- Authors' response to comments on "The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis" - [link](#)
- A model for identifying potentially inappropriate medication used in older people with dementia: a machine learning study - [link](#)
- Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes - [link](#)

JAMA

- Essential Tremor - [link](#)
- Patient page: What Are Food Allergies? - [link](#)

JAMA Cardiology

- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial - [link](#)
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial - [link](#)
- Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial - [link](#)
- Dual vs Single Cardioversion of Atrial Fibrillation in Patients with Obesity: A Randomized Clinical Trial - [link](#)

JAMA Dermatology

- Dupilumab in Adults with Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study - [link](#)
- Immunotherapy for Advanced Skin Cancer in Kidney Transplant Recipients—The High-Risk Balancing Act - [link](#)

JAMA Internal Medicine

- Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity - [link](#)

JAMA Network Open

- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients with Type 2 Diabetes - [link](#)
- Interventions for Weight Management in Children and Adolescents Updated Evidence Report and Systematic Review for the US Preventive Services Task Force - [link](#)

JAMA Neurology

- Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events - [link](#)

JAMA Oncology

- Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement - [link](#)

JAMA Ophthalmology

- Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide - [link](#)

J Am Coll Clin Pharm

- Impact of pharmacist-led discharge medication reconciliation on error and patient harm prevention at a large academic medical center - [link](#)

Journal of Clinical Oncology

- Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Sepsis call emergency department pharmacist service: a single healthcare network cohort study - [link](#)
- Pharmacist's role in influenza immunisation: a scoping review - [link](#)
- Implementation of hospital electronic medical record Patient Friendly Medication Lists and Interim Medication Administration Charts - [link](#)
- Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals - [link](#)

Lancet

- The CONCORD–Lancet Global Commission on Cancer - [link](#)
- Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment - [link](#)

Lancet Diabetes & Endocrinology

- Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials - [link](#)
- Precision nutrition: a step too far? - [link](#)

Lancet Gastroenterology and Hepatology

- Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies - [link](#)

Lancet Haematology

- Diagnosis and management of Evans syndrome in adults: first consensus recommendations - [link](#)

Lancet Infectious Diseases

- Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - [link](#)

Lancet Oncology

- Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study - [link](#)

- NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address - [link](#)
- Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis – [link](#)

Lancet Respiratory Medicine

- Rethinking bronchiectasis as an inflammatory disease - [link](#)
- Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Factors Determining Quality of Drug Information by Hospital Pharmacies—Results from Five-Year Annual Quality Assessment - [link](#)
- Adapting the Opening Minds Stigma Scale for Healthcare Providers to Measure Opioid-Related Stigma - [link](#)
- Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study - [link](#)

Medical Journal of Australia

- National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030 - [link](#)
- Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)
- Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study – [link](#) - [editorial](#)

New England Journal of Medicine

- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer - [link](#)
- Nirsevimab and Hospitalization for RSV Bronchiolitis - [link](#)
- Malnutrition in Adults - [link](#)
- Anticipating the Next Pandemic - [link](#)

Neurology

- Efficacy of Atogepant in Chronic Migraine with and without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial - [link](#)

Pediatrics

- Infantile and Very Early Onset Inflammatory Bowel Disease: A Multicenter Study - [link](#)
- Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary Morbidity - [link](#)
- The Importance of Timing When Evaluating PDA Treatment Outcomes - [link](#)
- Quality Improvement Interventions to Prevent Intraventricular Hemorrhage: A Systematic Review - [link](#)
- Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine - [link](#)
- Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments - [link](#)

Pharmaceutical Journal

- Scottish government publishes prescribing guidance aiming to save millions of pounds - [link](#)

Pharmacotherapy

- Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An [executive summary](#) - [link](#)
- Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection - [link](#)

Prescriber UK

- Antipsychotics: beyond dopamine - [link](#)
- Deprescribing in people living with frailty, multimorbidity and polypharmacy - [link](#)

Thorax

- Antibiotic pharmacokinetics in infected pleural effusions - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 167](#) – Diagnosis and management of obstructive sleep apnoea in adults

Purple Pen Podcast

- [PPP 163](#) - Monoclonal Antibodies

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC) - NMS 2024 – save the date, 19 November 2024 - [link](#)

Australian Healthcare and Hospitals Association (AHHA)

- Enabling hospitals and healthcare leaders to advance their sustainability journey, FREE WEBINAR, Thursday 25 July 16:00-17:00 AEST – [register](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

Fortnightly TAG Mail – resources list

4th July 2024

NSW TAG ACTIVITIES

Current Email Discussions

- Feedback for TGA Proposed Updates to Medicine Labelling Rules. Closes 8th July 2024
- Implementation of the Guiding Principles for Transition of Young People on Complex and/or Costly Medicines from Paediatric to Adult Care. Closes 12th July 2024

Recently Completed Email Discussions

- Virtual Pharmacy Service for Patients being discharged from Hospital
- Shingrix (updated following TAG General meeting 19th July)
- Local protocols for COVID-19 antivirals.

Coming soon: Survey about protocols for critical care medicines.

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Optimizing discharge antimicrobial therapy - [link](#)

AJHP: Impact of automated alerts on discharge opioid overprescribing after general surgery - [link](#)

AJHP: Effect of pharmacist care on clinical outcomes and therapy optimization in perioperative settings - [link](#)

BJCP: Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet- α , protamine) - [link](#)

BJCP: Management of serotonin syndrome (toxicity) - [link](#)

BJCP: Moderate and serious adverse reactions to antimicrobials among hospitalized children: A systematic review - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

BMJ: Philip Morris: Leaked documents show how company tries to influence science and policy on heated tobacco - [link](#)
BMJ QS: Viewpoint: Need to systematically identify and mitigate risks upon hospitalisation for patients with chronic health conditions - [link](#)
CATAG: Off label medicines consumer counselling tool - [link](#)
CATAG: Preventing progression to persistent pain toolkit- [link](#)
Circulation: CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy- [link](#)
DC: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report - [link](#)
EHJ: - Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies- [link](#)
EjHP: A single harmonised pharmacy process to improve clinical trial set-up times - [link](#)
IJQHC: Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)
IMJ: Tocilizumab use in giant cell arteritis: comparing PBS eligible and ineligible cases in SA - [link](#)
JAMA IM: Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data - [link](#)
JAMA Psych: Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia - [link](#)
JAGS: Antibiotics for delirium in older adults with pyuria or bacteriuria: A systematic review - [link](#)
Lancet Neur: Sleep and sleep disorders in people with Parkinson's disease - [link](#)
MJA: - Contextualising the benefits and risks of anti-amyloid therapy for patients with Alzheimer disease and their care team - [link](#)
Nature Medicine: Benefits for children with suspected cancer from routine whole-genome sequencing - [link](#)
Pediatrics QS: A Quality Initiative to Improve Appropriate Medication Dosing in Pediatric Patients with Obesity - [link](#)

OTHER NEWS

NSW Health

- Warning: Hospitalisations after consuming Uncle Frog's Mushroom Gummies - [link](#)
- Three new mpox cases detected in NSW - [link](#)
- NSW Health warns of high seasonal influenza activity - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

ACSQHC Radar Issue 1 July 2024 - [link](#)

- Nirmatrelvir and ritonavir (Paxlovid®) and molnupiravir (Lagevrio®) for COVID-19 (amended PBS listing)
- Type 2 diabetes mellitus (T2DM) medicines (amended PBS restrictions).

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Institute for Health and Welfare (AIHW)

- Health checks and follow-ups for Aboriginal and Torres Strait Islander people - [link](#)
- Australia's Health 2024- [link](#)
- Medicare Benefits Scheme funded services: monthly data- [link](#)
- Injury in Australia - [link](#)

CATAG

- **Collaborating with consumers: off-label medicines consumer counselling tool** based on the [Rethinking medicines decision-making in Australian Hospitals](#) to support Medicines and Therapeutics Advisory Committees in implementing the Guiding Principles for the quality use of off-label medicines alongside consumers. It is designed to assist hospital-based health professionals and promote shared-decision making when considering treatment with an off-label medicine. It is written in plain English to suit a wide audience and explains the important information consumers need to know about off-label medicines - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- **MAIA: Preventing progression to persistent pain toolkit- [link](#)**

CATAG has developed a Preventing progression persistent pain toolkit for Medicines and Therapeutics Advisory Committees and hospitals. The toolkit can assist in increasing understanding of the nature of pain and provide strategies to prevent progression to persistent pain. The toolkit supports the implementation of local stewardship opioid analgesic programs and promotes effective patient-centred education across the perioperative continuum of care. The toolkit includes: [Practice tool](#) to guide Medicines and Therapeutics Advisory Committees [Teaching tool](#) that can be used by clinical educators; it provides a clinical example of opportunities to prevent progression to persistent pain.

Next CATAG Meeting: 25th July 10am- noon.

MIMS monthly updates

- New Products

-- [Etrasimod](#) (as arginine) for adults with moderately to severely active UC who have had inadequate response, loss of response or intolerance to conventional, biologic or Janus kinase inhibitor therapies. Velsipity is contraindicated in patients who in the last 6 months, have experienced a myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalisation, or New York Heart Association class III/IV heart failure; in patients with a history or presence of Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker; during pregnancy and in women of childbearing potential not using effective contraception; in breastfeeding women; and in active malignancies.

-- [Spesolimab](#) (rch) (Spevigo) is a humanised antagonistic monoclonal immunoglobulin G1 antibody blocking human interleukin-36 receptor (IL36R) signalling for flares in adult patients with generalised pustular psoriasis

- New Presentation

-- Semaglutide ([Wegovy FlexTouch](#)) now available as a product specifically indicated for weight management as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity; and for weight management in adolescents ages 12 years and above with initial obesity [(BMI \geq 95th percentile) as defined on sex and age-specific BMI growth charts (CDC.gov)] and body weight above 60 kg

- New Indication

-- Tozinameran and famtozinameran ([Comirnaty Original](#)/Omicron BA.4-5) now indicated (with provisional approval) for active immunisation to prevent COVID-19 in individuals 6 months of age and older in accordance with official recommendations

PBS

- Expansion of the CTG PBS Co-Payment Program - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- ORENCIA abatacept 125 mg solution for injection in pre-filled pen (Germany) - Not on the ARTG but approved for import and supply in Australia until 15/12/2024 due to a shortage of another medicine or for public health reasons

- AusPARs:

-- [ADCETRIS](#) (brentuximab vedotin) approved for the treatment of Hodgkin lymphoma in patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma

-- [NUVAXOVID](#) approved for the prevention of coronavirus disease 2019 (COVID-19) caused by SARSCoV-2 in individuals 12 years of age and older

-- [XEOMIN](#) (Botulinum toxin type A) approved for the treatment of chronic sialorrhea (hypersalivation or excessive drooling) in children and adults

-- [ERWINASE](#) indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia

-- [Givlaari](#) (givosiran sodium) for treatment of acute hepatic porphyria

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Australian prescription medicine decision summaries:
- [TRUQAP](#) (capiasertib), in combination with fulvestrant, is for adults with locally advanced or metastatic breast cancer
- [EBGLYSS](#) (lebrikizumab) or moderate to severe atopic dermatitis in patients older than 12 years.
- [VELSIPITY](#) (Etrasimod) treats moderately to severely active ulcerative colitis
- [TEVIMBRA](#) (tislelizumab) for patients with various types of oesophageal squamous cell carcinoma and non-small cell lung cancer
- Registration of [new or extended uses](#) of registered medicine:
- [KEYTRUDA](#) ; [COMIRNATY ORIGINAL/OMICRON](#) ; [SAIZEN](#) ; [BIMZELX](#) ; [DYMISTA/ DYLASTINE](#) ; [ONIVYDE](#) ; [KEYTRUDA](#) ; [JARDIANCE](#) ; [TRIKAFTA](#) ; [RYEQO](#) ; [ULTOMIRIS](#) ; [ADCETRIS](#) ; [PREVENAR](#) ; [OPDIVO](#) ; [WEGOVY](#)
- Registration of [new chemical entities](#) in Australia:
- [AMVUTTRA](#) ; [TEVIMBRA](#) ; [VELSIPITY](#) ; [EBGLYSS](#) ; [TRUQAP](#) ; [CIBINQO](#) ; [TERIPARATIDE RBX/ RITOSA/ TERIPARATIDE SUN](#) ; [LOKELMA](#) ; [NELARABINE-REACH](#) ; [ABRYSVO](#) ; [HEMGENIX](#) ; [WINLEVI](#) ; [VEOZA](#) ; [VERDYE](#) ; [SPY AGENT GREEN](#) ; [ERWINASE](#) ; [AREXVY](#)
- Registration of [new generic medicines](#) and [new biosimilar medicines](#):
- [MEROPENEM-AFT](#) ; [RASAGILINE JAMP/ RASAGILINE GXMED](#) ; [CIPFOSIN/ CIPLA FOSFOMYCIN](#) ; [PALIPERIDONE-TEVA](#) ; [NOVADAC ONCE DAILY GEL](#) ; [URSODOX GH/ URSODOX LAPL](#) ; [ENZALINE/ LUTACIP/ ENZACIP/ CIP ENZALUTAMIDE](#) ; [BENZYLPENICILLIN KABI](#) ; [GONADRON/ TESTOSTERONE RBX/ TESTOSTERONE SUN](#) ; [OXONAL](#) ; [ATOVACUE](#) ; [CIP APIXABAN/ XABANIL/ APIXABAN CIPLA/ APIXAIR](#) ; [PLERIXAFOR-AFT](#) ; [PIPTAZ MEDICIANZ/ PIPTAZ MEDSURGE](#) ; [FULVESTRANT EUGIA/ EUG-FULVESTRANT/ FULVESTRANT EPSL](#) ; [WEZLANA](#) ; [ONBEVZI](#)

REPORTS AND PUBLICATIONS – INTERNATIONAL

British National Formulary

- BNF/BNFC newsletter: [June 2024](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Campona Airmaster (salmeterol, fluticasone propionate) for asthma where use of a combination product (long- acting β 2 agonist and inhaled corticosteroid) is appropriate, and also for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal and repeated exacerbations.
- Cytisine 1.5 mg tablets - similar to nicotine, but weaker, allowing for a gradual reduction of nicotine dependence by relieving withdrawal symptoms. Licensed for smoking cessation & reduction of nicotine cravings in smokers willing to stop smoking.
- Fluenz Trivalent nasal spray suspension Influenza vaccine (live attenuated, nasal) - licensed for the prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Use should be based on official recommendations.
- Melatonin Orion generic tablets licensed for short-term treatment of jet lag in adults and for insomnia in children and adolescents aged 6– 17 years with ADHD where sleep hygiene measures have been insufficient.

-[Updated SPCs](#)

- Rabipur pre-filled syringe (rabies vaccine) - updated to include a 2 dose regimen for immunocompetent patients on day 0 and day 7
- Veltassa (Patiromer) now licensed for the treatment of hyperkalaemia in adolescents aged 12-17 years, as well as in adults. A new 1g powder for oral suspension formulation is also now available
- VeraSeal (human fibrinogen, human thrombin) - information on use in children, including a note that application of the product must be individualised by the treating physician, with doses ranging from 0.6 to 12mL in the paediatric clinical trial. Details of the trial have been added to section 5.1
- Xtandi (enzalutamide) - licence extension for use as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage-radiotherapy

European Medicines Agency (EMA)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- European CHMP recommends
- first nasal adrenaline spray for emergency treatment against allergic reactions - [link](#)
- [sotatercept](#) (Winrevair) to treat adults with pulmonary arterial hypertension (PAH)
- Duchenne muscular dystrophy medicine Translarna - [link](#)
- revoking conditional marketing authorisation for [obeticholic acid](#) (Ocaliva)
- [crovalimab](#) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)
- [durvalumab olaparib](#) for the treatment of endometrial cancer
- [epcoritamab](#) for the treatment of adults with relapsed or refractory follicular lymphoma
- [erdafitinib](#) for urothelial carcinoma harbouring susceptible FGFR3 genetic alterations
- [faricimab](#) for the treatment of retinal vein occlusion
- [flortaucipir](#) (18F) for the diagnosis of Alzheimer's disease
- [isavuconazole](#) for use in paediatric patients
- [mirabegron](#) (Betmiga) for use in children and adolescents with neurogenic detrusor overactivity
- [peginterferon alfa-2a](#) for the treatment of polycythaemia vera and essential thrombocythaemia
- [setmelanotide](#) for use in children aged 2 years and above
- [mResvia](#) vaccine [nirsevimab](#) for prevention of lower respiratory tract (LRT) disease caused by respiratory syncytial virus
- [crizotinib](#) to include treatment of children from 1 year of age
- [odronextamab](#) (Ordspono) for treatment of follicular lymphoma and diffuse large B-cell lymphoma
- [Enzalutamide Viatris](#), generic and bioequivalent to Xtandi, for prostate cancer
- [Nilotinib Accord](#), generic and bioequivalent to Tassigna, for Philadelphia chromosome positive chronic myelogenous leukaemia
- [ustekinumab](#) (Steqeyma) biosimilar to Stelara, for the treatment of adults with moderately to severely active Crohn's disease, plaque psoriasis, paediatric plaque psoriasis and psoriatic arthritis
- Company withdraws application for a marketing authorisation of [Dabigatran etexilate Teva](#) in the EU
- European CHMP adopts a change to the existing indication for [Infanrix Hex](#)
- refusal of marketing authorisation for [masitinib](#) for amyotrophic lateral sclerosis (ALS)
- refusal of marketing authorisation for [pegcetacoplan](#) (Syfovre) for geographic atrophy caused by age-related macular degeneration (AMD)
- [Lorazepam Macure](#) 4 mg/ml, solution for injection: CHMP opinion on update to include control of status epilepticus in adults, adolescents and children from 1 month of age

Food and Drug Administration (FDA) USA

- New Drug approvals
- treatment for adults with Alzheimer's disease - [Kisunla](#) (donanemab-azbt)
- epcoritamab-bysp for relapsed or refractory follicular lymphoma - epcoritamab-bysp ([Epkiny](#))
- treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults - [Vyvgart Hytrulo](#) (efgartigimod alfa and hyaluronidase-qvfc)
- [adagrasib](#) with cetuximab for KRAS G12C-mutated colorectal cancer
- Ohtuvayre ensifentrine to treat chronic obstructive pulmonary disease
- Piasky Crovalimab-Akz for adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg – [PI/label](#)

General Pharmaceutical Council

- Statement on self-selection of pharmacy medicines - [link](#)

Health Foundation, UK

- Priorities for an AI in health care strategy - [link](#)

MIMS, UK

- More than 18,500 inhalers recycled over six months in pioneering pharmacist-led pilot - [link](#)

NHS England

- Clinical commissioning policy statement (2317): treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB, pre-extensively drug-resistant (pre-XDR) TB and extensively drug-resistant (XDR-TB) including bedaquiline and delamanid (all ages) - [link](#)

- Clinical commissioning policy: bedaquiline, pretomanid, linezolid +/- moxifloxacin (BPaLM/BPaL) for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant tuberculosis (TB), multidrug-resistant TB or pre-extensively drug resistant TB - [link](#)

National Institute for Health and Care Excellence (NICE) UK

- QuiremSpheres for treating unresectable advanced hepatocellular carcinoma ([TA985](#))

National Institute for Health and Care Research (NIHR)

- Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews - [link](#)
- Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model - [link](#)

Nuffield Trust, UK

- What health and care need from the next government: #4 – Improving access to treatment - [link](#)

Professional Record Standards Body, UK

- New transfer of care toolkit - [link](#)

Specialist Pharmacy Services NHS UK

- Using domperidone for low milk supply - [link](#)
- Hormone replacement therapy (HRT): resources for answering questions – [link](#)
- SPS Spotlight Monthly Digest – [June 2024](#)
- New Medicines News [June 2024](#)

UK Health Security Agency

- Updated antimicrobial intravenous-to-oral switch: criteria for prompt switch - [link](#)
- Administration of human normal immunoglobulin (HNIG) for measles post-exposure prophylaxis - [link](#)
- Guidance - Complete routine immunisation schedule – [link](#)
- Guidance - Immunoglobulin: when to use - [link](#)

World Health Organisation (WHO)

- WHO clinical treatment guideline for tobacco cessation in adults - [link](#)
- World Health Organization (WHO) issues warning on falsified medicines used for diabetes treatment and weight loss - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)
-- Enbrel (etanercept) - frequency of adverse drug reaction 'glomerulonephritis' as rare
-- Exforge (amlodipine besilate, valsartan) – risk of drug-drug interaction between amlodipine and tacrolimus that may increase blood levels of tacrolimus with concomitant use. Tacrolimus blood level monitoring is recommended and dose adjustment when appropriate
-- Cell-based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus - strains in the qualitative and quantitative composition section updated for Northern Hemisphere season 2024-2025
-- Finlee (dabrafenib mesilate) - peripheral neuropathy as an ADR (frequency not specified). Although this (& certain other ADRs) only been reported in adults, safety profile in children is largely consistent
-- Ibrance (palbociclib) – Palbociclib/statins interaction may increase the risk of rhabdomyolysis due to increased statin plasma concentration. Increased blood creatinine added as a common ADR
-- Jentadueto (metformin hydrochloride, linagliptin) - use in children and adolescents not recommended; clinical trial related information included stating that no significant improvement on HbA1c levels was provided with use of linagliptin in the paediatric population
-- Libtayo (cemiplimab) - immune checkpoint inhibitor class effects added advising on cases of coeliac disease and pancreatic exocrine insufficiency reported during treatment with other PD-1/PD-L1 inhibitors

- Luxturna (voretigene neparvovec) - chorioretinal atrophy (which includes retinal degeneration, retinal depigmentation and injection site atrophy) added as an ADR of unknown frequency. This was reported in post marketing studies and is progressive in some patients
- Numeta G19%E (parenteral nutrition) - further information on 'fat overload syndrome' added, including that it has been associated with metabolic acidosis and respiratory distress in neonates & infants, & that severe cases treated with exchange transfusions have been reported
- Nuwiq (simoctocog alfa) - information about sodium content, anaemia and chest pain added as 'uncommon' possible ADRs
- Oxycontin (oxycodone) - Use with caution in patients with pancreatitis and biliary tract disease. Dysfunction and spasm of Sphincter of Oddi included as possible ADR, 'frequency not known'
- Rizatriptan - moderate amount of data on pregnant women indicate no malformative toxicity following first trimester exposure. There are limited data in relation to use in the second and third trimester; use may be considered during pregnancy, if clinically necessary
- Spexotras (trametinib dimethyl sulfoxide) - peripheral neuropathy added as an ADR (frequency not specified). Although this (& certain other adverse effects) only been reported in adults, safety profile in children is largely consistent
- Targinact (oxycodone hydrochloride, naloxone hydrochloride dihydrate) - information on drug withdrawal syndrome, including symptoms, the need to taper the dose gradually when stopping therapy, and the fact that if taken during pregnancy, there is a risk that newborn infants will experience neonatal withdrawal syndrome
- Xromi (hydroxycarbamide) - recommended duration of contraception in male & female patients following the end of treatment with hydroxycarbamide should be 3 & 6 months, respectively. Both should be advised to use contraceptive measures before, during & after treatment
- Risk minimisation materials
- [Lecigon](#) (levodopa, carbidopa monohydrate, entacapone) intestinal gel - materials to inform healthcare providers (HCPs) & patients about the GI, device and procedure-related risks associated with Lecigon®, to educate HCPs on PEG-J and NJ tube insertion procedures, and to inform HCPs & patients about aftercare for long-term PEG-J placement
- topiramate products: Pregnancy Prevention Programme - A number of resources are now available aimed at minimising pregnancy exposure during treatment with topiramate. Educational materials for patients include a patient guide, risk awareness form and patient card

EMA

- EU actions to tackle shortages of GLP-1 receptor agonists - [link](#)

Health Canada – MedEffect Notice

- Health Product InfoWatch, [June 2024](#)

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Drug Safety Update June 2024
- Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme - [link](#)
- Warfarin: be alert to the risk of drug interactions with tramadol - [link](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Outcome of Clozapine Survey/Consultation 2023 - [link](#)

MIMS monthly updates

- New Contraindications
- Bupropion hydrochloride ([Zyban SR](#)) is now contraindicated in children
- Rifampicin ([Rifadin](#)) is now contraindicated for concomitant administration with lurasidone

Specialist Pharmacy Services NHS UK

- Medicines suitable for adults with swallowing difficulties, updated 20 June 2024: AVE inhibitors, ARBs, SSRIs - [link](#)
- Searching for presence or absence of an excipient in medicines - [link](#)
- Understanding excipients in medicines - [link](#)

- Medication Safety Update – [June 2024](#)

TGA

- Update on oral opioids - [link](#)
- Product Information safety updates - [June 2024](#)
- Medicines containing *Andrographis paniculata* safety advisory - [link](#)
- Compounded colic preparations containing *Atropa belladonna* - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Investigating the link between antipsychotic use and post-stroke infections in older people: multi-centre propensity score analysis - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Optimizing discharge antimicrobial therapy: Evaluation of a transitions of care process and electronic scoring system for patients with community-acquired pneumonia or chronic obstructive pulmonary disease - [link](#)
- Impact of automated alerts on discharge opioid overprescribing after general surgery - [link](#)
- Effect of pharmacist care on clinical outcomes and therapy optimization in perioperative settings: A systematic review - [link](#)
- Comparison of clevidipine vs nicardipine in the treatment of hypertensive urgency and emergency in critically ill patients - [link](#)
- Towards consensus recommendations for pharmacogenetics testing - [link](#)

Annals of Internal Medicine

- Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials - [link](#)
- Medication-Induced Weight Change Across Common Antidepressant Treatments: A Target Trial Emulation Study - [link](#)

Arthritis & Rheumatology

- A Comparison of Gout Flares with the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-hoc Analysis of a Randomized Multicenter Trial - [link](#)
- Association of Cardiovascular Outcomes with Low-Dose Glucocorticoid Use in Patients with Rheumatoid Arthritis - [link](#)

British Journal of Clinical Pharmacology

- The pharmacokinetic differences between 10- and 15- μ g daily vitamin D doses - [link](#)
- Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet- α , protamine) - [link](#)
- Management of serotonin syndrome (toxicity) - [link](#)
- Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects - [link](#)
- Cassia angustifolia and tacrolimus interaction in a liver transplant patient, a case report - [link](#)
- Moderate and serious adverse reactions to antimicrobials among hospitalized children: A systematic review - [link](#)

British Journal of General Practice

- Patients' perspectives about the role of primary healthcare providers in long-term opioid therapy: a qualitative study in Dutch primary care - [link](#)
- Risk of Parkinson's disease in people aged ≥ 50 years with new-onset anxiety: a retrospective cohort study in UK primary care - [link](#)
- Collaborative discussions between pharmacists and general practitioners to optimise patient medication: a qualitative study within a clinical trial - [link](#)

- Recurrent urinary tract infections and prophylactic antibiotic use in women: cross-sectional study - [link](#)

British Medical Journal (BMJ)

- Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial - [link](#)
- Diagnosis and management of resistant hypertension - [link](#)
- Reducing unnecessary investigations in paediatric seizures in the emergency department - [link](#)
- Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial - [link](#)
- SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study - [link](#)
- Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study - [link](#)
- Clinical Update: Analgesia for non-specific low back pain - [link](#)
- Acute painful crisis in adults with sickle cell disease - [link](#)
- Peer support in chronic health conditions - [link](#)
- Philip Morris: Leaked documents show how company tries to influence science and policy on heated tobacco - [link](#)

BMJ Quality and Safety

- Viewpoint: Need to systematically identify and mitigate risks upon hospitalisation for patients with chronic health conditions - [link](#)

Circulation

- CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association - [link](#)
- Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study - [link](#)
- Effect of apixaban on clinical outcomes in outpatients with COVID-19: The APOLLO randomized clinical trial - [link](#)

Cochrane

- Treatments for intractable constipation in childhood - [link](#)

Diabetes Care

- Suicidal Ideation, Suicide Attempts, and Suicide Deaths in Adolescents and Young Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis - [link](#)
- Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial - [link](#)
- Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT - [link](#)
- Hyperglycemic Crises in Adults With Diabetes: A Consensus Report - [link](#)
- The Final Frontier in Diabetes Care: Implementing Research in Real-World Practice - [link](#)
- Excess Risk of Injury in Individuals With Type 1 or Type 2 Diabetes Compared With the General Population - [link](#)
- Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes - [link](#)
- Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial - [link](#)
- Dulaglutide and glomerular hyperfiltration, proteinuria, and albuminuria in youth with type 2 diabetes: post hoc analysis of the AWARD-PEDS study - [link](#)

Drug and Therapeutics Bulletin

- DTB select: Dupilumab for treating chronic obstructive pulmonary disease - [link](#)

- Investing in COPD: biologics or smoking cessation and pulmonary rehabilitation? - [link](#)
- Managing COPD exacerbations in primary care - [link](#)

European Heart Journal

- Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC - [link](#)
- Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies- a review- [link](#)

European Journal of Hospital Pharmacy

- Natural language processing assisted detection of inappropriate proton pump inhibitor use in adult hospitalised patients - [link](#)
- Prevalence of compliance with PIMDINAC criteria among elderly people living with HIV and in non-infected outpatients with other chronic diseases - [link](#)
- A single harmonised pharmacy process to improve clinical trial set-up times - [link](#)
- Antifungal prophylaxis against invasive Candida and Aspergillus infection in adult heart transplant recipients: protocol for a systematic review and meta-analysis - [link](#)

Heart

- Intracoronary thrombolysis in ST-elevation myocardial infarction: a systematic review and meta-analysis - [link](#)

Internal Medicine Journal

- Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia - [link](#)
- Tinnitus update: what can be done for the ringing? - [link](#)

International Journal of Clinical Pharmacy

- Identification of seniors at risk (ISAR) score and potentially inappropriate prescribing: a retrospective cohort study - [link](#)
- Genetic influence of meningioma on cisplatin resistance: a Mendelian randomization analysis - [link](#)
- Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data - [link](#)

International Journal for Quality in Health Care

- Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)

JAMA

- Perioperative Management of Antithrombotic Therapy - [link](#)
- Therapies to Decrease Severe Respiratory Syncytial Virus Illness - [link](#)
- Patient page: What Is Age-Related Macular Degeneration? - [link](#) - What Is Thyroid Cancer? - [link](#)
- Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen - [link](#)
- A More Selective vs a Standard Risk-Stratified, Heparin-Based, Obstetric Thromboprophylaxis Protocol - [link](#)

JAMA Internal Medicine

- Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19 - [link](#)
- Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data - [link](#)
- Time- vs Step-Based Physical Activity Metrics for Health - [link](#)

JAMA Network Open

- Internet and Telephone Support for Discontinuing Long-Term Antidepressants: The REDUCE Cluster Randomized Trial - [link](#)

JAMA Neurology

- Recurrent Ischemic Stroke in Patients with Atrial Fibrillation While Receiving Oral Anticoagulants - [link](#)

JAMA Oncology

- Post-recurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review - [link](#)
- Survival in Patients with Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial - [link](#)
- Current Management of Desmoid Tumors - [link](#)

JAMA Psychiatry

- Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia - [link](#)

Journal of the American College of Cardiology

- Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure with Preserved Ejection Fraction: STEP-HFpEF Trials - [link](#)
- Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program - [link](#)

Journal of the American Geriatrics Society

- Antibiotics for delirium in older adults with pyuria or bacteriuria: A systematic review - [link](#)

Journal of Clinical Oncology

- Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Breast Cancer - [link](#)
- Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Two instances of successful oral desensitisation following hypersensitivity reaction in a patient receiving osimertinib: a case report - [link](#)

Lancet

- Colorectal cancer - [link](#) ; Gestational diabetes - [series](#) - Neonatal bacterial sepsis - [link](#)
- Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial - [link](#)
- Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis - [link](#)

Lancet Diabetes & Endocrinology

- Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts - [link](#)

Lancet Global Health

- National, regional, and global trends in insufficient physical activity among adults from 2000 to 2022: a pooled analysis of 507 population-based surveys with 5.7 million participants - [link](#)

Lancet HIV

- Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation - [link](#)

Lancet Neurology

- Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Sleep and sleep disorders in people with Parkinson's disease - [link](#)

Lancet Oncology

- Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group - [link](#)

- Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study - [link](#)

Lancet Psychiatry

- Concomitant use of antidepressants and benzodiazepines during pregnancy and associated risk of congenital malformations: a population-based cohort study in Taiwan - [link](#)

Lancet Public Health

- The effects of alcohol container labels on consumption behaviour, knowledge, and support for labelling: a systematic review - [link](#)

Lancet Oncology

- Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Exploring the Significance of Pharmaceutical Care in Mental Health: A Spotlight on Cannabis - [link](#)

- Development of an Educational Brochure about Treatment Options for Pregnant Women with Opioid Use Disorders - [link](#)

- Considering the Possible Role of Pharmacists According to the Presence or Absence of Lifestyle-Related Diseases at the Time of Coronary CT Examination and Trends of Medication Use for These Diseases by Medical Doctors - [link](#)

Medical Journal of Australia

- Contextualising the benefits and risks of anti-amyloid therapy for patients with Alzheimer disease and their care team - [link](#)

Nature Medicine

- Benefits for children with suspected cancer from routine whole-genome sequencing - [link](#)

NEJM Evidence

- Effect of Fenofibrate on Progression of Diabetic Retinopathy - [link](#)

New England Journal of Medicine

- A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia - [link](#)

- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma - [link](#)

- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma - [link](#)

- Noninvasive Ventilation for Preoxygenation during Emergency Intubation - [link](#)

- Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors - [link](#)

- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity - [link](#)

- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC - [link](#)

- Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age - [link](#)

- Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis - [link](#)

- Systemic Light Chain Amyloidosis - [link](#)

Pediatric Quality & Safety

- A Quality Initiative to Improve Appropriate Medication Dosing in Pediatric Patients with Obesity - [link](#)

Pharmaceutical Journal

- Study results suggest greener inhaler propellant (HFA-152a) is therapeutically equivalent to traditional alternatives (HFA-134a) - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- 'Beyond weight loss': what is the future of semaglutide? - [link](#)

Pharmacotherapy

- Platelet glycoprotein IIb/IIIa antagonists in ischemic stroke patients without endovascular therapy: A meta-analysis - [link](#)
- Evolving resistance landscape in gram-negative pathogens: An update on β -lactam and β -lactam-inhibitor treatment combinations for carbapenem-resistant organisms - [link](#)
- Thirty-day risk of digoxin toxicity among older adults co-prescribed trimethoprim-sulfamethoxazole versus amoxicillin: A population-based cohort study - [link](#)
- Effect of proton pump inhibitors versus histamine-2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers - [link](#)

Prescribe International

- Issue 261- [July 2024](#) includes: Methadone: an analysis of adverse effects reported in France - [link](#)

PROSPERO - International prospective register of systematic reviews

- The Efficacy and Safety of Gene Therapy Approaches in Parkinson's Disease: A Systematic Review - [link](#)
- Association of Proton Pump Inhibitors and Chronic Kidney Disease. A Systematic Review and Meta-analysis - [link](#)
- Meta-analysis: Fostamatinib treatment vs other therapy in refractory immune thrombocytopenia - [link](#)
- Azvudine compared to nirmatrelvir/ritonavir (Paxlovid) in COVID-19: A systematic review and meta-analysis - [link](#)

Stroke

- Dual antiplatelet therapy after embolic stroke of undetermined source: A subgroup analysis of the CHANCE-2 trial - [link](#)

CONSULTATIONS

Pharmacy Board of Australia

- Have your say on the draft Criminal history registration standard and supporting materials, closes 30 July 2024 - [link](#)

TGA

- Consultation: updates to Australian medicine labelling rules to support medicine safety, closes 11 July 2024 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 166](#) – Biologic therapies for severe asthma with persistent type 2 inflammation

MJA Podcasts

- [Episode 21](#): "By the community, for the community"

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- NMS 2024 – save the date, 19 November 2024 - [link](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 – [abstract submission](#) closes 15 July 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024